: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Diabetes

Free Subscription

Articles published in Diabetes Obes Metab
Retrieve available abstracts of 1286 articles:
HTML format

Single Articles

February 2025

COSENTINO F, Dagogo-Jack S, Frederich R, Cannon CP, et al
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
Diabetes Obes Metab. 2025;27:583-594.
PubMed Abstract available

HE Q, Cheng Z, Li Y, Xing X, et al
A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
Diabetes Obes Metab. 2025;27:965-975.
PubMed Abstract available

MORENO-LOPEZ M, Louvet I, Delalleau N, Acosta-Montalvo A, et al
The role of the glucagon-FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition.
Diabetes Obes Metab. 2025;27:885-898.
PubMed Abstract available

CERSOSIMO E, YueJuan Q, Baskoy G, Chavez A, et al
Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients.
Diabetes Obes Metab. 2025;27:944-952.
PubMed Abstract available

NEYER M, Vogel JB, Elsner P, Kuehrer H, et al
Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.
Diabetes Obes Metab. 2025;27:835-844.
PubMed Abstract available

USUI R, Hamamoto Y, Imura M, Omori Y, et al
Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial.
Diabetes Obes Metab. 2025;27:856-865.
PubMed Abstract available

ZHANG M, Lin C, Cai X, Jiao R, et al
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.
Diabetes Obes Metab. 2025;27:806-815.
PubMed Abstract available

SONG ZQ, Chen YQ, Xuan CH, Ni TT, et al
Effect of smoking behaviour and related blood DNA methylation on visceral adipose tissues.
Diabetes Obes Metab. 2025;27:619-628.
PubMed Abstract available

AO N, Du J, Jin S, Suo L, et al
The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease.
Diabetes Obes Metab. 2025;27:457-467.
PubMed Abstract available

HAGGAG AZ, Xu J, Butcher L, Pagnussat S, et al
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Diabetes Obes Metab. 2025;27:551-562.
PubMed Abstract available

January 2025

LEITE NC, Villela-Nogueira CA, Santos LV, Cardoso CRL, et al
Prognostic value of changes in vibration-controlled transient elastography parameters for liver, cardiovascular and mortality outcomes in individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: The Rio de Janeiro
Diabetes Obes Metab. 2025 Jan 16. doi: 10.1111/dom.16195.
PubMed Abstract available

SUN M, Liu Q, Liu Y, Ning N, et al
Baseline and cumulative Chinese visceral adiposity index and diabetic kidney disease: A prospective cohort study.
Diabetes Obes Metab. 2025 Jan 15. doi: 10.1111/dom.16184.
PubMed Abstract available

MATSUBAYASHI Y, Fujihara K, Khin L, Ferreira ED, et al
Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease.
Diabetes Obes Metab. 2025 Jan 15. doi: 10.1111/dom.16196.
PubMed Abstract available

SUZUKI R, Shoji S, Yoshinaga Y, Kosakai Y, et al
Risk of insulin initiation with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A real-world claims database study in Japan.
Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16188.
PubMed Abstract available

WU X, Huang Q, Ding Y, Cao Q, et al
Effect of insulin sensitivity, insulin secretion, and beta cell function on the remission of type 2 diabetes: A post hoc analysis of the IDEATE trial.
Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16180.
PubMed Abstract available

LIN CM, Chen JC, Meyerowitz-Katz G, Huang YN, et al
Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.
Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16191.
PubMed Abstract available

LU W, Xie L, Zhang Y, Gao H, et al
Long-term blood glucose control via glucose-activated transcriptional regulation of insulin analogue in type 1 diabetes mice.
Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16197.
PubMed Abstract available

WANG Y, Lin T, Lu J, He W, et al
Trends and analysis of risk factor differences in the global burden of chronic kidney disease due to type 2 diabetes from 1990 to 2021: A population-based study.
Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16183.
PubMed Abstract available

Correction to "Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study".
Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16204.
PubMed

FIORE V, Carbotta G, Barraco S, Falasca P, et al
Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly).
Diabetes Obes Metab. 2025 Jan 10. doi: 10.1111/dom.16174.
PubMed Abstract available

RUBINO DM, Pedersen SD, Connery L, Cao D, et al
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
Diabetes Obes Metab. 2025 Jan 9. doi: 10.1111/dom.16176.
PubMed Abstract available

TANG C, Hao J, Tao F, Feng Q, et al
Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16192.
PubMed Abstract available

HANSEN AL, Andersen MK, Engelhard LM, Brons C, et al
Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes.
Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16193.
PubMed Abstract available

ALKHUZAM K, Li P, Abuloha S, Xue Q, et al
Long-term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes.
Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16168.
PubMed Abstract available

STICE E, Rohde P, Desjardins CD, Gee K, et al
A preliminary randomized trial of a brief dissonance-based type 2 diabetes prevention programme for adults with pre-diabetes.
Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16170.
PubMed Abstract available

ZHAO J, Sun Z, Li Z, Xu M, et al
MicroRNA-mediated Ets1 repression in retinal endothelial cells: A novel anti-angiogenic mechanism in nonproliferative diabetic retinopathy.
Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16182.
PubMed Abstract available

SON H, Sohn SH, Kim HA, Choe HJ, et al
Real-time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial.
Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16177.
PubMed Abstract available

VERMILLAC G, Lafont C, Godot C, Kerbourc'h S, et al
Paediatric-to-adult transition in type 1 diabetes: A two-centre experience of a structured program, 2014 to 2022.
Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16140.
PubMed Abstract available

CHEN M, Dou C, Ye C, Kong L, et al
Socioeconomic and mental health inequalities in global burden of type 2 diabetes: Evidence from the Global Burden of Disease Study 2021.
Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16173.
PubMed Abstract available

HOPKINS R, Young KG, Thomas NJ, Jones AG, et al
Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study.
Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16163.
PubMed Abstract available

SEUFERT J, Wiesner T, Pegelow K, Kenzler J, et al
Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16161.
PubMed Abstract available

PODOBNIK J, Prentice KJ
Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives.
Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16154.
PubMed Abstract available

KIM MK, Kim J, Park SJ, Song YJ, et al
Impact of caloric restriction on diabetes remission in Korean adults with obesity (CREDO-K study).
Diabetes Obes Metab. 2025 Jan 3. doi: 10.1111/dom.16166.
PubMed

HALLIG SJ, Aalders J, Christensen MH, Andersen MS, et al
The cardio-metabolic protein profile is associated with development of type 2 diabetes at long term follow-up after gestational diabetes mellitus: Results from the OGFUS study.
Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16148.
PubMed Abstract available

AZHAR K, Ramirez-Obermayer A, Sourij C, Knoll L, et al
Sustained weight reduction following 12 weeks of intermittent fasting intervention in people with insulin-treated type 2 diabetes-Two-year follow-up of the randomised controlled InterFast-2 trial.
Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16158.
PubMed

LEE DY, Moon JS, Jung I, Chung SM, et al
Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease.
Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16165.
PubMed Abstract available

SANTOS-BAEZ LS, Diaz-Rizzolo DA, Borhan R, Popp CJ, et al
Predictive models of post-prandial glucose response in persons with prediabetes and early onset type 2 diabetes: A pilot study.
Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16160.
PubMed Abstract available

GROSICKI GJ, Thomas JG, Dhurandhar NV, Lofton H, et al
Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes.
Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16151.
PubMed

LOU Y, Xie Y, Jiang Q, Huang S, et al
The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study.
Diabetes Obes Metab. 2025;27:291-299.
PubMed Abstract available

JIAO R, Lin C, Cai X, Wang J, et al
Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.
Diabetes Obes Metab. 2025;27:259-267.
PubMed Abstract available

December 2024

XIE C, Iroga P, Bound MJ, Grivell J, et al
Impact of the timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes.
Diabetes Obes Metab. 2024 Dec 27. doi: 10.1111/dom.16169.
PubMed

BAECHLE C, Rosenbauer J, Stahl-Pehe A, Seufert J, et al
Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study.
Diabetes Obes Metab. 2024 Dec 27. doi: 10.1111/dom.16149.
PubMed

WONG HJ, Lin NHY, Teo YH, Yeo BSY, et al
Anti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review.
Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16136.
PubMed Abstract available

FUKUNAGA K, Morishita A, Imachi H, Oura K, et al
Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study.
Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16157.
PubMed Abstract available

TAKAHASHI A, Nomoto H, Yokoyama H, Yokozeki K, et al
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel
Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16150.
PubMed Abstract available

BORYSOWSKI J, Klosowska D, Paczek L, Ordak M, et al
Exclusion of older persons from randomized controlled trials in type 2 diabetes: A cross-sectional study.
Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16137.
PubMed Abstract available

XU Z, Wen S, Dong M, Zhou L, et al
Targeting central pathway of Glucose-Dependent Insulinotropic Polypeptide, Glucagon and Glucagon-like Peptide-1 for metabolic regulation in obesity and type 2 diabetes.
Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16146.
PubMed Abstract available

ZHAO X, Xu X, Wang S, Zhang X, et al
Heterogeneous blood pressure treatment effects on cognitive decline in type 2 diabetes: A machine learning analysis of a randomized clinical trial.
Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16145.
PubMed Abstract available

GUO L, Chen L, Zhao F, Liu X, et al
Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.
Diabetes Obes Metab. 2024 Dec 20. doi: 10.1111/dom.16139.
PubMed Abstract available

SOHN M, Park YH, Lim S
Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double-blind, randomized, placebo-controlled trial.
Diabetes Obes Metab. 2024 Dec 20. doi: 10.1111/dom.16131.
PubMed Abstract available

WANG Y, Lu J, Yu J, Ni J, et al
Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes.
Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16143.
PubMed Abstract available

MOURA FA, Kamanu FK, Wiviott SD, Giugliano RP, et al
Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers.
Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16123.
PubMed Abstract available

HERMAN WH, Kuo S, Zhang P
A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was".
Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16124.
PubMed

CHEN L, Wan H, Han J, Yang C, et al
Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study.
Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16144.
PubMed Abstract available

GARGOURI I, Charfi H, Belabed W, Outenah C, et al
Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed 780G according to patient characteristics.
Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16118.
PubMed Abstract available

YANG S, Yuan Y, Zhang B, Wu T, et al
Identification of adipose tissue-derived exosomal microRNA as a novel causal biomarker for cognitive impairment in type 2 diabetes mellitus: Triangulating evidence from Mendelian randomization and multicentre population studies.
Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16121.
PubMed Abstract available

HUANG CC, Hsu RF, Chen WM, Shia BC, et al
Metformin lowers risk of hearing loss and mortality in type 2 diabetes.
Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16128.
PubMed Abstract available

ERWIN AP, Patrie JT, Horton WB
Heart failure phenotypes in people with type 1 diabetes.
Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16133.
PubMed

MOURA FS, Amaral MJM, Lima LCV, Souza M, et al
Prevalence of MASLD in children and adolescents with type 1 diabetes: A meta-analysis.
Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16125.
PubMed

YU YH, Platt RW, Reynier P, Yu OHY, et al
Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population-based cohort study.
Diabetes Obes Metab. 2024 Dec 16. doi: 10.1111/dom.16115.
PubMed Abstract available

SSEMMONDO E, Shah N, Newham M, Rigby A, et al
Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non-insulin therapies-A randomised controlled trial.
Diabetes Obes Metab. 2024 Dec 11. doi: 10.1111/dom.16116.
PubMed Abstract available

WANG Y, Wen Q, Lu Y, Yang J, et al
Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial.
Diabetes Obes Metab. 2024 Dec 9. doi: 10.1111/dom.16111.
PubMed Abstract available

BAEK S, Park J, Chung JY, Kwak SH, et al
Short-term efficacy and safety of metformin in individuals with type 2 diabetes and mild hepatic impairment: A propensity score-matched real-world study.
Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16108.
PubMed

WANG G, Fu J, Li X, Wang J, et al
Comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes mellitus: A network meta-analysis.
Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16114.
PubMed Abstract available

BAO Y, Hu Y, Shi M, Zhao Z, et al
SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.
Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16107.
PubMed Abstract available

LI M, Yu H, Wan S, Hu F, et al
The fibrosis investigating navigator in diabetes (FIND): A tool to predict liver fibrosis risk in subjects with diabetes.
Diabetes Obes Metab. 2024 Dec 5. doi: 10.1111/dom.16109.
PubMed Abstract available

FINKELSTEIN EA, Gardner DS, Tham KW, Gandhi M, et al
Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial.
Diabetes Obes Metab. 2024 Dec 5. doi: 10.1111/dom.16067.
PubMed Abstract available

WANG X, Pei J, Zheng K, Liu M, et al
The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes.
Diabetes Obes Metab. 2024 Dec 3. doi: 10.1111/dom.16112.
PubMed Abstract available

MEULMEESTER FL, van Dijk KW, van Heemst D, Noordam R, et al
Association of a composite trait for anthropometrics, adiposity and energy expenditure with cardiometabolic diseases: An age-stratified cohort and genetic risk score analysis.
Diabetes Obes Metab. 2024;26:5922-5930.
PubMed Abstract available

DUBIN RL, Heymsfield SB, Ravussin E, Greenway FL, et al
Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
Diabetes Obes Metab. 2024;26:5503-5518.
PubMed Abstract available

CHEN C, Liu X, Zhang J, Hu S, et al
Changes in insulin utilization in China from 2020 to 2022.
Diabetes Obes Metab. 2024;26:5681-5689.
PubMed Abstract available

GABE MBN, Fuhr R, Sinn A, Eliasen A, et al
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
Diabetes Obes Metab. 2024;26:5805-5811.
PubMed Abstract available

ZOU Y, Jiang F, Sun C, Zhao C, et al
Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus.
Diabetes Obes Metab. 2024 Dec 1. doi: 10.1111/dom.16080.
PubMed Abstract available

LIU R, Zhang J, Chen S, Xiao Y, et al
Intestinal mucosal immunity and type 1 diabetes: Non-negligible communication between gut and pancreas.
Diabetes Obes Metab. 2024 Dec 1. doi: 10.1111/dom.16101.
PubMed Abstract available

AJJAN RA
The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control.
Diabetes Obes Metab. 2024;26 Suppl 7.
PubMed Abstract available

BENHALIMA K, Yamamoto JM
Use of continuous glucose monitoring and hybrid closed-loop therapy in pregnancy.
Diabetes Obes Metab. 2024;26 Suppl 7:74-91.
PubMed Abstract available

KONG YW, Morrison D, Lu JC, Lee MH, et al
Continuous ketone monitoring: Exciting implications for clinical practice.
Diabetes Obes Metab. 2024;26 Suppl 7.
PubMed Abstract available

ANANDHAKRISHNAN A, Hussain S
Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes.
Diabetes Obes Metab. 2024;26 Suppl 7:27-46.
PubMed Abstract available

November 2024

KRISTENSEN DK, Mose FH, Buus NH, Duus CL, et al
SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: A double-blind, randomized, placebo-controlled crossover trial.
Diabetes Obes Metab. 2024 Nov 29. doi: 10.1111/dom.16097.
PubMed Abstract available

WU A, Pu J, Emery A, Harris SB, et al
Role of the liver in the sustained normalisation of A1c over 2 years following short-term insulin therapy in early type 2 diabetes.
Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16099.
PubMed Abstract available

WANG W, Han Y, Jiang X, Shao J, et al
Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials.
Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16095.
PubMed Abstract available

ARMSTRONG MJ, Okanoue T, Sundby Palle M, Sejling AS, et al
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16065.
PubMed Abstract available

VALE C, Lourenco IM, Jordan G, Golovaty I, et al
Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes.
Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16077.
PubMed Abstract available

ADDALA A, Ritter V, Schneider-Utaka AK, Alamarie SA, et al
Psychosocial outcomes in a diverse sample of youth and their families who initiated continuous glucose monitoring within the first year of type 1 diabetes diagnosis.
Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16093.
PubMed Abstract available

ENG PC, Lee SH, Der Teo AE, Lim DST, et al
Postnatal glycaemic outcomes in women with high-risk gestational diabetes: Identifying key predictors for early intervention.
Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16085.
PubMed Abstract available

LUNDEMOSE SB, McCarthy OM, Christensen MB, Laugesen C, et al
Is low-dose glucagon needed and effective in preventing fasted exercise-induced hypoglycaemia in type 1 diabetes treated with the MiniMed 780G, an automated insulin delivery system?
Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16103.
PubMed Abstract available

WHELEHAN G, Dirks ML, West S, Abdelrahman DR, et al
High-protein vegan and omnivorous diets improve peripheral insulin sensitivity to a similar extent in people with type 2 diabetes.
Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16100.
PubMed Abstract available

UMPIERREZ G, Gill J, Hood D, Li X, et al
Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.
Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16075.
PubMed Abstract available

KASTRATI L, Alvarez-Martinez M, Thomas A, Thevis M, et al
Effect of exercise on plasma insulin levels in individuals with type 1 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16088.
PubMed Abstract available

JIANG Y, Zhu H, Gong F
Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?
Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16106.
PubMed Abstract available

GENG J, Ruan X, Wu X, Chen X, et al
Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease.
Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16087.
PubMed Abstract available

SINGH J, Adel FW, Scott CG, Chen HH, et al
Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.
Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16073.
PubMed Abstract available

DICEMBRINI I, Cavallo G, Ranaldi F, Scoccimarro D, et al
Glycaemic response to pasta from three different wheat varieties in individuals with type 2 diabetes.
Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16082.
PubMed

LIU W, Hu X, Fang Y, Hong S, et al
Development and external validation of an algorithm for self-identification of risk for microvascular complications in patients with type 1 diabetes.
Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16068.
PubMed Abstract available

SHAH R, Finlay AY, Ali FM, Otwombe K, et al
Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross-sectional study.
Diabetes Obes Metab. 2024 Nov 24. doi: 10.1111/dom.16058.
PubMed Abstract available

ZOU Y, Yang Q, Lang Y, Liu K, et al
The prognostic impact of the Stress Hyperglycemia Ratio on End-Stage Renal Disease among patients with Diabetic Kidney Disease.
Diabetes Obes Metab. 2024 Nov 21. doi: 10.1111/dom.16056.
PubMed Abstract available

TYRER F, Gharibzadeh S, Gillies C, Lawson C, et al
Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study.
Diabetes Obes Metab. 2024 Nov 20. doi: 10.1111/dom.16071.
PubMed Abstract available

SRIDHAR VS, Davies MJ, Banks P, Girard M, et al
Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4.
Diabetes Obes Metab. 2024 Nov 20. doi: 10.1111/dom.16079.
PubMed

FU X, Zhao Y, Wu Y, Wen L, et al
Relationship between trajectory of Chinese visceral adiposity index and risk of type 2 diabetes mellitus: Evidence from the China-PAR project.
Diabetes Obes Metab. 2024 Nov 19. doi: 10.1111/dom.16074.
PubMed Abstract available

VAN HECK JIP, Ajie M, Joosten LAB, Tack CJ, et al
Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications.
Diabetes Obes Metab. 2024 Nov 19. doi: 10.1111/dom.16066.
PubMed Abstract available

ZHENG T, Yang R, Li X, Dai Z, et al
Integrative transcriptome analysis reveals Serpine2 promotes glomerular mesangial cell proliferation and extracellular matrix accumulation via activating ERK1/2 signalling pathway in diabetic nephropathy.
Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16069.
PubMed Abstract available

Correction to "Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus".
Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16083.
PubMed

SARABHAI T, Kostev K
Incidence and risk factors of new-onset diabetes mellitus: A five-year follow-up study in solid organ transplant recipients in Germany.
Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16072.
PubMed

GOLUBIC R, Car J, Nicolaides K
Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies.
Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16070.
PubMed

GETHER IM, Andersen ES, Foghsgaard S, Ellegaard AM, et al
Increased gallbladder emptying and reduced GLP-1 response in pregnancy with and without gestational diabetes mellitus.
Diabetes Obes Metab. 2024 Nov 14. doi: 10.1111/dom.16064.
PubMed Abstract available

RODRIGUEZ P, Breslaw N, Xiao H, Bena J, et al
De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
Diabetes Obes Metab. 2024 Nov 12. doi: 10.1111/dom.16057.
PubMed Abstract available

RILEY DR, Henney A, Anson M, Hernadez G, et al
The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes.
Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16059.
PubMed Abstract available

ZHANG Z, Wang Y, Lu J, Zhou J, et al
Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics.
Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16033.
PubMed Abstract available

MAGAGNOLI J, Cummings TH, Hardin JW, Ambati J, et al
Targeting the cholinergic anti-inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study.
Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16060.
PubMed Abstract available

GOLOMB RC, Tittel SR, Welters A, Karges W, et al
Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria.
Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16048.
PubMed Abstract available

MILDER TY, Lin J, Pearson SA, de Oliveira Costa J, et al
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
Diabetes Obes Metab. 2024 Nov 7. doi: 10.1111/dom.16061.
PubMed

GREGORIC N, Sikonja J, Janez A, Jensterle M, et al
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
Diabetes Obes Metab. 2024 Nov 7. doi: 10.1111/dom.16042.
PubMed Abstract available

SMEIJER JD, Gomez MF, Rossing P, Heerspink HJL, et al
The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab. 2024 Nov 6. doi: 10.1111/dom.16041.
PubMed Abstract available

HE B, Lam HS, Qiu X, Shen S, et al
Association and mediation pathways of maternal hyperglycaemia and liability to gestational diabetes with neonatal outcomes: A two-sample Mendelian randomization study.
Diabetes Obes Metab. 2024 Nov 6. doi: 10.1111/dom.16045.
PubMed Abstract available

LEE CH, Lui DT, Mak LY, Fong CH, et al
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study.
Diabetes Obes Metab. 2024 Nov 5. doi: 10.1111/dom.16049.
PubMed Abstract available

WONDIMKUN YA, Caughey GE, Inacio MC, Air T, et al
Glucose-lowering medicines use before and after entry into long-term care facilities.
Diabetes Obes Metab. 2024;26:4966-4975.
PubMed Abstract available

LIU Q, Celis-Morales C, Sattar N, Welsh P, et al
Association of glycaemic control with intraocular pressure in a large general population: Results from the UK Biobank.
Diabetes Obes Metab. 2024;26:5192-5201.
PubMed Abstract available

GENG L, Sun B, Chen Y
A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations.
Diabetes Obes Metab. 2024;26:5376-5389.
PubMed Abstract available

ELHENAWY YI, Abdel Kader MS, Thabet RA
Performance of the MiniMed 780G system on mitigating menstrual cycle-dependent glycaemic variability.
Diabetes Obes Metab. 2024;26:4916-4923.
PubMed Abstract available

FESTA A, Saely CH, Drexel H
Sodium-glucose co-transporter-2 inhibitors: Writing the next chapter of a unique success story.
Diabetes Obes Metab. 2024;26:4816-4819.
PubMed

HAMBLIN PS, Earnest A, Russell AW, Talic S, et al
Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023.
Diabetes Obes Metab. 2024;26:4924-4932.
PubMed Abstract available

FUJIHARA K, Matsubayashi Y, Kitazawa M, Sato T, et al
Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.
Diabetes Obes Metab. 2024;26:5304-5311.
PubMed Abstract available

KNOP FK, Urva S, Rettiganti M, Benson CT, et al
A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy.
Diabetes Obes Metab. 2024;26:5474-5478.
PubMed

GOEAU-BRISSONNIERE M, Rives-Lange C, Phan A, Kourti E, et al
Real-life use of liraglutide 3 mg in obesity management: The SAX-RL study.
Diabetes Obes Metab. 2024;26:5488-5491.
PubMed

KIM TH, Lee K, Park S, Cho H, et al
Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.
Diabetes Obes Metab. 2024;26:5183-5191.
PubMed Abstract available

WHELEHAN G, Bello O, Hakim O, Ladwa M, et al
Ethnic differences in the relationship between ectopic fat deposition and insulin sensitivity in Black African and White European men across a spectrum of glucose tolerance.
Diabetes Obes Metab. 2024;26:5211-5221.
PubMed Abstract available

SHEN TH, Aby ES, Vock D, Farley JF, et al
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.
Diabetes Obes Metab. 2024;26:5116-5125.
PubMed Abstract available

SELBY NM, Taal MW
What every clinician needs to know about chronic kidney disease: Detection, classification and epidemiology.
Diabetes Obes Metab. 2024;26 Suppl 6:3-12.
PubMed Abstract available

BAKRIS G
Mineralocorticoid receptor antagonists and reno-protection: What's the evidence & where do they fit? A guide for non-specialists.
Diabetes Obes Metab. 2024;26 Suppl 6:33-42.
PubMed Abstract available

MAYNE KJ, Hanlon P, Lees JS
Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.
Diabetes Obes Metab. 2024;26 Suppl 6:43-54.
PubMed Abstract available

October 2024

MA J, Dong Y, Liu J, Gao S, et al
The role of GRB2 in diabetes, diabetes complications and related disorders.
Diabetes Obes Metab. 2024 Oct 30. doi: 10.1111/dom.16015.
PubMed Abstract available

DAI N, Su X, Wang Y
Cost-utility analysis of once-weekly insulin icodec and once-daily insulin glargine in patients with type 2 diabetes receiving basal-bolus insulin therapy in China.
Diabetes Obes Metab. 2024 Oct 30. doi: 10.1111/dom.16031.
PubMed Abstract available

YU XF, Lim CED, Chen H
The role of vitamin D in glycaemic control in patients with type 2 diabetes-A pilot D4D trial.
Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16023.
PubMed

PRATTICHIZZO F, Veronesi V, Rigoni M, La Grotta R, et al
Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study.
Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16038.
PubMed Abstract available

HTUN HL, Lian W, Phua HP, Lim MY, et al
Visit-to-visit HbA1c variability and risk of potentially avoidable hospitalisations in adults with type 2 diabetes receiving outpatient care at a tertiary hospital.
Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16026.
PubMed Abstract available

WASEHUUS V, Rotbain Curovic V, Tofte N, Lindhardt M, et al
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.
Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16037.
PubMed Abstract available

ISMAIL HM, Liu J, Netherland M Jr, Hasan NA, et al
Safety and effects of acetylated and butyrylated high-amylose maize starch on youths recently diagnosed with type 1 diabetes: A pilot study.
Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16039.
PubMed

DONG Q, Xi Y, Brandmaier S, Fuchs M, et al
Subphenotypes of adult-onset diabetes: Data-driven clustering in the population-based KORA cohort.
Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16022.
PubMed Abstract available

HORIKAWA C, Takahara M, Katakami N, Takeda Y, et al
Dietary potassium intake and its interaction with sodium intake on risk of developing cardiovascular disease in persons with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study (JDCP study 12).
Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16035.
PubMed Abstract available

ANDERSEN LL, Calatayud J, Nunez-Cortes R, Polo-Lopez A, et al
Graded association of muscle strength with all-cause and cause-specific mortality in older adults with diabetes: Prospective cohort study across 28 countries.
Diabetes Obes Metab. 2024 Oct 23. doi: 10.1111/dom.16019.
PubMed Abstract available

QIAN XX
BreathSpec holds potential suitability for real-time detection of halitosis-associated volatile organic compounds in diabetes and other diseases.
Diabetes Obes Metab. 2024 Oct 22. doi: 10.1111/dom.16032.
PubMed

DAI J, Chang J, Choi JM, Bullock A, et al
Trends in anti-diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009-2013.
Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16021.
PubMed Abstract available

FAN X, Liu Y, Chen X, Xu Y, et al
Synergies between diabetes and hyperhomocysteinaemia: New insights to predict and prevent adverse cardiovascular effects.
Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.15947.
PubMed Abstract available

FRIIS BRYDE NIELSEN C, Moller Thysen S, Bach Kampmann F, Hansen TW, et al
The associations between functional vitamin K status and all-cause mortality, cardiovascular disease and end-stage kidney disease in persons with type 1 diabetes.
Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16025.
PubMed Abstract available

CARLSSON LMS, Carlsson B, Jacobson P, Andersson-Assarsson JC, et al
Association between delay in diabetes development and mortality in people with obesity: Up to 33 years follow-up of the prospective Swedish Obese Subjects study.
Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16010.
PubMed Abstract available

GAO L, Bian F, Pan T, Jiang H, et al
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial.
Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16014.
PubMed Abstract available

ZHANG L, Shen Y, Liu H, Li W, et al
Body mass index trajectories and time in target range after delivery and long-term type 2 diabetes risk in women with a history of gestational diabetes mellitus.
Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16020.
PubMed Abstract available

CHENG YW, Chan YH, Chuang C, Chen SW, et al
Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium-glucose cotransporter-2 inhibitor therapy: A multicentre database analysis in Taiwan.
Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16011.
PubMed Abstract available

CHEN HL, Wang IT, Tsai YW, Lee YH, et al
Superior benefits of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors for diabetic kidney disease: A cohort study.
Diabetes Obes Metab. 2024 Oct 18. doi: 10.1111/dom.15998.
PubMed Abstract available

GOURDY P, Bonadonna RC, Mauricio D, Muller-Wieland D, et al
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive individuals according to diabetes duration: Results from the REALI European pooled data analysis.
Diabetes Obes Metab. 2024 Oct 17. doi: 10.1111/dom.16008.
PubMed Abstract available

RODRIGO-CARBO C, Madinaveitia-Nisarre L, Perez-Calahorra S, Gracia-Rubio I, et al
Low-calorie, high-protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity.
Diabetes Obes Metab. 2024 Oct 17. doi: 10.1111/dom.16013.
PubMed Abstract available

AMIN NB, Frederich R, Tsamandouras N, Haggag AZ, et al
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
Diabetes Obes Metab. 2024 Oct 16. doi: 10.1111/dom.16005.
PubMed Abstract available

LIU M, Pei J, Zeng C, Xin Y, et al
Association of non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus: Evidence from the ACCORD cohort.
Diabetes Obes Metab. 2024 Oct 16. doi: 10.1111/dom.16018.
PubMed Abstract available

ROTBAIN CUROVIC V, Stougaard EB, Hansen TW
Slowing the progression of diabetic and non-diabetic kidney disease: A summary of the current evidence base for sodium-glucose co-transporter-2 inhibitors.
Diabetes Obes Metab. 2024 Oct 15. doi: 10.1111/dom.16007.
PubMed Abstract available

OSTROMINSKI JW, Cho SMJ, Vaduganathan M, Honigberg MC, et al
Cause-specific death in adults with type 1 diabetes and type 2 diabetes: Insights from the UK Biobank.
Diabetes Obes Metab. 2024 Oct 14. doi: 10.1111/dom.16009.
PubMed

DOVER AR, Wright RJ, Forbes S, Strachan MWJ, et al
Change in glycated haemoglobin in adults with type 2 diabetes on basal-bolus insulin regimens following commencement of Freestyle Libre use.
Diabetes Obes Metab. 2024 Oct 10. doi: 10.1111/dom.16003.
PubMed

DICKER D, Pinto D, Reges O
Metformin continuation post-metabolic bariatric surgery and relapse of diabetes.
Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15962.
PubMed Abstract available

BELL DSH, Jerkins T
Diabetic Charcot neuroarthropathy: A threat to both limb and life.
Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15994.
PubMed Abstract available

DAVIS GM, Peters AL, Bode BW, Carlson AL, et al
Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod(R) 5 automated insulin delivery system.
Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15993.
PubMed Abstract available

ZHENG C, Wu J, Li N, Wei X, et al
Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States.
Diabetes Obes Metab. 2024 Oct 8. doi: 10.1111/dom.15997.
PubMed Abstract available

HONG JH, Kim MJ, Min KW, Won JC, et al
Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.
Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15985.
PubMed Abstract available

KONG X, Wang W
Prevalence of individuals with diabetes and chronic kidney disease indicated for finerenone treatment in the United States: A National Health and Nutrition Examination Survey-based estimation.
Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.16006.
PubMed

HERMANNS N, Ehrmann D, Kulzer B, Klinker L, et al
Somatic and mental symptoms associated with dysglycaemia, diabetes-related complications and mental conditions in people with diabetes: Assessments in daily life using continuous glucose monitoring and ecological momentary assessment.
Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15983.
PubMed Abstract available

KARAKUS KE, Mason E, Akturk HK
Long-term glycaemic improvement with the initiation of an automated insulin delivery system in insulin pump-naive older adults with type 1 diabetes.
Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15996.
PubMed

ZHU Y, Liu J, Wang B
Integrated approach of machine learning, Mendelian randomization and experimental validation for biomarker discovery in diabetic nephropathy.
Diabetes Obes Metab. 2024 Oct 6. doi: 10.1111/dom.15933.
PubMed Abstract available

WONG BWX, Tan DYZ, Li LJ, Yong EL, et al
Individual and combined effects of muscle strength and visceral adiposity on incident prediabetes and type 2 diabetes in a longitudinal cohort of midlife Asian women.
Diabetes Obes Metab. 2024 Oct 4. doi: 10.1111/dom.15995.
PubMed Abstract available

YUAN X, Li D, Wang K, Lauand F, et al
iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study.
Diabetes Obes Metab. 2024 Oct 3. doi: 10.1111/dom.15968.
PubMed Abstract available

SOURIJ H, Azhar K, Aziz F, Kojzar H, et al
Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care - The countrywide cross-sectional AUSTRO-PROFIT study.
Diabetes Obes Metab. 2024 Oct 3. doi: 10.1111/dom.15988.
PubMed Abstract available

CHEN W, Liu L, Hu F
Efficacy of vitamin D supplementation on glycaemic control in type 2 diabetes: An updated systematic review and meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2024 Oct 2. doi: 10.1111/dom.15941.
PubMed Abstract available

LE TN, Bright R, Truong VK, Li J, et al
Key biomarkers in type 2 diabetes patients: A systematic review.
Diabetes Obes Metab. 2024 Oct 2. doi: 10.1111/dom.15991.
PubMed Abstract available

BANO A, Kunzler J, Wehrli F, Kastrati L, et al
Clinical evidence for high-risk CE-marked medical devices for glucose management: A systematic review and meta-analysis.
Diabetes Obes Metab. 2024;26:4753-4766.
PubMed Abstract available

CZUPRYNIAK L, Mosenzon O, Rychlik I, Clodi M, et al
Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.
Diabetes Obes Metab. 2024;26:4165-4177.
PubMed Abstract available

LI T, Sang M, Wang J, Sun Z, et al
Dark tea consumption is associated with a reduced risk of dysglycaemia and increased urinary glucose and sodium excretion in Chinese adults.
Diabetes Obes Metab. 2024;26:4705-4712.
PubMed Abstract available

KASSEM S, Khalaila B, Stein N, Saliba W, et al
Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data.
Diabetes Obes Metab. 2024;26:4646-4652.
PubMed Abstract available

HASHIMOTO H, Satoh M, Nakayama S, Toyama M, et al
Comparison of renal prognosis between dipeptidyl peptidase-4 inhibitor users and non-users.
Diabetes Obes Metab. 2024;26:4460-4467.
PubMed Abstract available

LU Y, Tang H, Kotecha P, Cho H, et al
Newer glucose-lowering drugs and risk of suicidal ideation and behaviours: A network meta-analysis of randomized outcome trials.
Diabetes Obes Metab. 2024;26:4783-4786.
PubMed

JIMBA T, Kaneko H, Azegami T, Suzuki Y, et al
Body weight change associated kidney outcomes of sodium-glucose cotransporter new users.
Diabetes Obes Metab. 2024;26:4535-4543.
PubMed Abstract available

FORST T, De Block C, Del Prato S, Armani S, et al
The role of incretin receptor agonists in the treatment of obesity.
Diabetes Obes Metab. 2024;26:4178-4196.
PubMed Abstract available

HUANG P, Zhu Y, Qin J
Research advances in understanding crosstalk between organs and pancreatic beta-cell dysfunction.
Diabetes Obes Metab. 2024;26:4147-4164.
PubMed Abstract available

JOHNSON CE, Sussman WB, Weeda ER
Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis.
Diabetes Obes Metab. 2024;26:4544-4550.
PubMed Abstract available

PATEL PM, Thomas D, Liu Z, Aldrich-Renner S, et al
Systematic review of disparities in continuous glucose monitoring and insulin pump utilization in the United States: Key themes and evidentiary gaps.
Diabetes Obes Metab. 2024;26:4293-4301.
PubMed Abstract available

TKAC I, Kozarova M, Stancakova Yaluri A, Javorsky M, et al
Treatment with sodium-glucose cotransporter 2 inhibitors and risk of lower-limb amputations.
Diabetes Obes Metab. 2024;26:4803-4805.
PubMed

NAGENDRA L, Dutta D, Kamrul-Hasan ABM
Bariatric surgery and tirzepatide-Friends, not foes!
Diabetes Obes Metab. 2024;26:4806.
PubMed

MATTHEWS DR
Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes.
Diabetes Obes Metab. 2024;26 Suppl 5:3-4.
PubMed

NYSTROM T
Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk.
Diabetes Obes Metab. 2024;26 Suppl 5:35-57.
PubMed Abstract available

LI S, Yang B, Shang S, Jiang W, et al
Association of hypertension and long-term blood pressure changes with new-onset diabetes in the elderly: A 10-year cohort study.
Diabetes Obes Metab. 2024 Oct 1. doi: 10.1111/dom.15986.
PubMed Abstract available

September 2024

KHIAR H, Leveque E, Lopez AG, Moreau-Grange L, et al
Serum levels of the incretin-like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa-Ba-S study.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15871.
PubMed Abstract available

IWAMOTO Y, Kimura T, Dan K, Iwamoto H, et al
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic beta-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15972.
PubMed Abstract available

HANNAH K, Nemlekar P, Bushman JS, Norman GJ, et al
Risk of hypoglycaemia among people with type 2 diabetes not treated with insulin: A retrospective analysis of Medicare Advantage beneficiaries.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15982.
PubMed Abstract available

LI H, Su W, Zheng Z, Li J, et al
The coexistence of low muscle mass and obesity evaluated by dual energy X-ray absorptiometry, rather than low muscle mass or obesity alone, is associated with macrovascular but not microvascular complications in patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15978.
PubMed Abstract available

DYER BP, Burton C, Rathod-Mistry T, Blagojevic-Bucknall M, et al
Are patients with newly diagnosed frozen shoulder more likely to be diagnosed with type 2 diabetes? A cohort study in UK electronic health records.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15965.
PubMed Abstract available

SADEGHI S, Hosseinpanah F, Khalaj A, Ebadinejad A, et al
Remission and relapse of diabetes after sleeve gastrectomy and one-anastomosis gastric bypass: The Tehran Obesity Treatment Study.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15974.
PubMed Abstract available

HU S, Wang S, Gu S, Qi C, et al
Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15973.
PubMed Abstract available

SHAN S, Luo Z, Yao L, Zhou J, et al
Cross-country inequalities in disease burden and care quality of chronic kidney disease due to type 2 diabetes mellitus, 1990-2021: Findings from the global burden of disease study 2021.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15969.
PubMed Abstract available

KARAKASIS P, Koufakis T, Patoulias D, Barkas F, et al
Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15979.
PubMed Abstract available

LI P, Spector E, Alkhuzam K, Patel R, et al
Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15987.
PubMed Abstract available

MAFFEIS C, Piona C, Morandi A, Marigliano M, et al
Glycaemic control metrics and metabolic dysfunction-associated steatotic liver disease in children and adolescents with type 1 diabetes.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15961.
PubMed Abstract available

GROBMAN B, Mansur A, Lu CY
Disparities in suicide rates among patients with diabetes in the United States.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15989.
PubMed

JIANG H, Zhang K, Zhang X
Mendelian randomization analysis of the association between childhood overweight or obesity and gestational diabetes mellitus.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15975.
PubMed Abstract available

WATADA H, Asbjornsdottir B, Nishida T, Nishimura R, et al
Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15960.
PubMed Abstract available

MARUYAMA-SAKURAI K, Tachimori H, Saito E, Kohsaka S, et al
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15832.
PubMed Abstract available

KIILAVUORI M, Varimo T, Tuomaala AK, Pulkkinen MA, et al
Children and adolescent with suboptimal control of type 1 diabetes improve during the first 2 years on automated insulin delivery system.
Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15992.
PubMed Abstract available

LI J, Cui HL, Xie DD, Wang QY, et al
Global and regional estimates of hip fracture burden associated with type 1 diabetes from 1990 to 2021.
Diabetes Obes Metab. 2024 Sep 26. doi: 10.1111/dom.15970.
PubMed Abstract available

CASTANEDA J, de Galan BE, van Kuijk SMJ, Arrieta A, et al
The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery.
Diabetes Obes Metab. 2024 Sep 26. doi: 10.1111/dom.15955.
PubMed Abstract available

ELKABBANY ZA, Ismail EAR, Hamed ET, Elbarbary NS, et al
The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: A randomized controlled trial.
Diabetes Obes Metab. 2024 Sep 24. doi: 10.1111/dom.15958.
PubMed Abstract available

REN Q, Li L, Su X, Hu X, et al
Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.
Diabetes Obes Metab. 2024 Sep 23. doi: 10.1111/dom.15915.
PubMed Abstract available

REIS-BARBOSA PH, Aguila MB, Mandarim-de-Lacerda CA
Tirzepatide, a dual receptor agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, enhances beta-cell survival and maintenance markers in obese diabetic ovariectomized mice.
Diabetes Obes Metab. 2024 Sep 22. doi: 10.1111/dom.15937.
PubMed

RAZAGHIZAD A, Ni J, Marques P, Mavrakanas TA, et al
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15768.
PubMed Abstract available

MACLEISH SA, Hood KK, Polonsky WH, Wood JR, et al
Psychosocial outcomes with the Omnipod(R) 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.
Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15906.
PubMed Abstract available

LIU Y, Chen Y, Lam SHM, Huang B, et al
Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: A report from the GLORIA-AF registry phase III.
Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15950.
PubMed Abstract available

HENNIES N, Gorgens SW, Killer J, Otto T, et al
Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study.
Diabetes Obes Metab. 2024 Sep 19. doi: 10.1111/dom.15931.
PubMed Abstract available

STENBERG E, Cao Y, Ottosson J, Hedberg S, et al
Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.
Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15952.
PubMed Abstract available

WIEGAND S, Becker M, Schmid S, Weghuber D, et al
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German-speaking countries: Analysis based on the Diabetes Prospective Follow-up Registry.
Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15930.
PubMed

ZHANG TY, Zhang ZM, Wang XN, Kuang HY, et al
Relationship between weight-adjusted-waist index and all-cause and cardiovascular mortality in individuals with type 2 diabetes.
Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15929.
PubMed Abstract available

NICOLIER C, Kunzler J, Lizoain A, Kerber D, et al
Detection of hypoglycaemia in type 1 diabetes through breath volatile organic compound profiling using gas chromatography-ion mobility spectrometry.
Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15944.
PubMed Abstract available

POTTEGARD A, Andersen JH, Sondergaard J, Rasmussen L, et al
Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies.
Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15912.
PubMed Abstract available

JI L, Lu Y, Shen Z, Hu P, et al
Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15888.
PubMed Abstract available

TABESH M, Sacre JW, Mehta K, Chen L, et al
The association of glycaemic risk factors and diabetes duration with risk of heart failure in people with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Sep 13. doi: 10.1111/dom.15938.
PubMed Abstract available

GARG SK, Hirsch IB, Repetto E, Snell-Bergeon J, et al
Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis.
Diabetes Obes Metab. 2024 Sep 12. doi: 10.1111/dom.15866.
PubMed Abstract available

LUNDHOLM MD, Kirschling S, Hu B, Aminian A, et al
Long-term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction-associated fatty liver disease in adults with obesity and type 2 diabetes.
Diabetes Obes Metab. 2024 Sep 12. doi: 10.1111/dom.15932.
PubMed

GUO J, Tang H, Shao H, Lu Y, et al
Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.
Diabetes Obes Metab. 2024 Sep 10. doi: 10.1111/dom.15943.
PubMed Abstract available

PIKKEMAAT M, Woodward M, Af Geijerstam P, Harrap S, et al
Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study.
Diabetes Obes Metab. 2024 Sep 10. doi: 10.1111/dom.15935.
PubMed Abstract available

LONG W, Light PE, Simpson SH
Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study.
Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15917.
PubMed Abstract available

KELLY MS, Scopelliti EM, Goodson KE, Lo CMA, et al
Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15934.
PubMed Abstract available

PAI YW, Chen IC, Lin JF, Chen XH, et al
Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15918.
PubMed Abstract available

MAYER CS, Fontelo P
Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.
Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15911.
PubMed Abstract available

HALUZIK M, Al-Sofiani ME, Cheng AYY, Lauand F, et al
Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
Diabetes Obes Metab. 2024 Sep 8. doi: 10.1111/dom.15811.
PubMed Abstract available

PUNTHAKEE Z, Hall S, McInnes N, Sherifali D, et al
Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
Diabetes Obes Metab. 2024 Sep 6. doi: 10.1111/dom.15926.
PubMed Abstract available

WANG S, Song S, Gao J, Duo Y, et al
Glycated haemoglobin variability and risk of renal function decline in type 2 diabetes mellitus: An updated systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15861.
PubMed Abstract available

VAN DEN HEUVEL T, Castaneda J, Arrieta A, Voelker B, et al
Generating real-world evidence on diabetes technology using the CareLink Personal data management system.
Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15868.
PubMed Abstract available

CHEN MD, Deng CF, Chen PF, Li A, et al
Non-invasive metabolic biomarkers in initial cognitive impairment in patients with diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15916.
PubMed Abstract available

VAN HULTEN V, Driessen JHM, Andersen S, Kvist A, et al
Fracture risk revisited: Bone mineral density T-score and fracture risk in type 2 diabetes.
Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15890.
PubMed Abstract available

FU L, Cheng H, Xiong J, Xiao P, et al
Mediating role of inflammatory biomarkers in the causal effect of body composition on glycaemic traits and type 2 diabetes.
Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15923.
PubMed Abstract available

MEHROTRA-VARMA S, Lu JY, Boparai MS, Henry S, et al
Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID-19: Up to 40 months' follow-up.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15900.
PubMed Abstract available

ARAI T, Atsukawa M, Tsubota A, Oikawa T, et al
Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15898.
PubMed Abstract available

VAN HULTEN V, Souverein PC, Starup-Linde J, Viggers R, et al
The association of type 2 diabetes-related characteristics with fracture risk at different sites.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15884.
PubMed Abstract available

JEONG IK, Choi KM, Han KA, Kim KA, et al
Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15838.
PubMed Abstract available

KAFAI YAHYAVI S, Kristensen PL, Hjorthoj C, Hansen KB, et al
The use of composite endpoints in cardiovascular outcome trials for diabetes: A review of 22 randomized clinical trials published since 2008.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15907.
PubMed Abstract available

BASU A, Montano-Campos F, Huang ES, Laiteerapong N, et al
Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15878.
PubMed Abstract available

GIUGLIANO D, Esposito K, De Nicola L
Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15892.
PubMed

SRIDHAR VS, Cosentino F, Dagogo-Jack S, McGuire DK, et al
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15895.
PubMed Abstract available

LIANG G, Lai M, Wang Y, Li N, et al
Decreased complexity of glucose time series index associated with adverse pregnancy outcomes in gestational diabetes mellitus.
Diabetes Obes Metab. 2024;26:3587-3596.
PubMed Abstract available

RASMUSSEN DGK, Hansen MK, Frederiksen P, Luo Y, et al
Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.
Diabetes Obes Metab. 2024;26:4060-4068.
PubMed Abstract available

PALMIOTTI A, Berk KA, Koehorst M, Hovingh MV, et al
Reversal of insulin resistance in people with obesity by lifestyle-induced weight loss does not impact the proportion of circulating 12alpha-hydroxylated bile acids.
Diabetes Obes Metab. 2024;26:4019-4029.
PubMed Abstract available

CARDOZA K, Kang A, Smyth B, Yi TW, et al
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
Diabetes Obes Metab. 2024;26:3530-3540.
PubMed Abstract available

PELEKANOU C, Anastasiou CA, Mavrogianni C, Cardon G, et al
Physical activity in relation to metabolic health and obesity: The Feel4Diabetes study.
Diabetes Obes Metab. 2024;26:3705-3714.
PubMed Abstract available

XUAN X, Zhang Y, Song Y, Zhang B, et al
Role of protein arginine methyltransferase 1 in obesity-related metabolic disorders: Research progress and implications.
Diabetes Obes Metab. 2024;26:3491-3500.
PubMed Abstract available

DASH S
Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.
Diabetes Obes Metab. 2024;26 Suppl 4:3-15.
PubMed Abstract available

NEELAND IJ, Linge J, Birkenfeld AL
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
Diabetes Obes Metab. 2024;26 Suppl 4:16-27.
PubMed Abstract available

August 2024

LIARAKOS AL, Crabtree TSJ, Wilmot EG
Patient-reported outcomes in studies of diabetes technology: What matters.
Diabetes Obes Metab. 2024 Aug 31. doi: 10.1111/dom.15858.
PubMed Abstract available

LASSEN MCH, Johansen ND, Modin D, Catarig AM, et al
Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.
Diabetes Obes Metab. 2024 Aug 31. doi: 10.1111/dom.15872.
PubMed Abstract available

YEN YH, Yen FS, Ko FS, Wei JC, et al
Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan.
Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15908.
PubMed Abstract available

XU W, Wang Y, Tanuseputro P, Lam CLK, et al
Optimizing physician-encounter frequency for type 2 diabetes patients in primary care based on cardiovascular risk assessment: A target trial emulation study.
Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15899.
PubMed Abstract available

DAVIDSON MB
Glycaemic treatment of newly diagnosed type 2 diabetes.
Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15904.
PubMed

HIRSCH IB, Parkin CG, Cavaiola TS, Bergenstal RM, et al
Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes.
Diabetes Obes Metab. 2024 Aug 28. doi: 10.1111/dom.15883.
PubMed Abstract available

STEENACKERS N, Sparso T, Charleer S, De Block C, et al
Health-related quality of life of people with type 1 diabetes: An IMI2 SOPHIA post hoc analysis of FUTURE and ADJUNCT-ONE.
Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15886.
PubMed Abstract available

SHARMA A, Mariam A, Zacherle E, Milinovich A, et al
Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.
Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15896.
PubMed Abstract available

JIANG L, Lai J, Xu X, Lu Y, et al
Reduced insulin clearance in paediatric metabolic (dysfunction)-associated fatty liver disease and its dual role in beta-cell offload and diabetes risk.
Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15902.
PubMed Abstract available

AO Y, Ye H, Liu X, Li Y, et al
Fish oil supplementation in relation to the risk of chronic kidney disease among patients with diabetes.
Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15880.
PubMed Abstract available

DEJGAARD TF, Frandsen CS, Kielgast U, Storling J, et al
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15889.
PubMed Abstract available

TANDAY N, Zhu W, Tarasov AI, Flatt PR, et al
[P(3)]PP, a stable, long-acting pancreatic polypeptide analogue, evokes weight lowering and pancreatic beta-cell-protective effects in obesity-associated diabetes.
Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15897.
PubMed Abstract available

WANG J, Yang J, Jiang W, Liu W, et al
Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15860.
PubMed Abstract available

HUANG YN, Liao WL, Huang JY, Lin YJ, et al
Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
Diabetes Obes Metab. 2024 Aug 22. doi: 10.1111/dom.15869.
PubMed Abstract available

THABIT H, Rubio J, Karuppan M, Mubita W, et al
Use of real-time continuous glucose monitoring in non-critical care insulin-treated inpatients under non-diabetes speciality teams in hospital: A pilot randomized controlled study.
Diabetes Obes Metab. 2024 Aug 21. doi: 10.1111/dom.15885.
PubMed

ZHOU Y, Liu S, Zhang Q, Zhang S, et al
Bidirectional association between type 2 diabetes and irritable bowel syndrome: A large-scale prospective cohort study.
Diabetes Obes Metab. 2024 Aug 20. doi: 10.1111/dom.15852.
PubMed Abstract available

RASMUSSEN L, Andersen JH, Karlstad O, Giunta DH, et al
Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.
Diabetes Obes Metab. 2024 Aug 20. doi: 10.1111/dom.15876.
PubMed

SAETANG T, Greeviroj P, Thavaraputta S, Santisitthanon P, et al
The effectiveness of telemonitoring and integrated personalized diabetes management in people with insulin-treated type 2 diabetes mellitus.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15870.
PubMed Abstract available

GAN X, Ye Z, Zhang Y, He P, et al
Sweetened beverages and atrial fibrillation in people with prediabetes or diabetes.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15859.
PubMed Abstract available

HORTON WB, Dart ME, Kavuru VS, Girton MR, et al
Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost-effectiveness analysis.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15873.
PubMed

WANG Y, Chin WY, Lam CLK, Wan EYF, et al
Trajectory of haemoglobin A1c and incidence of cardiovascular disease in patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15856.
PubMed Abstract available

FARZANBAKHSH S, Amini MR, Madani H, Sadri B, et al
Safety evaluation of bi-layered allogenic keratinocyte and fibroblast skin substitute for diabetic foot ulcers-SAFESKIN-DFU: A Phase 1 clinical trial.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15843.
PubMed Abstract available

ASTBURY NM
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15855.
PubMed Abstract available

JI L, Gao L, Feng Z, Chen G, et al
The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15862.
PubMed

MU Y
The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15857.
PubMed

INOUE M, Sakanaka A, Katakami N, Furuno M, et al
Periodontal tissue susceptibility to glycaemic control in type 2 diabetes.
Diabetes Obes Metab. 2024 Aug 14. doi: 10.1111/dom.15835.
PubMed Abstract available

RITTENHOUSE BE, Alolayan S, Eguale T, Segal AR, et al
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was.
Diabetes Obes Metab. 2024 Aug 14. doi: 10.1111/dom.15851.
PubMed Abstract available

CHEN TY, Lee HF, Chan YH, Chuang C, et al
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium-glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching National Cohort Study.
Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15804.
PubMed Abstract available

KOTECHA P, Chen W, Donahoo WT, Jaffee M, et al
Continuous glucose monitoring and all-cause mortality in insulin-using population with diabetes and cognitive impairment.
Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15842.
PubMed

TSABAN G, Aharon-Hananel G, Shalem S, Zelicha H, et al
The effect of Mankai plant consumption on postprandial glycaemic response among patients with type 2 diabetes: A randomized crossover trial.
Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15840.
PubMed Abstract available

BOLDUC ME, Potter KJ, Olmos M, Bonhoure A, et al
Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance.
Diabetes Obes Metab. 2024 Aug 9. doi: 10.1111/dom.15844.
PubMed Abstract available

YALE JF, Major-Pedersen A, Catarig AM, Jain R, et al
Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.
Diabetes Obes Metab. 2024 Aug 8. doi: 10.1111/dom.15794.
PubMed Abstract available

GOLL N, Moszka N, Kantartzis K, Preissl H, et al
Oxytocin does not acutely improve glucose tolerance in men with type 2 diabetes.
Diabetes Obes Metab. 2024 Aug 8. doi: 10.1111/dom.15812.
PubMed Abstract available

REIS-BARBOSA PH, Marcondes-de-Castro I, Marinho TS, Aguila MB, et al
The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15820.
PubMed Abstract available

CHU L, Bradley RM, Auerbach P, Abitbol A, et al
Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor:
Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15834.
PubMed Abstract available

WANG Z, Lu J
Adapting study designs of Mendelian randomization for disease complications: Insights from type 1 diabetes complications research.
Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15813.
PubMed

ANDERSEN G, Eloy R, Heise T, Gaudier M, et al
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.
Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15827.
PubMed Abstract available

WAN EYF, Wong ZCT, Yan VKC, Chui CSL, et al
Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15830.
PubMed Abstract available

HENNEY AE, Riley DR, Heague M, Hydes TJ, et al
Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.
Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15833.
PubMed Abstract available

HOLMAN N, Young B, Gregg EW, Wareham N, et al
Trends in hospitalization for cardio-renal disease and mortality in people with type 1 diabetes in England, 2009-2019.
Diabetes Obes Metab. 2024 Aug 5. doi: 10.1111/dom.15783.
PubMed Abstract available

MAJIC TENGG A, Cigrovski Berkovic M
Immune checkpoint inhibitor-induced diabetes: Twists and turns of diabetology.
Diabetes Obes Metab. 2024 Aug 2. doi: 10.1111/dom.15848.
PubMed

BABA Y, Watanabe S, Hayashi S, Sakai T, et al
Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2024 Aug 2. doi: 10.1111/dom.15823.
PubMed

DAVIDSON MB, Davidson SJ
Real-world evidence for computerized insulin dose-adjustment algorithms in the effective use of continuous glucose monitoring by primary care clinicians.
Diabetes Obes Metab. 2024;26:3475-3477.
PubMed

XIE P, Abildlund MT, Baekdal TA, He X, et al
A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
Diabetes Obes Metab. 2024;26:3068-3077.
PubMed Abstract available

TANGRI N, Ferguson TW, Bamforth RJ, Leon SJ, et al
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab. 2024;26:3371-3380.
PubMed Abstract available

CHEUNG JTK, Yang A, Wu H, Lau ESH, et al
Association of dipeptidyl peptidase-4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability.
Diabetes Obes Metab. 2024;26:3339-3351.
PubMed Abstract available

RIESTER MR, Zullo AR, Joshi R, Daiello LA, et al
Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
Diabetes Obes Metab. 2024;26:3403-3417.
PubMed Abstract available

MOHAMMEDI K, Hess S, McQueen M, Pigeyre M, et al
Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trial.
Diabetes Obes Metab. 2024;26:3272-3280.
PubMed Abstract available

HAKARIYA H, Ohnishi M, Tanimoto T
Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
Diabetes Obes Metab. 2024;26:3006-3008.
PubMed

KLONOFF DC, Kim SH, Galindo RJ, Joseph JI, et al
Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
Diabetes Obes Metab. 2024;26:3128-3136.
PubMed Abstract available

CEFALO CMA, Riccio A, Succurro E, Marini MA, et al
Frequency of prediabetes in individuals with increased adiposity and metabolically healthy or unhealthy phenotypes.
Diabetes Obes Metab. 2024;26:3191-3199.
PubMed Abstract available

JONES KL, Marathe CS, Wu T, Rayner CK, et al
Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure.
Diabetes Obes Metab. 2024;26:3003-3005.
PubMed

ASLAM A, Chapman A, Urwin A, Ohol S, et al
Real-world data from first UK Omnipod 5 users: A single-centre observational study.
Diabetes Obes Metab. 2024;26:3462-3465.
PubMed

DIMAKOS J, Cui Y, Platt RW, Renoux C, et al
Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population-based cohort study.
Diabetes Obes Metab. 2024;26:3088-3098.
PubMed Abstract available

BERGENSTAL RM, Philis-Tsimikas A, Wysham C, Carr MC, et al
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
Diabetes Obes Metab. 2024;26:3020-3030.
PubMed Abstract available

SILVERII GA
Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes.
Diabetes Obes Metab. 2024;26 Suppl 3:42-54.
PubMed Abstract available

SOLINI A, Trico D
Clinical efficacy and cost-effectiveness of metformin in different patient populations: A narrative review of real-world evidence.
Diabetes Obes Metab. 2024;26 Suppl 3:20-30.
PubMed Abstract available

July 2024

OULHAJ A, Aziz F, Suliman A, Eller K, et al
Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
Diabetes Obes Metab. 2024 Jul 31. doi: 10.1111/dom.15817.
PubMed Abstract available

CHEN L, Wen B, Liu H, Wu H, et al
Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study.
Diabetes Obes Metab. 2024 Jul 29. doi: 10.1111/dom.15814.
PubMed Abstract available

BAK JCG, de Vries SAG, Serne EH, Groenwold RHH, et al
Mortality patterns in Dutch diabetes outpatients.
Diabetes Obes Metab. 2024 Jul 29. doi: 10.1111/dom.15750.
PubMed Abstract available

MOURA FA, Bellavia A, Berg DD, Melloni GEM, et al
Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy.
Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15798.
PubMed Abstract available

SOLIMAN Y, Everett K, Shulman R, Austin PC, et al
Persistent disparities in insulin pump uptake despite a universal pump programme for type 1 diabetes in Ontario, Canada.
Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15799.
PubMed Abstract available

ZHENG K, Azhie A, You X, Naghibzadeh M, et al
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.
Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15769.
PubMed Abstract available

PARK S, Ballreich J, Ward T, Shi L, et al
Cost-effectiveness analysis of a digital diabetes-prevention programme versus an in-person diabetes-prevention programme in people with prediabetes in the United States.
Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15807.
PubMed Abstract available

CHERUBINI V, Mozzillo E, Iafusco D, Bonfanti R, et al
Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy.
Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15779.
PubMed Abstract available

KWAK SH, Han KA, Kim ES, Choi SH, et al
Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.
Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15738.
PubMed Abstract available

CHAUDHRY K, Karalliedde J
Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial.
Diabetes Obes Metab. 2024 Jul 23. doi: 10.1111/dom.15765.
PubMed Abstract available

SHAMIM MA, Patil AN, Amin U, Roy T, et al
Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
Diabetes Obes Metab. 2024 Jul 23. doi: 10.1111/dom.15777.
PubMed Abstract available

IWAMOTO H, Kimura T, Fushimi Y, Iwamoto M, et al
Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15784.
PubMed Abstract available

REZENDE LFM, de Almeida-Pittito B, Wahrhaftig J, Matos B, et al
Time trends in hypertension and diabetes prevalence by body mass index categories in Brazilian adults from 2006 to 2023.
Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15780.
PubMed Abstract available

SIRIYOTHA S, Lukkunaprasit T, Looareesuwan P, Kunakorntham P, et al
Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data.
Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15793.
PubMed Abstract available

CHEN AX, Fletcher R, Neuen BL, Neal B, et al
An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.
Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15751.
PubMed Abstract available

LIN DS, Lo HY, Huang KC, Lin TT, et al
Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.
Diabetes Obes Metab. 2024 Jul 19. doi: 10.1111/dom.15788.
PubMed Abstract available

NEUPANE S, Florkowski WJ, Dhakal U, Dhakal C, et al
Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States.
Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15797.
PubMed

ESCOBAR VASCO MA, Fantaye SH, Raghunathan S, Solis-Herrera C, et al
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease.
Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15773.
PubMed Abstract available

ZHANG YY, Chen BX, Yang Q, Wan Q, et al
The causal relationship between plasma protein-to-protein ratios and type 2 diabetes and its complications: Proteomics mendelian randomization study.
Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15792.
PubMed Abstract available

PIONA C, Passanisi S, Bombaci B, Marigliano M, et al
Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes.
Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15791.
PubMed

ZHAO L, Zeng Q, Zhou X, Tang L, et al
Impact of non-alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi-cohort longitudinal study.
Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15758.
PubMed Abstract available

WANG W, Qiao J, Zhang L, Zhang J, et al
Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: A population-based cross-sectional screening study.
Diabetes Obes Metab. 2024 Jul 17. doi: 10.1111/dom.15763.
PubMed Abstract available

LI J, Zhang R, Zhang C, Liu G, et al
Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age.
Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15770.
PubMed

LI J, Sun Y, Yu B, Cai L, et al
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status.
Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15782.
PubMed Abstract available

RIZZI A, Tartaglione L, Lucaccini Paoli L, Leo ML, et al
Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15766.
PubMed Abstract available

DONG W, Wan EYF, Fong DYT, Tan KC, et al
Development and validation of 10-year risk prediction models of cardiovascular disease in Chinese type 2 diabetes mellitus patients in primary care using interpretable machine learning-based methods.
Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15745.
PubMed Abstract available

SCHAEFER E, Lang A, Kupriyanova Y, Bodis KB, et al
Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet is associated with lower visceral and hepatic lipid content in recent-onset type 1 diabetes and type 2 diabetes.
Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15772.
PubMed Abstract available

CHAN JCN, Yang A, Chu N, Chow E, et al
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin.
Diabetes Obes Metab. 2024 Jul 11. doi: 10.1111/dom.15700.
PubMed Abstract available

LI W, Qin R, Tang Z, Wang C, et al
Inhibition of inflammation and apoptosis through the cyclic GMP-AMP synthase-stimulator of interferon genes pathway by stress granules after ALKBH5 demethylase activation during diabetic myocardial ischaemia-reperfusion injury.
Diabetes Obes Metab. 2024 Jul 11. doi: 10.1111/dom.15743.
PubMed Abstract available

WEIR MR
Cardiovascular risk reduction in type 2 diabetes: What the non-specialist needs to know about current guidelines.
Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15764.
PubMed Abstract available

KAZIBWE R, Singleton M, Bancks MP, Namutebi J, et al
Efficacy of Aspirin for primary prevention among adults with high-risk type 2 diabetes in the ACCORD trial.
Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15753.
PubMed Abstract available

AL-OZAIRI E, Irshad M, AlKandari J, Mashankar A, et al
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes.
Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15760.
PubMed Abstract available

ABBASI M, Heath B, McGinness L
Advances in metformin-delivery systems for diabetes and obesity management.
Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15759.
PubMed Abstract available

DE KLERK JA, Beulens JWJ, Bijkerk R, van Zonneveld AJ, et al
Circulating small non-coding RNAs are associated with the insulin-resistant and obesity-related type 2 diabetes clusters.
Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15786.
PubMed Abstract available

AUZANNEAU M, Seufert J, Zimny S, Haak T, et al
Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany.
Diabetes Obes Metab. 2024 Jul 9. doi: 10.1111/dom.15741.
PubMed

BRIEDITIS E, Li X, Sundquist K, Jansaker F, et al
Vulvovaginal candidiasis and type 2 diabetes: A nationwide retrospective cohort study.
Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15757.
PubMed Abstract available

HOU T, Li Y, Yan Q, Zhou Y, et al
The interaction effect between BMI, diabetes and age at diabetes onset on the risk of thyroid cancer: A population-based cohort study in Shanghai, China.
Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15746.
PubMed Abstract available

Correction to "Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study".
Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15806.
PubMed

HAN KA, Hwang YC, Moon SJ, Cho HC, et al
Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.
Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15717.
PubMed Abstract available

PETRIE JR
Metformin beyond type 2 diabetes: Emerging and potential new indications.
Diabetes Obes Metab. 2024 Jul 4. doi: 10.1111/dom.15756.
PubMed Abstract available

LI P, Kianmehr H, Guan D, Kulshreshtha A, et al
Renal function as an effect modifier of intensive glucose control in delaying cognitive function decline among individuals with type 2 diabetes: A revisit to the ACCORD MIND trial.
Diabetes Obes Metab. 2024 Jul 4. doi: 10.1111/dom.15744.
PubMed Abstract available

ZHANG D, Zhu J, Wewer Albrechtsen NJ, Rayner CK, et al
Impairments of insulin and glucagon sensitivity in Chinese women with gestational diabetes mellitus.
Diabetes Obes Metab. 2024 Jul 3. doi: 10.1111/dom.15740.
PubMed Abstract available

KHALAFI M, Habibi Maleki A, Symonds ME, Rosenkranz SK, et al
The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Jul 2. doi: 10.1111/dom.15730.
PubMed Abstract available

SUN M, Lu Z, Chen WM, Lv S, et al
Metformin monotherapy versus predominantly older non-metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management.
Diabetes Obes Metab. 2024 Jul 2. doi: 10.1111/dom.15739.
PubMed Abstract available

CHANG ML, Tai J, Cheng JS, Chen WT, et al
Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.
Diabetes Obes Metab. 2024;26:2969-2978.
PubMed Abstract available

ALMEIDA OP, Fong Z, Hill Almeida LM, Sanfilippo FM, et al
Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
Diabetes Obes Metab. 2024;26:2925-2932.
PubMed Abstract available

WHITE T, Selvarajah V, Wolfhagen-Sand F, Svangard N, et al
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.
Diabetes Obes Metab. 2024;26:2722-2731.
PubMed Abstract available

ZHANG J, Xu S, Liu X, Zhang J, et al
Time trends and regional variation in utilization of antidiabetic medicines in China, 2015-2022.
Diabetes Obes Metab. 2024;26:2752-2760.
PubMed Abstract available

BUTTICE L, Ghani M, Suthakar J, Gnanalingham S, et al
The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2024;26:2706-2721.
PubMed Abstract available

GOLDENBERG RM
A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
Diabetes Obes Metab. 2024;26:2997-2999.
PubMed

BAJAJ HS, Asbjornsdottir B, Bari TJ, Begtrup K, et al
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15726.
PubMed Abstract available

QUAST DR, Lancaster D, Xie C, Bound MJ, et al
Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.
Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15736.
PubMed Abstract available

WERKMAN NCC, Driessen JHM, Klungel OH, Schaper NS, et al
Incretin-based therapy and the risk of diabetic foot ulcers and related events.
Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15721.
PubMed Abstract available

ZHANG X, Su Y, Zhu X
The association of diabetes with progression of sleep-disordered breathing based on a prospective cohort.
Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15742.
PubMed Abstract available

KAO YW, Yen KC, Chen SW, Chao TF, et al
Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15734.
PubMed Abstract available

June 2024

LUO M, Sun M, Wang T, Wei J, et al
Type 2 diabetes, glycaemic traits, structural brain capacity and cognitive function: A Mendelian randomization analysis.
Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15702.
PubMed Abstract available

HAGI K, Kochi K, Watada H, Kaku K, et al
Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.
Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15716.
PubMed Abstract available

ABERER F, Haberl HC, Elsayed H, Pottler T, et al
Accuracy of the professional flash glucose monitoring system FreeStyle Libre Pro in hospitalized individuals with type 2 diabetes mellitus receiving standardized basal-bolus insulin therapy.
Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15719.
PubMed

AERNOUTS C, Belde SPW, Lambrechts J, Mertens J, et al
Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15723.
PubMed Abstract available

AYESH H, Suhail S, Ayesh S, Niswender K, et al
Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15725.
PubMed Abstract available

LIU M, Gu W, Chen L, Li Y, et al
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
Diabetes Obes Metab. 2024 Jun 22. doi: 10.1111/dom.15724.
PubMed Abstract available

AJIE M, van Heck JIP, Verhulst CEM, Fabricius TW, et al
Real-life hypoglycaemia partially blunts the inflammatory response to experimental hypoglycaemia in people with type 1 diabetes.
Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15712.
PubMed Abstract available

HENNEY AE, Riley DR, O'Connor B, Hydes TJ, et al
Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15708.
PubMed Abstract available

LI P, Alkhuzam K, Brown J, Zhang Y, et al
Association between low cognitive performance and diabetes-related health indicators across racial and ethnic groups in adults with diabetes.
Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15715.
PubMed Abstract available

BONNET F, Cooper ME, Kopp L, Fouque D, et al
A review of the latest real-world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?
Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15710.
PubMed Abstract available

RYBA-STANISLAWOWSKA M, Slominski B, Mysliwiec M
Association of KLF14 rs4731702 gene polymorphism with metabolic phenotype in young patients with type 1 diabetes.
Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15707.
PubMed Abstract available

YANG Q, Zeng B, Hao J, Yang Q, et al
Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysis.
Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15718.
PubMed Abstract available

GUPTA Y, Goyal A, Tandon N
Implications of antenatal 1-hour postload plasma glucose (>/= 11.6 mmol/L) for postpartum diabetes and cardiometabolic risk assessment in women with gestational diabetes: Post hoc analysis from the CHIP-F study.
Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15722.
PubMed

ZHOU Y, Xu M, Yin X, Gong Y, et al
Association between new-onset atrial fibrillation and dementia among individuals with type 2 diabetes.
Diabetes Obes Metab. 2024 Jun 14. doi: 10.1111/dom.15714.
PubMed Abstract available

AL-ABDULLAH L, Ahern A, Welsh P, Logue J, et al
A predictive model for medium-term weight loss response in people with type 2 diabetes engaging in behavioural weight management interventions.
Diabetes Obes Metab. 2024 Jun 14. doi: 10.1111/dom.15706.
PubMed Abstract available

WELK B, McClure JA, Carter B, Clarke C, et al
No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.
Diabetes Obes Metab. 2024 Jun 11. doi: 10.1111/dom.15711.
PubMed

TINTI D, Nobili C, Baretta I, Rosso A, et al
Paediatric type 1 diabetes mellitus: A comparison between multi-injection therapy and advanced hybrid closed-loop pump in the first year after diabetes onset.
Diabetes Obes Metab. 2024 Jun 11. doi: 10.1111/dom.15704.
PubMed

KIM NH, Moon JS, Lee YH, Cho HC, et al
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naive patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, o
Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15705.
PubMed Abstract available

DEL PRATO S, Giorgino F, Szafranski K, Poon Y, et al
Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective.
Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15703.
PubMed Abstract available

ZU C, Liu M, Wang G, Meng Q, et al
Association between longitudinal changes in body composition and the risk of kidney outcomes in participants with overweight/obesity and type 2 diabetes mellitus.
Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15699.
PubMed Abstract available

NAPOLI R, Nicolucci A, Larosa M, Rossi MC, et al
Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study.
Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15697.
PubMed Abstract available

TANG F, Wang W, Wang Y, Lee Y, et al
Moderate resistance training reduces intermuscular adipose tissue and risk factors of atherosclerotic cardiovascular disease for elderly patients with type 2 diabetes.
Diabetes Obes Metab. 2024 Jun 9. doi: 10.1111/dom.15684.
PubMed Abstract available

WINTHER JB, Holst JJ
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
Diabetes Obes Metab. 2024 Jun 9. doi: 10.1111/dom.15693.
PubMed Abstract available

ODUTAYO A, Cosentino F, Pratley RE, Dagogo-Jack S, et al
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15687.
PubMed

SUN CJ, Nguyen E, Prentki M, Rabasa-Lhoret R, et al
The daunting task of recruiting insulin-treated patients living with type 2 diabetes mellitus for intensive lifestyle interventions.
Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15688.
PubMed

YOSHIDA Y, Zu Y, Fan B, Li S, et al
Cumulative effect of metabolic risk factors on left ventricular geometry in those with versus without early-onset type 2 diabetes or prediabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study.
Diabetes Obes Metab. 2024 Jun 4. doi: 10.1111/dom.15681.
PubMed Abstract available

MARQUES P, Mavrakanas TA, Guida J, Gedeon T, et al
Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme.
Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15691.
PubMed Abstract available

LONG J, Fang Q, Shi Z, Miao Z, et al
Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin.
Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15689.
PubMed Abstract available

GONZALEZ-VIDAL T, Rivas-Otero D, Ramos-Ruiz G, Agueria-Cabal P, et al
Impact of the basal/bolus ratio on continuous glucose monitoring parameters in patients with type 1 diabetes.
Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15690.
PubMed

HE Y, Kunutsor SK, Kingsnorth AP, Gillies C, et al
Differential associations of risk factors with severe and non-severe hypoglycaemia: the Hypoglycaemia Assessment Tool prospective observational study in people with insulin-treated type 1 diabetes and type 2 diabetes.
Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15677.
PubMed Abstract available

THOMAS L, Martel E, Rist W, Uphues I, et al
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Diabetes Obes Metab. 2024;26:2368-2378.
PubMed Abstract available

MILANOVIC S, Dedic N, Lew R, Burton D, et al
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Diabetes Obes Metab. 2024;26:2466-2475.
PubMed Abstract available

LIU Y, Kimita W, Shamaitijiang X, Skudder-Hill L, et al
Intra-pancreatic fat is associated with continuous glucose monitoring metrics.
Diabetes Obes Metab. 2024;26:2359-2367.
PubMed Abstract available

STRATMANN B, Eggers B, Mattern Y, de Carvalho TS, et al
Maladaptive response following glucose overload in GLUT4-overexpressing H9C2 cardiomyoblasts.
Diabetes Obes Metab. 2024;26:2379-2389.
PubMed Abstract available

LUIZ MM, Maximo RO, de Oliveira DC, Ramirez PC, et al
Could poor glycaemic control be a predictor of walking speed decline in older adults? Evidence from the English Longitudinal Study of Ageing.
Diabetes Obes Metab. 2024;26:2349-2358.
PubMed Abstract available

PULKKINEN MA, Varimo TJ, Hakonen ET, Hero MT, et al
During an 18-month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range.
Diabetes Obes Metab. 2024;26:2431-2438.
PubMed Abstract available

ABDELMALEK MF, Harrison SA, Sanyal AJ
The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
Diabetes Obes Metab. 2024;26:2001-2016.
PubMed Abstract available

HASHEMY H, Nguyen A, Khafagy R, Roshandel D, et al
Analyses of potential causal contributors to increased waist/hip ratio-associated cardiometabolic disease: A combined and sex-stratified Mendelian randomization study.
Diabetes Obes Metab. 2024;26:2284-2291.
PubMed Abstract available

TOSHIMITSU T, Gotou A, Sashihara T, Hojo K, et al
Ingesting probiotic yogurt containing Lactiplantibacillus plantarum OLL2712 improves glycaemic control in adults with prediabetes in a randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2024;26:2239-2247.
PubMed Abstract available

SILVERII GA, Marinelli C, Mannucci E, Rotella F, et al
Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2024;26:2505-2508.
PubMed

PETERMANN-ROCHA F, Apolinar E, Nazar G, Diaz-Toro F, et al
Associations of diabesity with all-cause and cardiovascular disease mortality: Findings from the Mexico City Prospective Study.
Diabetes Obes Metab. 2024;26:2199-2208.
PubMed Abstract available

May 2024

KHAWAGI WY, Al-Kuraishy HM, Hussein NR, Al-Gareeb AI, et al
Depression and type 2 diabetes: A causal relationship and mechanistic pathway.
Diabetes Obes Metab. 2024 May 27. doi: 10.1111/dom.15630.
PubMed Abstract available

BAILEY CJ
Metformin: Therapeutic profile in the treatment of type 2 diabetes.
Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15663.
PubMed Abstract available

BUCKLEY A, Suliman S, Allum M, Mohammed N, et al
Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.
Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15680.
PubMed Abstract available

WANG D, Chen Z, Wu Y, Ren J, et al
Association between two novel anthropometric measures and type 2 diabetes in a Chinese population.
Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15651.
PubMed Abstract available

SUN Y, Li W, Zhou Y, Wang B, et al
Long-term changes in frailty and incident type 2 diabetes: A prospective cohort study based on the UK Biobank.
Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15676.
PubMed Abstract available

SVENSSON CH, Fabricius TW, Verhulst CEM, Kristensen PL, et al
Association between recent exposure to continuous glucose monitoring-recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes.
Diabetes Obes Metab. 2024 May 22. doi: 10.1111/dom.15649.
PubMed Abstract available

SUGIMOTO T, Saji N, Omura T, Tokuda H, et al
Cross-sectional association of continuous glucose monitoring-derived metrics with cerebral small vessel disease in older adults with type 2 diabetes.
Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15659.
PubMed Abstract available

TSUKAMOTO S, Kobayashi K, Toyoda M, Tone A, et al
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652.
PubMed Abstract available

LEITER LA, Raal FJ, Schwartz GG, Koenig W, et al
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.
Diabetes Obes Metab. 2024 May 17. doi: 10.1111/dom.15650.
PubMed Abstract available

SEGEV O, Raz I, Gerstein HC, Aviezer H, et al
Development and first-stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes.
Diabetes Obes Metab. 2024 May 17. doi: 10.1111/dom.15657.
PubMed Abstract available

BUCKERIDGE C, Tsamandouras N, Carvajal-Gonzalez S, Brown LS, et al
Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
Diabetes Obes Metab. 2024 May 16. doi: 10.1111/dom.15643.
PubMed Abstract available

GUO K, Ye J, Li J, Huang J, et al
Effects of gut microbiome on type 1 diabetes susceptibility and complications: A large-scale bidirectional Mendelian randomization and external validation study.
Diabetes Obes Metab. 2024 May 16. doi: 10.1111/dom.15658.
PubMed Abstract available

BOURRON O, Mohammedi K, De Keizer J, Schneider F, et al
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes.
Diabetes Obes Metab. 2024 May 15. doi: 10.1111/dom.15656.
PubMed Abstract available

GREENE E, Green CL, Hurst J, MacIver NJ, et al
Metformin use associated with lower rate of hospitalization for influenza in individuals with diabetes.
Diabetes Obes Metab. 2024 May 14. doi: 10.1111/dom.15655.
PubMed Abstract available

HU S, Shi C, Ma Y, Wang S, et al
Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
Diabetes Obes Metab. 2024 May 13. doi: 10.1111/dom.15645.
PubMed Abstract available

ALMUALLEM S, Ali AK, Vourtzoumis P, Demyttenaere S, et al
Validation of the Individualized Metabolic Surgery score in predicting long-term remission of diabetes after duodenal switch-type procedures.
Diabetes Obes Metab. 2024 May 9. doi: 10.1111/dom.15647.
PubMed Abstract available

KANAOKA T, Wakui H, Yano Y, Nagasu H, et al
Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database.
Diabetes Obes Metab. 2024 May 8. doi: 10.1111/dom.15611.
PubMed Abstract available

MORIOKA T, Takeuchi M, Ozeki A, Emoto M, et al
A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
Diabetes Obes Metab. 2024 May 7. doi: 10.1111/dom.15644.
PubMed Abstract available

SHIKAMURA M, Takayama A, Takeuchi M, Kawakami K, et al
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A
Diabetes Obes Metab. 2024 May 6. doi: 10.1111/dom.15632.
PubMed Abstract available

TAKAHASHI A, Nomoto H, Onishi K, Manda S, et al
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15639.
PubMed

YANG M, Yue H, Xu Q, Shao S, et al
Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: A single-centre, randomized, crossover trial.
Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15641.
PubMed Abstract available

SMATI S, Sotin T, Deniel P, Ducheix S, et al
Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes.
Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15634.
PubMed

TIRADO-AGUILAR OA, Martinez-Cruz N, Arce-Sanchez L, Borboa-Olivares H, et al
Earlier detection of gestational diabetes impacts on medication requirements, neonatal and maternal outcomes.
Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15633.
PubMed Abstract available

XIANG C, Sun Y, Luo Y, Xie C, et al
Gastric emptying is slower in women than men with type 2 diabetes and impacts on postprandial glycaemia.
Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15635.
PubMed Abstract available

SUN Y, Luo Y, Xiang C, Xie C, et al
Gastric emptying in newly diagnosed, treatment-naive Han Chinese with type 2 diabetes and the impact of 4-week insulin pump therapy.
Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15626.
PubMed Abstract available

CHEN J, Li YT, Niu Z, He Z, et al
Investigating the causal association of generalized and abdominal obesity with microvascular complications in patients with type 2 diabetes: A community-based prospective study.
Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15598.
PubMed Abstract available

LI S, Pan S, Jiang S, Shin JI, et al
Prescription medication use among patients with type 2 diabetes in the United States: 1999-2020.
Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15619.
PubMed Abstract available

LASSEN MCH, Johansen ND, Modin D, Nealon J, et al
Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.
Diabetes Obes Metab. 2024;26:1821-1829.
PubMed Abstract available

THIRUMALAI A, Chao JH, Kaleru T, Dong X, et al
Bridging dose of U-100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice-daily glargine users.
Diabetes Obes Metab. 2024;26:1868-1876.
PubMed Abstract available

TAN YH, Tan WL, Eichinger V, Ruch B, et al
Blood glucose control using a mobile health application in Singapore, Philippines and Hong Kong: a retrospective real-world data analysis.
Diabetes Obes Metab. 2024;26:1990-1992.
PubMed

WU Y, Zhang C, Duan S, Li Y, et al
TEAD1, MYO7A and NDUFC2 are novel functional genes associated with glucose metabolism in BXD recombinant inbred population.
Diabetes Obes Metab. 2024;26:1775-1788.
PubMed Abstract available

SALERNO PRVO, Qian A, Dong W, Deo S, et al
County-level socio-environmental factors and obesity prevalence in the United States.
Diabetes Obes Metab. 2024;26:1766-1774.
PubMed Abstract available

YEW MJ, Heywood SE, Ng J, West OM, et al
ACAD10 is not required for metformin's metabolic actions or for maintenance of whole-body metabolism in C57BL/6J mice.
Diabetes Obes Metab. 2024;26:1731-1745.
PubMed Abstract available

GILBERT MP, Skelly J, Hernandez AF, Green JB, et al
Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.
Diabetes Obes Metab. 2024;26:1714-1722.
PubMed Abstract available

DIALLO A, Diallo MF, Carlos-Bolumbu M, Galtier F, et al
Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta-analysis.
Diabetes Obes Metab. 2024;26:1980-1985.
PubMed Abstract available

CHAN SY, Zhang H, Wong JT, Chang HF, et al
Higher early pregnancy plasma myo-inositol associates with increased postprandial glycaemia later in pregnancy: Secondary analyses of the NiPPeR randomized controlled trial.
Diabetes Obes Metab. 2024;26:1658-1669.
PubMed Abstract available

DE GERMAY S, Pambrun E, Pariente A, Grenet G, et al
Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
Diabetes Obes Metab. 2024;26:1678-1686.
PubMed Abstract available

SOURIJ C, Oulhaj A, Aziz F, Tripolt NJ, et al
Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial.
Diabetes Obes Metab. 2024;26:1971-1975.
PubMed

VERNSTROM L, Gullaksen S, Sorensen SS, Funck KL, et al
Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
Diabetes Obes Metab. 2024;26:1624-1635.
PubMed Abstract available

April 2024

SU J, Fan X, Li M, Yu H, et al
Association of lifestyle with reduced stroke risk in 41 314 individuals with diabetes: Two prospective cohort studies in China.
Diabetes Obes Metab. 2024 Apr 29. doi: 10.1111/dom.15606.
PubMed Abstract available

SEUFERT J, Freemantle N, Guja C, Haluzik M, et al
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.
Diabetes Obes Metab. 2024 Apr 29. doi: 10.1111/dom.15609.
PubMed

NAKHLEH A, Abdul-Ghani M, Gazit S, Gross A, et al
Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15623.
PubMed Abstract available

MICHALOPOULOU M, Piernas C, Jebb SA, Gao M, et al
Association of gestational diabetes with long-term risk of premature mortality, and cardiovascular outcomes and risk factors: A retrospective cohort analysis in the UK Biobank.
Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15612.
PubMed Abstract available

REED J, Dong T, Eaton E, Friswold J, et al
Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15608.
PubMed Abstract available

IWAMOTO Y, Kimura T, Shimoda M, Morimoto Y, et al
C-peptide index at 2 h post-meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes.
Diabetes Obes Metab. 2024 Apr 22. doi: 10.1111/dom.15595.
PubMed Abstract available

BIAN YC, Meng J, Hu T, Ma S, et al
Biotransformation and disposition characteristics of HSK7653, a novel long-acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Obes Metab. 2024 Apr 22. doi: 10.1111/dom.15605.
PubMed Abstract available

KIM JH, Lyu YS, Kim B, Kim MK, et al
Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history.
Diabetes Obes Metab. 2024 Apr 21. doi: 10.1111/dom.15565.
PubMed Abstract available

Correction to "Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time".
Diabetes Obes Metab. 2024 Apr 19. doi: 10.1111/dom.15618.
PubMed

MALIK RA, Hwu CM, Jammah AA, Arteaga-Diaz JM, et al
Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15599.
PubMed Abstract available

WILSON M, Al-Hamid A, Abbas I, Birkett J, et al
Identification of diagnostic biomarkers used in the diagnosis of cardiovascular diseases and diabetes mellitus: A systematic review of quantitative studies.
Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15593.
PubMed Abstract available

HU Y, Li X, Wang X, Ma H, et al
Smoking timing, genetic susceptibility and the risk of incident type 2 diabetes: A cohort study from the UK Biobank.
Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15603.
PubMed Abstract available

DE OLIVEIRA COSTA J, Lin J, Milder TY, Greenfield JR, et al
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15597.
PubMed Abstract available

JEONG SI, Ban MS, Hwang JG, Park MK, et al
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15573.
PubMed Abstract available

WANG Y, Jiang C, Dong X, Chen M, et al
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15596.
PubMed Abstract available

DENG S, Hu X, Zhang X
Association of single-point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes.
Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15600.
PubMed Abstract available

IRLIK K, Aldosari H, Hendel M, Kwiendacz H, et al
Artificial intelligence-enhanced electrocardiogram analysis for identifying cardiac autonomic neuropathy in patients with diabetes.
Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15578.
PubMed Abstract available

GRANDO ALVES G, Cunha L, Henkes Machado R, Lins de Menezes V, et al
Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15581.
PubMed Abstract available

GUO L, Tian F, Liu L, Chen M, et al
Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15601.
PubMed Abstract available

GUO L, Xi Y, Li L, Guo K, et al
Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
Diabetes Obes Metab. 2024 Apr 10. doi: 10.1111/dom.15590.
PubMed

SAID F, Arnott C, Voors AA, Heerspink HJL, et al
Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15592.
PubMed Abstract available

SIMON SL, Snell-Bergeon JK, Schafer M, Barker AJ, et al
Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR-T1D study.
Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15582.
PubMed Abstract available

VIVIAN EM, Chewning BA, Voils CI, Brown RL, et al
Healthy Outcomes through Peer Educators: Feasibility of a peer support diabetes prevention programme for African-American grandmother caregivers.
Diabetes Obes Metab. 2024 Apr 3. doi: 10.1111/dom.15574.
PubMed Abstract available

CHEN GL, Liu Y, Gao XF, Wu KQ, et al
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
Diabetes Obes Metab. 2024;26:1395-1406.
PubMed Abstract available

GUY A, Azab AN, Liberty IF, Afawi Z, et al
Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.
Diabetes Obes Metab. 2024;26:1346-1354.
PubMed Abstract available

LAU D, Gamble JM
Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?
Diabetes Obes Metab. 2024;26:1150-1156.
PubMed

HOPE DCD, Ansari S, Choudhury S, Alexiadou K, et al
Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
Diabetes Obes Metab. 2024;26:1479-1491.
PubMed Abstract available

BAZYDLO-GUZENDA K, Jarus-Dziedzic K, Gierczak-Pachulska A, Buda P, et al
First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
Diabetes Obes Metab. 2024;26:1376-1385.
PubMed Abstract available

CUKIERMAN-YAFFE T, Ramasundarahettige C, Bosch J, Gerstein HC, et al
Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the ORIGIN trial.
Diabetes Obes Metab. 2024;26:1180-1187.
PubMed Abstract available

NERILD HH, Bronden A, Haddouchi AE, Ellegaard AM, et al
Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer.
Diabetes Obes Metab. 2024;26:1252-1263.
PubMed Abstract available

TOMLINSON JW
Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.
Diabetes Obes Metab. 2024;26 Suppl 2:13-24.
PubMed Abstract available

GOLUBIC R, Kennet J, Parker V, Robertson D, et al
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15579.
PubMed Abstract available

LUO J, Zhao X, Li Q, Zou B, et al
Evaluating the global impact of low physical activity on type 2 diabetes: Insights from the global burden of disease 2019 study.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15568.
PubMed Abstract available

SAFDAR NZ, Alobaid AM, Hopkins M, Dempsey PC, et al
Short, frequent, light-intensity walking activity improves postprandial vascular-inflammatory biomarkers in people with type 1 diabetes: The SIT-LESS randomized controlled trial.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15564.
PubMed Abstract available

KUHNE T, Wallace E, Herzig D, Helleputte S, et al
Combined intake of caffeine and low-dose glucose to reduce exercise-related hypoglycaemia in individuals with type 1 diabetes on ultra-long-acting insulin degludec: A randomized, controlled, double-blind, cross-over trial.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15580.
PubMed Abstract available

DARSALIA V, Vercalsteren E, Karampatsi D, Romanitan MO, et al
The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15577.
PubMed

CHRISTOFIDES EA, Puente O, Norwood P, Denham D, et al
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus(R)) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15560.
PubMed Abstract available

HUANG ZG, Gao JW, Zhang HF, You S, et al
Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15583.
PubMed Abstract available

TALHA KM, Green J, Filippatos G, Pocock S, et al
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15572.
PubMed Abstract available

MAHMOUD F, Mueller T, Mullen A, Sainsbury C, et al
Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15584.
PubMed Abstract available

ANSON M, Henney AE, Zhao SS, Ibarburu GH, et al
Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated dat
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15576.
PubMed Abstract available

KANBAY M, Copur S, Topcu AU, Guldan M, et al
An update review of post-transplant diabetes mellitus: Concept, risk factors, clinical implications and management.
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15575.
PubMed Abstract available

HODGSON A, Gillies CL, Highton P, Haddon L, et al
Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: A systematic review and meta-analysis of observational cohort st
Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15571.
PubMed

March 2024

Correction to 'In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank'.
Diabetes Obes Metab. 2024 Mar 27. doi: 10.1111/dom.15591.
PubMed

SUZUKI Y, Kaneko H, Nagasawa H, Okada A, et al
Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15561.
PubMed Abstract available

CARIOU B, Linge J, Neeland IJ, Dahlqvist Leinhard O, et al
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15566.
PubMed Abstract available

ZHANG Y, Yang D, Jia Q, Yan J, et al
The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15557.
PubMed Abstract available

BELL DSH, Jerkins T
The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
Diabetes Obes Metab. 2024 Mar 22. doi: 10.1111/dom.15559.
PubMed Abstract available

RODBARD HW, Barnard-Kelly K, Pfeiffer AFH, Mauersberger C, et al
Practical strategies to manage obesity in type 2 diabetes.
Diabetes Obes Metab. 2024 Mar 21. doi: 10.1111/dom.15556.
PubMed Abstract available

RIVERA FB, Lumbang GNO, Gaid DRM, Cruz LLA, et al
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Diabetes Obes Metab. 2024 Mar 20. doi: 10.1111/dom.15529.
PubMed Abstract available

DEN BROK EJ, Svensson CH, Panagiotou M, van Greevenbroek MMJ, et al
The effect of bolus advisors on glycaemic parameters in adults with diabetes on intensive insulin therapy: A systematic review with meta-analysis.
Diabetes Obes Metab. 2024 Mar 19. doi: 10.1111/dom.15521.
PubMed Abstract available

BORNSTEIN SR, de Zeeuw D, Heerspink HJL, Schulze F, et al
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15518.
PubMed Abstract available

SHI C, Tan Y, Hu S, Qin Y, et al
Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.
Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15552.
PubMed

PENG M, He S, Wang J, An Y, et al
Efficacy of 1-hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes-related complications: A post hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study.
Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15547.
PubMed Abstract available

LAU D, Pearson GJ, Raggi P, Klarenbach S, et al
Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost-effective in select individuals.
Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15558.
PubMed

FADINI GP, Bonora BM, Ghiani M, Anichini R, et al
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Diabetes Obes Metab. 2024 Mar 13. doi: 10.1111/dom.15554.
PubMed Abstract available

JAIN AB, Reichert SM, Amadid H, Braae UC, et al
Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15493.
PubMed Abstract available

NYSTROM T, Andersson Franko M, Ludvigsson J, Lind M, et al
Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes.
Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15545.
PubMed

ZHAO H, Wu Y, Xie Y, Li Y, et al
Hydrogel dressings for diabetic foot ulcer: A systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15544.
PubMed Abstract available

DOMAZET SL, Olesen TB, Stidsen JV, Svensson CK, et al
Low-grade inflammation in persons with recently diagnosed type 2 diabetes: The role of abdominal adiposity and putative mediators.
Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15514.
PubMed Abstract available

HELMINK MAG, Hageman SHJ, Eliasson B, Sattar N, et al
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15531.
PubMed Abstract available

SOHN TS, Han KA, Kim Y, Lee BW, et al
A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15537.
PubMed Abstract available

POPOVIC DS, Patoulias D, Karakasis P, Koufakis T, et al
Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes.
Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15535.
PubMed

YANG J, Shangguan Q, Xie G, Yang M, et al
Sex-specific associations between haemoglobin glycation index and the risk of cardiovascular and all-cause mortality in individuals with pre-diabetes and diabetes: A large prospective cohort study.
Diabetes Obes Metab. 2024 Mar 7. doi: 10.1111/dom.15541.
PubMed Abstract available

IVERSEN E, Christensen KM, Walls AB, Eickhoff MK, et al
Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes.
Diabetes Obes Metab. 2024 Mar 6. doi: 10.1111/dom.15536.
PubMed

HUANG Y, Wang S, Cai C, Huang X, et al
Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease.
Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15492.
PubMed Abstract available

TURNER LV, Riddell MC
Pre-dinner walks may be superior to post-dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed-loop insulin delivery systems.
Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15532.
PubMed

HOYT JA, Cozzi E, D'Alessio DA, Thompson CC, et al
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.
Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15533.
PubMed Abstract available

BATDORF HM, Lawes LL, Cassagne GA, Fontenot MS, et al
Accelerated onset of diabetes in non-obese diabetic mice fed a refined high-fat diet.
Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15522.
PubMed Abstract available

ALI S, Baig S, Wanninayake S, da Silva Xavier G, et al
Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alstrom syndrome patients.
Diabetes Obes Metab. 2024;26:989-996.
PubMed Abstract available

AL-SOFIANI ME, Petrovski G, Al Shaikh A, Alguwaihes A, et al
The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan.
Diabetes Obes Metab. 2024;26:937-949.
PubMed Abstract available

WU J, Zhou R, Zhang Q, Zhang Q, et al
Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and
Diabetes Obes Metab. 2024;26:901-910.
PubMed Abstract available

HUANG X, Dannya E, Liu X, Yu Y, et al
Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
Diabetes Obes Metab. 2024;26:1040-1049.
PubMed Abstract available

MARITSCH M, Foll S, Lehmann V, Styger N, et al
Smartwatches for non-invasive hypoglycaemia detection during cognitive and psychomotor stress.
Diabetes Obes Metab. 2024;26:1133-1136.
PubMed

SILVERII GA, Monami M, Gallo M, Ragni A, et al
Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2024;26:891-900.
PubMed Abstract available

ALKABBANI W, Maxwell CJ, Marrie RA, Tyas SL, et al
Insulin, hypoglycaemia and dementia: A causal mediation analysis showcasing challenges and potential opportunities.
Diabetes Obes Metab. 2024;26:1120-1124.
PubMed

LEE YJ, Lee SH, You SC, Lee YH, et al
Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial.
Diabetes Obes Metab. 2024;26:829-839.
PubMed Abstract available

REDDY M, Oliver N
The role of real-time continuous glucose monitoring in diabetes management and how it should link to integrated personalized diabetes management.
Diabetes Obes Metab. 2024;26 Suppl 1:46-56.
PubMed Abstract available

February 2024

LIM S, Lee SH, Min KW, Lee CB, et al
A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15526.
PubMed Abstract available

VARGAS KG, Rutten T, Siemes B, Brockmeyer M, et al
Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta-regression analysis of 120 randomized controlled trials.
Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15519.
PubMed Abstract available

WILLIG MR, Stinson EJ, Looker HC, Piaggi P, et al
Insulin resistance before type 2 diabetes onset is associated with increased risk of albuminuria after diabetes onset: A prospective cohort study.
Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15505.
PubMed Abstract available

SWIFT C, Frazer M, Gronroos NN, Sargent A, et al
Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15516.
PubMed Abstract available

BONNET F, Balkau B, Lambert O, Diawara Y, et al
The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD-REIN cohort study.
Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15507.
PubMed Abstract available

ZHAO Y, Han M, Qie R, Zhang Y, et al
Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China-PAR project.
Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15508.
PubMed Abstract available

IIJIMA H, Gouda M, Hida H, Mori-Anai K, et al
Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.
Diabetes Obes Metab. 2024 Feb 27. doi: 10.1111/dom.15461.
PubMed Abstract available

KUNUTSOR SK, Balasubramanian VG, Zaccardi F, Gillies CL, et al
Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15511.
PubMed Abstract available

SHAO X, Lu J, Tao R, Wu L, et al
Clinically relevant stratification of patients with type 2 diabetes by using continuous glucose monitoring data.
Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15512.
PubMed Abstract available

SHEN W, Cai L, Wang B, Li J, et al
Associations of a proinflammatory diet, habitual salt intake, and the onset of type 2 diabetes: A prospective cohort study from the UK Biobank.
Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15517.
PubMed Abstract available

MESQUITA LA, Spiazzi BF, Piccoli GF, Nogara DA, et al
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysis.
Diabetes Obes Metab. 2024 Feb 23. doi: 10.1111/dom.15509.
PubMed Abstract available

WAN EYF, Xu W, Mok AHY, Chin WY, et al
Evaluating different low-density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: A target trial emulation study.
Diabetes Obes Metab. 2024 Feb 21. doi: 10.1111/dom.15503.
PubMed Abstract available

GOMEZ-PERALTA F, Chico Ballesteros A, Marco Martinez A, Perez Corral B, et al
Insulin glargine 300 U/ml versus insulin degludec 100 U/ml improves nocturnal glycaemic control and variability in type 1 diabetes under routine clinical practice: A glucodensities-based post hoc analysis of the OneCare study.
Diabetes Obes Metab. 2024 Feb 20. doi: 10.1111/dom.15496.
PubMed

KUNUTSOR SK, Zaccardi F, Balasubramanian VG, Gillies CL, et al
Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.
Diabetes Obes Metab. 2024 Feb 20. doi: 10.1111/dom.15500.
PubMed Abstract available

HOVELMANN U, Engberg S, Heise T, Kristensen NR, et al
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
Diabetes Obes Metab. 2024 Feb 20. doi: 10.1111/dom.15510.
PubMed Abstract available

MISHRIKY BM, Cummings DM, Fu Y, Halladay JR, et al
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data.
Diabetes Obes Metab. 2024 Feb 15. doi: 10.1111/dom.15499.
PubMed Abstract available

HIRONAKA J, Okada H, Minamida M, Kondo Y, et al
Impact of an online nutrition management application service on glycaemic management in individuals with diabetes: A propensity-score-matched retrospective cohort study.
Diabetes Obes Metab. 2024 Feb 14. doi: 10.1111/dom.15487.
PubMed Abstract available

JACOBSEN JR, Westergaard LM, Fosbol EL, Kristensen SL, et al
Association of carpal tunnel syndrome with incident diabetes.
Diabetes Obes Metab. 2024 Feb 14. doi: 10.1111/dom.15482.
PubMed

GULDEMOND N
What is meant by 'integrated personalized diabetes management': A view into the future and what success should look like.
Diabetes Obes Metab. 2024 Feb 8. doi: 10.1111/dom.15476.
PubMed Abstract available

FADINI GP, Buzzetti R, Pitocco D, Tortato E, et al
IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.
Diabetes Obes Metab. 2024 Feb 8. doi: 10.1111/dom.15486.
PubMed Abstract available

MARUHASHI T, Tanaka A, Takahashi K, Higashi Y, et al
Erythropoiesis and estimated fluid volume regulation following initiation of ipragliflozin treatment in patients with type 2 diabetes mellitus and chronic kidney disease: A post-hoc analysis of the PROCEED trial.
Diabetes Obes Metab. 2024 Feb 7. doi: 10.1111/dom.15481.
PubMed Abstract available

HERMANNS N, Kulzer B, Ehrmann D
Person-reported outcomes in diabetes care: What are they and why are they so important?
Diabetes Obes Metab. 2024 Feb 4. doi: 10.1111/dom.15471.
PubMed Abstract available

FENG L, Chen C, Guo Q, Chen L, et al
Improvement of early-phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study.
Diabetes Obes Metab. 2024;26:745-753.
PubMed Abstract available

CUI C, Cao F, Kong II, Wu Q, et al
A model-informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong-acting dipeptidyl peptidase-4 inhibitor.
Diabetes Obes Metab. 2024;26:592-601.
PubMed Abstract available

CRATER GD, Lalonde K, Ravenelle F, Harvey M, et al
Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study.
Diabetes Obes Metab. 2024;26:642-649.
PubMed Abstract available

ROSENSTOCK J, Cariou B, Eliasson J, Frappin G, et al
Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
Diabetes Obes Metab. 2024;26:532-539.
PubMed Abstract available

LIEVERSE TTGF, Puchades MJ, Mulder UDJ, Provenzano M, et al
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study.
Diabetes Obes Metab. 2024;26:576-582.
PubMed Abstract available

WEN WL, Lee YJ, Hwu DW, Chang YH, et al
Age- and gender-adjusted estimated glomerular filtration rate definition reveals hyperfiltration as a risk factor for renal function deterioration in type 2 diabetes.
Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15465.
PubMed Abstract available

DE KLERK JA, Bijkerk R, Beulens JWJ, van Zonneveld AJ, et al
Branched-chain amino acid levels are inversely associated with incident and prevalent chronic kidney disease in people with type 2 diabetes.
Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15475.
PubMed Abstract available

LIU Y, Yu S, Feng W, Mo H, et al
A meta-analysis of diabetes risk prediction models applied to prediabetes screening.
Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15457.
PubMed Abstract available

MA J, Liu M, Wang R, Du L, et al
Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15446.
PubMed Abstract available

January 2024

JIAO T, Kianmehr H, Lin Y, Li P, et al
Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post-hoc machine learning analysis of ACCORD trial data.
Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15453.
PubMed Abstract available

ZHANG Y, Jiong OX, Tang S, Tang YC, et al
Comparison of prediction models for cardiovascular and mortality risk in people with type 2 diabetes: An external validation in 23 685 adults included in the UK Biobank.
Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15474.
PubMed Abstract available

MADDALONI E, Naciu AM, Mignogna C, Galiero R, et al
Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of beta-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study.
Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15469.
PubMed Abstract available

EBEKOZIEN O, Fantasia K, Farrokhi F, Sabharwal A, et al
Technology and health inequities in diabetes care: How do we widen access to underserved populations and utilize technology to improve outcomes for all?
Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15470.
PubMed Abstract available

JAFAR A, Pasqua MR
Postprandial glucose-management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence.
Diabetes Obes Metab. 2024 Jan 23. doi: 10.1111/dom.15463.
PubMed Abstract available

HOWELL CR, Zhu S, Malla G, Carson G, et al
Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time.
Diabetes Obes Metab. 2024 Jan 22. doi: 10.1111/dom.15450.
PubMed

REZNIK Y, Bonnemaison E, Fagherazzi G, Renard E, et al
The use of an automated insulin delivery system is associated with a reduction in diabetes distress and improvement in quality of life in people with type 1 diabetes.
Diabetes Obes Metab. 2024 Jan 22. doi: 10.1111/dom.15462.
PubMed

NAKAMURA Y, Horie I, Kitamura T, Kusunoki Y, et al
Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study.
Diabetes Obes Metab. 2024 Jan 22. doi: 10.1111/dom.15458.
PubMed Abstract available

ISHIBASHI R, Inaba Y, Koshizaka M, Takatsuna Y, et al
Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A co
Diabetes Obes Metab. 2024 Jan 19. doi: 10.1111/dom.15454.
PubMed Abstract available

LONGO M, Caruso P, Scappaticcio L, Maiorino MI, et al
Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes
Diabetes Obes Metab. 2024 Jan 17. doi: 10.1111/dom.15451.
PubMed Abstract available

REBORDOSA C, Thomsen RW, Tave AK, Madsen M, et al
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
Diabetes Obes Metab. 2024 Jan 17. doi: 10.1111/dom.15429.
PubMed Abstract available

WANG X, Ma H, Li X, Liang Z, et al
Risk factor control and incident cardiovascular disease in patients with diabetes: Sex-specific relations.
Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15443.
PubMed Abstract available

DE VRIES SAG, Sas TCJ, Bak JCG, Mul D, et al
Socio-economic disparities in hospital care among Dutch patients with diabetes mellitus.
Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15440.
PubMed Abstract available

SAMUELS SL, Chajecki A, Hu P, Kayser M, et al
Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.
Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15430.
PubMed Abstract available

MICHALOPOULOU M, Jebb SA, MacKillop LH, Dyson P, et al
REduced-Carbohydrate intervention for managing Obesity and Reduction of gestational Diabetes (RECORD): A randomized controlled feasibility trial.
Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15442.
PubMed Abstract available

Correction to 'Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model'.
Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15452.
PubMed

SSEMMONDO E, Deshmukh H, Wilmot EG, Adeleke KA, et al
Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation.
Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15435.
PubMed Abstract available

SLOAN L, Cheng AYY, Escalada J, Haluzik M, et al
The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review.
Diabetes Obes Metab. 2024 Jan 15. doi: 10.1111/dom.15425.
PubMed Abstract available

MUNTIS FR, Crandell JL, Evenson KR, Maahs DM, et al
Pre-exercise protein intake is associated with reduced time in hypoglycaemia among adolescents with type 1 diabetes.
Diabetes Obes Metab. 2024 Jan 15. doi: 10.1111/dom.15438.
PubMed Abstract available

WANG W, Guo X, Zhang C, Ning T, et al
Prusogliptin (DBPR108) monotherapy in treatment-naive patients with type 2 diabetes: A randomized, double-blind, active and placebo-controlled, phase 3 study.
Diabetes Obes Metab. 2024 Jan 15. doi: 10.1111/dom.15433.
PubMed Abstract available

SHIVAM V, Gillies CL, Goff LM, Zaccardi F, et al
Taste perception genomics in gestational diabetes mellitus: A systematic review.
Diabetes Obes Metab. 2024 Jan 9. doi: 10.1111/dom.15449.
PubMed

SHETTY S, Suvarna R
Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
Diabetes Obes Metab. 2024 Jan 8. doi: 10.1111/dom.15408.
PubMed Abstract available

HENSON J, Tziannou A, Rowlands AV, Edwardson CL, et al
Twenty-four-hour physical behaviour profiles across type 2 diabetes mellitus subtypes.
Diabetes Obes Metab. 2024 Jan 8. doi: 10.1111/dom.15437.
PubMed Abstract available

RHEE JJ, Han J, Montez-Rath ME, Chertow GM, et al
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
Diabetes Obes Metab. 2024 Jan 8. doi: 10.1111/dom.15427.
PubMed Abstract available

TONG G, Lu S, Kuang H, Li Y, et al
Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.
Diabetes Obes Metab. 2024 Jan 7. doi: 10.1111/dom.15416.
PubMed

MARIGLIANO M, Piona C, Mancioppi V, Morotti E, et al
Glucose sensor with predictive alarm for hypoglycaemia: Improved glycaemic control in adolescents with type 1 diabetes.
Diabetes Obes Metab. 2024 Jan 4. doi: 10.1111/dom.15432.
PubMed Abstract available

YANG W, Guo X, Lauand F, Li L, et al
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
Diabetes Obes Metab. 2024 Jan 3. doi: 10.1111/dom.15414.
PubMed Abstract available

YU L, Wang J, Gong Q, An Y, et al
Influence of a diet and/or exercise intervention on long-term mortality and vascular complications in people with impaired glucose tolerance: Da Qing Diabetes Prevention Outcome study.
Diabetes Obes Metab. 2024 Jan 2. doi: 10.1111/dom.15413.
PubMed Abstract available

DESHMUKH H, Adeleke K, Wilmot EG, Folwell A, et al
Clinical features of type 1 diabetes in older adults and the impact of intermittently scanned continuous glucose monitoring: An Association of British Clinical Diabetologists (ABCD) study.
Diabetes Obes Metab. 2024 Jan 2. doi: 10.1111/dom.15434.
PubMed Abstract available

KIM T, Campbell DB, Au F, Ronksley PE, et al
Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada.
Diabetes Obes Metab. 2024 Jan 2. doi: 10.1111/dom.15419.
PubMed Abstract available

HANKOSKY ER, Wang H, Neff LM, Kan H, et al
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.
Diabetes Obes Metab. 2024;26:319-328.
PubMed Abstract available

ZHU Y, Wang Q, Dai H, Hou T, et al
Sex-specific causality of MRI-derived body compositions on glycaemic traits: Mendelian randomization and observational study.
Diabetes Obes Metab. 2024;26:373-384.
PubMed Abstract available

ROSENSTOCK J, Lee CJ, Fernandez Lando L, Liu M, et al
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial.
Diabetes Obes Metab. 2024;26:396-399.
PubMed

DIALLO A, Carlos-Bolumbu M, Galtier F
Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium-glucose cotransporter 2 inhibitors? A correlation meta-analysis.
Diabetes Obes Metab. 2024;26:392-395.
PubMed

TANDAY N, Tarasov AI, Moffett RC, Flatt PR, et al
Pancreatic islet cell plasticity: Pathogenic or therapeutically exploitable?
Diabetes Obes Metab. 2024;26:16-31.
PubMed Abstract available

DAI H, Hou T, Wang Q, Zhu Z, et al
The effect of metformin on urate metabolism: Findings from observational and Mendelian randomization analyses.
Diabetes Obes Metab. 2024;26:242-250.
PubMed Abstract available

CHEN J, Feng X, Zhou X, Li Y, et al
Role of the tripartite motif-containing (TRIM) family of proteins in insulin resistance and related disorders.
Diabetes Obes Metab. 2024;26:3-15.
PubMed Abstract available

December 2023

MORENO-PEREZ O, Reyes-Garcia R, Modrego-Pardo I, Doulatram-Gamgaram VK, et al
Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO(2) S-RWD).
Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15431.
PubMed

AZIZ F, Sternad C, Sourij C, Knoll L, et al
Glycated haemoglobin, HOMA2-B, C-peptide to glucose ratio and type 2 diabetes clusters as predictors for therapy failure in individuals with type 2 diabetes without insulin therapy: A registry analysis.
Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15409.
PubMed Abstract available

MCMURRAY JJV, Solomon SD, Lock JP, Massaro JM, et al
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.
Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15394.
PubMed Abstract available

LEI M, Ling P, Ni Y, Chen D, et al
The efficacy of glucose-responsive insulin and glucagon delivery on exercise-induced hypoglycaemia among adults with type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15422.
PubMed

ABDELGANI S, Khattab A, Adams J, Baskoy G, et al
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals.
Diabetes Obes Metab. 2023 Dec 22. doi: 10.1111/dom.15404.
PubMed Abstract available

YE M, Vena JE, Shen-Tu G, Johnson JA, et al
Reduced incidence of diabetes during the COVID-19 pandemic in Alberta: A time-segmented longitudinal study of Alberta's Tomorrow Project.
Diabetes Obes Metab. 2023 Dec 22. doi: 10.1111/dom.15420.
PubMed Abstract available

MEHMOOD S, Ye C, Hanley AJ, Connelly PW, et al
Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy.
Diabetes Obes Metab. 2023 Dec 20. doi: 10.1111/dom.15415.
PubMed Abstract available

KARAKASIS P, Patoulias D, Fragakis N, Klisic A, et al
Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.
Diabetes Obes Metab. 2023 Dec 20. doi: 10.1111/dom.15410.
PubMed Abstract available

GERSTEIN HC, Mian R, Ramasundarahettige C, Branch KRH, et al
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
Diabetes Obes Metab. 2023 Dec 20. doi: 10.1111/dom.15417.
PubMed Abstract available

TSUR N, Pollack R, Frankel M, Tsur A, et al
Future diabetes risk can be predicted by the number of abnormal oral glucose tolerance test values during pregnancy.
Diabetes Obes Metab. 2023 Dec 19. doi: 10.1111/dom.15406.
PubMed Abstract available

LI Y, Cheng Z, Lu W, Li P, et al
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Diabetes Obes Metab. 2023 Dec 17. doi: 10.1111/dom.15407.
PubMed Abstract available

YATES T, Biddle GJH, Henson J, Edwardson CL, et al
Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: A prospective cohort analysis.
Diabetes Obes Metab. 2023 Dec 14. doi: 10.1111/dom.15400.
PubMed Abstract available

TAKAHASHI H, Asakawa K, Kosakai Y, Lee T, et al
Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
Diabetes Obes Metab. 2023 Dec 12. doi: 10.1111/dom.15399.
PubMed Abstract available

MUNSHI M, Ritzel R, Jude EB, Dex T, et al
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15377.
PubMed Abstract available

STROMBOTNE KL, Lum J, Pizer SD, Figueroa S, et al
Clinical effectiveness and cost-impact after 2 years of a ketogenic diet and virtual coaching intervention for patients with diabetes.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15401.
PubMed Abstract available

KOBO O, Cavender MA, Jensen TJ, Kuhlman AB, et al
Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15396.
PubMed

DAVIS TME, Davis WA
An assessment of factors contributing to the decline in risk of stroke complicating type 2 diabetes: The Fremantle Diabetes Study.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15391.
PubMed

DRENTHEN LCA, Ajie M, Teerenstra S, Abbink EJ, et al
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15397.
PubMed

WANG X, He C, Wu N, Tian Y, et al
Establishment and validation of a prediction model for gestational diabetes.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15356.
PubMed Abstract available

MIKLOSZ A, Chabowski A
Efficacy of adipose-derived mesenchymal stem cell therapy in the treatment of chronic micro- and macrovascular complications of diabetes.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15375.
PubMed Abstract available

FURUSAWA S, Nomoto H, Yokoyama H, Suzuki Y, et al
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15393.
PubMed Abstract available

CHOE HJ, Oh HR, Bu D, An N, et al
Evaluation of the efficacy of a combination of dapagliflozin and lobeglitazone on glucose concentrations and body fat in patients with type 2 diabetes: Location-F study.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15388.
PubMed

LEE KS, Lee YH, Lee SG
Alanine to glycine ratio is a novel predictive biomarker for type 2 diabetes mellitus.
Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15395.
PubMed Abstract available

WEN Q, Chowdhury AI, Aydin B, Shekha M, et al
Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets.
Diabetes Obes Metab. 2023;25:3757-3765.
PubMed Abstract available

SOHN M, Frias JP, Lim S
Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023;25:3560-3577.
PubMed Abstract available

TAYLOR SI, Cherng HR, Shahidzadeh Yazdi Z, Montasser ME, et al
Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
Diabetes Obes Metab. 2023;25:3512-3520.
PubMed Abstract available

TONDA K, Iwabuchi Y, Shiga T, Owaki Y, et al
Impact of patient characteristic factors on the dynamics of liver glucose metabolism: Evaluation of multiparametric imaging with dynamic whole-body (18) F-fluorodeoxyglucose-positron emission tomography.
Diabetes Obes Metab. 2023;25:3521-3528.
PubMed Abstract available

ALKABBANI W, Shah BR, Zongo A, Eurich DT, et al
Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
Diabetes Obes Metab. 2023;25:3490-3500.
PubMed Abstract available

November 2023

EISSING T, Goulooze SC, van den Berg P, van Noort M, et al
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Diabetes Obes Metab. 2023 Nov 30. doi: 10.1111/dom.15387.
PubMed Abstract available

CHEN X, Hou X, Gao J, Yu X, et al
Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program.
Diabetes Obes Metab. 2023 Nov 30. doi: 10.1111/dom.15380.
PubMed Abstract available

BANTOUNOU MA, Sardellis P, Thuemmler R, Black Boada D, et al
Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023 Nov 29. doi: 10.1111/dom.15364.
PubMed Abstract available

IGWEOKPALA S, Sule NO, Douros A, Yu OHY, et al
Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.
Diabetes Obes Metab. 2023 Nov 29. doi: 10.1111/dom.15367.
PubMed Abstract available

GOLDENBERG RM
A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with t
Diabetes Obes Metab. 2023 Nov 28. doi: 10.1111/dom.15381.
PubMed

QIN W, Yang J, Deng C, Ruan Q, et al
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
Diabetes Obes Metab. 2023 Nov 28. doi: 10.1111/dom.15386.
PubMed Abstract available

WANG H, He S, Wang J, An Y, et al
Does high-normal blood pressure lead to excess cardiovascular disease events and deaths in Chinese people? A post-hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study.
Diabetes Obes Metab. 2023 Nov 27. doi: 10.1111/dom.15379.
PubMed Abstract available

PRATT E
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15372.
PubMed

LIU D, Li N, Zhou Y, Wang M, et al
Sex-specific associations between skeletal muscle mass and incident diabetes: A population-based cohort study.
Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15373.
PubMed Abstract available

FUJITA KK, Ye F, Collister D, Klarenbach S, et al
Sodium-glucose co-transporter-2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes.
Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15361.
PubMed Abstract available

YU C, Wang Y, Zhang B, Xu X, et al
Associations between complexity of glucose time series and cognitive function in adults with type 2 diabetes.
Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15376.
PubMed Abstract available

MATHER KJ, Coskun T, Pratt EJ, Milicevic Z, et al
Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Nov 21. doi: 10.1111/dom.15365.
PubMed

ZIMMER RT, Birnbaumer P, Sternad C, Zunner BEM, et al
Impact of a 4-week intensive track and field training intervention on glycaemia in adolescents with type 1 diabetes: The ChilDFiT1 study.
Diabetes Obes Metab. 2023 Nov 20. doi: 10.1111/dom.15352.
PubMed Abstract available

THABIT H, Boughton C, Mubita W, Rubio J, et al
Impact of hybrid closed-loop insulin delivery on cardiac rhythm in older adults with type 1 diabetes: A post hoc analysis of trial data.
Diabetes Obes Metab. 2023 Nov 20. doi: 10.1111/dom.15366.
PubMed

FAN Y, Xia M, Yan H, Li X, et al
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial.
Diabetes Obes Metab. 2023 Nov 17. doi: 10.1111/dom.15359.
PubMed

SAITO Y, Tanaka A, Imai T, Miura SI, et al
Factors associated with the uric acid-lowering effects of sodium-glucose cotransporter-2 inhibition in patients with type 2 diabetes: Insights from the randomized PROTECT trial.
Diabetes Obes Metab. 2023 Nov 14. doi: 10.1111/dom.15368.
PubMed

LI X, Zhang W, Bi Y, Chen J, et al
Non-alcoholic fatty liver disease is associated with brain function disruption in type 2 diabetes patients without cognitive impairment.
Diabetes Obes Metab. 2023 Nov 14. doi: 10.1111/dom.15354.
PubMed Abstract available

ZHOU L, Su W, Wang Y, Zhang Y, et al
FOXO1 reduces STAT3 activation and causes impaired mitochondrial quality control in diabetic cardiomyopathy.
Diabetes Obes Metab. 2023 Nov 14. doi: 10.1111/dom.15369.
PubMed Abstract available

WEN X, Yang H, Yang M, Tao W, et al
Factors that determine glucose variability, defined by the coefficient of variation in continuous glucose monitoring values, in a Chinese population with type 2 diabetes.
Diabetes Obes Metab. 2023 Nov 12. doi: 10.1111/dom.15350.
PubMed Abstract available

LEI M, Chen D, Ling P, Wang C, et al
Effect of artificial pancreas system use on glycaemic control among pregnant women with type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023 Nov 12. doi: 10.1111/dom.15357.
PubMed Abstract available

KIM J, Kim B, Kim MK, Baek KH, et al
Weight change in patients with new-onset type 2 diabetes mellitus and its association with remission: Comprehensive real-world data.
Diabetes Obes Metab. 2023 Nov 8. doi: 10.1111/dom.15345.
PubMed Abstract available

LIU W, Zhang D, Wang R, Chen J, et al
Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: An age-period-cohort analysis.
Diabetes Obes Metab. 2023 Nov 7. doi: 10.1111/dom.15349.
PubMed Abstract available

HELLMAN J, Hartvig NV, Kaas A, Moller JB, et al
Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes.
Diabetes Obes Metab. 2023 Nov 5. doi: 10.1111/dom.15316.
PubMed Abstract available

REZNIK Y, Carvalho M, Fendri S, Prevost G, et al
Should people with type 2 diabetes treated by multiple daily insulin injections with home health care support be switched to hybrid closed-loop? The CLOSE AP+ randomized controlled trial.
Diabetes Obes Metab. 2023 Nov 3. doi: 10.1111/dom.15351.
PubMed Abstract available

UEMURA T, Nishimoto M, Eriguchi M, Tamaki H, et al
Utility of serum beta2-microglobulin for prediction of kidney outcome among patients with biopsy-proven diabetic nephropathy.
Diabetes Obes Metab. 2023 Nov 3. doi: 10.1111/dom.15347.
PubMed Abstract available

JIANG P, Sun N, Yang W, Xiao L, et al
Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.
Diabetes Obes Metab. 2023;25:3356-3365.
PubMed Abstract available

GASBJERG LS, Rosenkilde MM, Meier JJ, Holst JJ, et al
The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Diabetes Obes Metab. 2023;25:3079-3092.
PubMed Abstract available

SANZ-GONZALEZ A, Cozar-Castellano I, Broca C, Sabatier J, et al
Pharmacological activation of insulin-degrading enzyme improves insulin secretion and glucose tolerance in diet-induced obese mice.
Diabetes Obes Metab. 2023;25:3268-3278.
PubMed Abstract available

RANGLANI S, Ward J, Sattar N, Strawbridge RJ, et al
Testing for associations between HbA1c levels, polygenic risk and brain health in UK Biobank (N = 39 283).
Diabetes Obes Metab. 2023;25:3136-3143.
PubMed Abstract available

STRATHE A, Horn DB, Larsen MS, Rubino D, et al
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.
Diabetes Obes Metab. 2023;25:3171-3180.
PubMed Abstract available

MADDALONI E, Carlone A, Pitocco D, Leanza G, et al
Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow-up study.
Diabetes Obes Metab. 2023;25:3415-3419.
PubMed

October 2023

HENRY Z, Villar Fimbel S, Bendelac N, Perge K, et al
Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics.
Diabetes Obes Metab. 2023 Oct 31. doi: 10.1111/dom.15344.
PubMed Abstract available

SOLIS-HERRERA C, Triplitt C
Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
Diabetes Obes Metab. 2023 Oct 27. doi: 10.1111/dom.15327.
PubMed Abstract available

BOONPOR J, Pell JP, Ho FK, Celis-Morales C, et al
In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank.
Diabetes Obes Metab. 2023 Oct 26. doi: 10.1111/dom.15338.
PubMed Abstract available

SHARMA A, Marques P, Neuen BL, Fletcher RA, et al
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab. 2023 Oct 26. doi: 10.1111/dom.15340.
PubMed

SHAH VN, Al-Karadsheh A, Barnes C, Mandry J, et al
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Diabetes Obes Metab. 2023 Oct 25. doi: 10.1111/dom.15341.
PubMed Abstract available

KIM JH, Lyu YS, Kim MK, Kim SY, et al
Repeated detection of non-alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults.
Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15304.
PubMed Abstract available

SCARAMUZZA AE, Marigliano M, Bonfanti R, Cherubini V, et al
Implementing Control-IQ technology after a virtual educational camp in children and adolescents with type 1 diabetes: Does time in range plateau over 1 year?
Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15343.
PubMed

MA J, Yan X, Feng Q, Liu W, et al
Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study.
Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15317.
PubMed Abstract available

DIALLO A, Villard O, Carlos-Bolumbu M, Renard E, et al
Effects of hypoglycaemic agents on reducing surrogate metabolic parameters for the prevention of cardiovascular events and death in patients with type 2 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15335.
PubMed Abstract available

BODIS K, Breuer S, Crepzia-Pevzner A, Zaharia OP, et al
Impact of physical fitness and exercise training on subcutaneous adipose tissue beiging markers in humans with and without diabetes and a high-fat diet-fed mouse model.
Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15322.
PubMed Abstract available

KUATE DEFO A, Bakula V, Pisaturo A, Labos C, et al
Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.
Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15331.
PubMed Abstract available

ZUCCHINI S, Ripoli C, Cherubini V, Coccioli MS, et al
Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real-world prospective cohort study.
Diabetes Obes Metab. 2023 Oct 22. doi: 10.1111/dom.15330.
PubMed

NIU S, Alkhuzam KA, Guan D, Jiao T, et al
5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
Diabetes Obes Metab. 2023 Oct 22. doi: 10.1111/dom.15332.
PubMed Abstract available

LANDGRAF W, Owens DR, Frier BM, Bolli GB, et al
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.
Diabetes Obes Metab. 2023 Oct 20. doi: 10.1111/dom.15336.
PubMed Abstract available

YANG Y, He L, Liu P, Wang J, et al
Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
Diabetes Obes Metab. 2023 Oct 20. doi: 10.1111/dom.15342.
PubMed Abstract available

SHABNAM S, Abner S, Gillies CL, Davies MJ, et al
Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real-world observational study.
Diabetes Obes Metab. 2023 Oct 19. doi: 10.1111/dom.15337.
PubMed Abstract available

TACK W, De Cock AM, Dirinck EL, Bastijns S, et al
Pathophysiological interactions between sarcopenia and type 2 diabetes: A two-way street influencing diagnosis and therapeutic options.
Diabetes Obes Metab. 2023 Oct 18. doi: 10.1111/dom.15321.
PubMed Abstract available

PATEL H, Khunti K, Rodbard HW, Bajaj HS, et al
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
Diabetes Obes Metab. 2023 Oct 18. doi: 10.1111/dom.15333.
PubMed Abstract available

FOGHSGAARD S, Vedtofte L, Andersen ES, Bahne E, et al
Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.
Diabetes Obes Metab. 2023 Oct 17. doi: 10.1111/dom.15306.
PubMed Abstract available

ABUSHANAB D, Al-Badriyeh D, Marquina C, Liew D, et al
Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model.
Diabetes Obes Metab. 2023 Oct 16. doi: 10.1111/dom.15299.
PubMed Abstract available

TSUKAMOTO S, Tanaka S, Yamada T, Uneda K, et al
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15312.
PubMed Abstract available

NESTI L, Pugliese NR, Santoni L, Armenia S, et al
Distinct effects of type 2 diabetes and obesity on cardiopulmonary performance.
Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15324.
PubMed Abstract available

GOHLKE B, Reschke F, Lanzinger S, Boettcher C, et al
Time trends towards earlier puberty in boys and girls with type 1 diabetes: Insights from the German Diabetes Prospective Follow-up (DPV) registry, 2000 to 2021.
Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15315.
PubMed Abstract available

LU J, Ying Z, Wang P, Fu M, et al
Effects of continuous glucose monitoring on glycaemic control in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15328.
PubMed Abstract available

LEE HA, Park H
Metabolically healthy obese individuals are still at high risk for diabetes: Application of the marginal structural model.
Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15329.
PubMed Abstract available

XIANG AH, Lin JC, Chow T, Martinez MP, et al
Types of diabetes during pregnancy and risk of depression and anxiety in offspring from childhood to young adulthood.
Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15308.
PubMed Abstract available

JI L, Ahmann AJ, Ahren B, Capehorn MS, et al
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.
Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15309.
PubMed Abstract available

PERAKAKIS N, Bornstein SR, Birkenfeld AL, Linkermann A, et al
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Diabetes Obes Metab. 2023 Oct 10. doi: 10.1111/dom.15305.
PubMed Abstract available

LEOHR J, Dellva MA, LaBell E, Coutant DE, et al
Ultra rapid lispro (Lyumjev(R)) shortens time to recovery from hyperglycaemia compared to Humalog(R) in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
Diabetes Obes Metab. 2023 Oct 9. doi: 10.1111/dom.15307.
PubMed Abstract available

YUAN K, Wu B, Zeng R, Zhou F, et al
Construction and validation of a nomogram for predicting diabetes remission at 3 months after bariatric surgery in patients with obesity combined with type 2 diabetes mellitus.
Diabetes Obes Metab. 2023 Oct 9. doi: 10.1111/dom.15303.
PubMed Abstract available

KLIIM-HANSEN V, Johansson KS, Gasbjerg LS, Jimenez-Solem E, et al
The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID-19 in the capital region of Denmark.
Diabetes Obes Metab. 2023 Oct 5. doi: 10.1111/dom.15302.
PubMed Abstract available

DAVIS TME, Davis W
The relationship between glycated haemoglobin and blood glucose-lowering treatment trajectories in type 2 diabetes: The Fremantle Diabetes Study Phase II.
Diabetes Obes Metab. 2023 Oct 5. doi: 10.1111/dom.15314.
PubMed Abstract available

OSONOI T, Oura T, Hirase T
Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
Diabetes Obes Metab. 2023 Oct 4. doi: 10.1111/dom.15296.
PubMed Abstract available

GUAN D, Lewis MO, Li P, Zhang Y, et al
Incremental burden on health-related quality of life, health service utilization and direct medical expenditures associated with cognitive impairment among non-institutionalized people with diabetes aged 65 years and older.
Diabetes Obes Metab. 2023 Oct 3. doi: 10.1111/dom.15313.
PubMed Abstract available

AVGERINOS I, Karagiannis T, Matthews DR, Tsapas A, et al
Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.
Diabetes Obes Metab. 2023;25:3020-3029.
PubMed Abstract available

DOI Y, Hamano T, Yamaguchi S, Sakaguchi Y, et al
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
Diabetes Obes Metab. 2023;25:2944-2953.
PubMed Abstract available

DWYER KM, Figtree P, Gupta A
Therapeutic carbohydrate restriction and sodium-glucose transporter 2 inhibitors in chronic kidney disease: A potentially powerful combination.
Diabetes Obes Metab. 2023;25:2791-2794.
PubMed

SONG SH, Frier BM
Severe hypoglycaemia in adults presenting to a hospital emergency department: Clinical characteristics, comorbidities, and mortality outcomes.
Diabetes Obes Metab. 2023;25:2824-2834.
PubMed Abstract available

ZOU X, Luo Y, Huang Q, Zhu Z, et al
Differential effect of interventions in patients with prediabetes stratified by a machine learning-based diabetes progression prediction model.
Diabetes Obes Metab. 2023 Oct 1. doi: 10.1111/dom.15291.
PubMed Abstract available

September 2023

CHRISTENSEN M, Laugesen ELG, Bibby BM, Hansen KW, et al
The glycaemic roller coaster phenomenon in type 1 diabetes.
Diabetes Obes Metab. 2023 Sep 28. doi: 10.1111/dom.15297.
PubMed

HARRIS SB, Mohammedi K, Bertolini M, Carlyle M, et al
Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross-sectional surveys.
Diabetes Obes Metab. 2023 Sep 25. doi: 10.1111/dom.15240.
PubMed Abstract available

DO QD, Haskova A, Radovnicka L, Konecna J, et al
Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study.
Diabetes Obes Metab. 2023 Sep 25. doi: 10.1111/dom.15289.
PubMed Abstract available

HONG T, Sun F, Wang Q, Chen X, et al
Global burden of diabetes mellitus from 1990 to 2019 attributable to dietary factors: An analysis of the Global Burden of Disease Study 2019.
Diabetes Obes Metab. 2023 Sep 25. doi: 10.1111/dom.15290.
PubMed Abstract available

RADEMAKER D, van der Wel AWT, van Eekelen R, Voormolen DN, et al
Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: A post-hoc analysis of the GlucoMOMS trial.
Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15276.
PubMed Abstract available

BEA S, Son H, Bae JH, Cho SW, et al
Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15292.
PubMed Abstract available

WAN EYF, Mathur S, Zhang R, Lam AHY, et al
Long-term effects of coronavirus disease 2019 on diabetes complications and mortality in people with diabetes: Two cohorts in the UK and Hong Kong.
Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15279.
PubMed Abstract available

WANG W, Yan X, Cheng Z, Zhang Q, et al
Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15263.
PubMed Abstract available

SUGIMOTO T, Tokuda H, Miura H, Kawashima S, et al
Longitudinal association of continuous glucose monitoring-derived metrics with cognitive decline in older adults with type 2 diabetes: A 1-year prospective observational study.
Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15275.
PubMed

SHAO Y, Shi L, Nauman E, Price-Haywood E, et al
Telehealth use and its impact on clinical outcomes in patients with type 2 diabetes during the COVID-19 pandemic.
Diabetes Obes Metab. 2023 Sep 19. doi: 10.1111/dom.15293.
PubMed Abstract available

DAVIS TME, Maxwell S, Chan C, Keen HI, et al
The effect of empagliflozin and fenofibrate therapies, alone and in combination, on the serum urate concentration in hyperuricaemic type 2 diabetes.
Diabetes Obes Metab. 2023 Sep 19. doi: 10.1111/dom.15295.
PubMed

JI L, Lu J, Gao L, Yan X, et al
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.
Diabetes Obes Metab. 2023 Sep 19. doi: 10.1111/dom.15274.
PubMed Abstract available

DRENTHEN LCA, Ajie M, Bakker EA, Abbink EJ, et al
Daily unstructured physical activity affects mean glucose, occurrence of hypoglycaemia and glucose variability in people with type 1 diabetes.
Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15277.
PubMed

DAVIES MJ, Alibegovic AC, Kelkar P, Braae UC, et al
Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice.
Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15278.
PubMed

STEDMAN M, Robinson A, Dunn G, Meza-Torres B, et al
Diabetes foot complications and standardized mortality rate in type 2 diabetes.
Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15260.
PubMed Abstract available

SIVALINGAM S, Wasehuus VS, Rotbain Curovic V, Blond MB, et al
Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15287.
PubMed Abstract available

WANG J, Liu H, Yue G, Deng Y, et al
Human placenta-derived mesenchymal stem cells ameliorate diabetic kidney disease by modulating the T helper 17 cell/ regulatory T-cell balance through the programmed death 1 / programmed death-ligand 1 pathway.
Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15282.
PubMed Abstract available

WILLIAMS KJ, Bashan E, Kruse C, Sritharan S, et al
Time in range in patients with type 2 diabetes who are long-term users of d-Nav(R), an artificial intelligence-driven technology for autonomous titration of insulin dosing.
Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15280.
PubMed

NADKARNI GN, Stapleton S, Takale D, Edwards K, et al
Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15273.
PubMed Abstract available

MARK-WAGSTAFF C, Deshmukh H, Wilmot EG, Walker N, et al
Intermittently scanned continuous glucose monitoring and hypoglycaemia awareness in drivers with diabetes: Insights from the Association of British Clinical Diabetologists Nationwide audit.
Diabetes Obes Metab. 2023 Sep 17. doi: 10.1111/dom.15283.
PubMed Abstract available

BOYE KS, Lebrec J, Dib A, Heitmann E, et al
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Diabetes Obes Metab. 2023 Sep 15. doi: 10.1111/dom.15145.
PubMed Abstract available

RATZKI-LEEWING A, Black JE, Kahkoska AR, Ryan BL, et al
Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States).
Diabetes Obes Metab. 2023 Sep 13. doi: 10.1111/dom.15268.
PubMed Abstract available

GIORGINO F, Guerci B, Fuchtenbusch M, Lebrec J, et al
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical
Diabetes Obes Metab. 2023 Sep 12. doi: 10.1111/dom.15244.
PubMed Abstract available

HANKOSKY ER, Wang H, Neff LM, Kan H, et al
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.
Diabetes Obes Metab. 2023 Sep 12. doi: 10.1111/dom.15269.
PubMed Abstract available

BRANDTS J, Tittel SR, Bramlage P, Danne T, et al
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Diabetes Obes Metab. 2023 Sep 11. doi: 10.1111/dom.15264.
PubMed Abstract available

PIEBER TR, Asong M, Fluhr G, Holler V, et al
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes.
Diabetes Obes Metab. 2023 Sep 11. doi: 10.1111/dom.15266.
PubMed Abstract available

YU J, Sweeting AN, Gianacas C, Houston L, et al
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab. 2023 Sep 6. doi: 10.1111/dom.15267.
PubMed Abstract available

KARAKASIS P, Patoulias D, Pamporis K, Popovic DS, et al
Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Obes Metab. 2023 Sep 5. doi: 10.1111/dom.15259.
PubMed Abstract available

RAJEEV SP, Roberts CA, Brown E, Sprung VS, et al
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
Diabetes Obes Metab. 2023 Sep 5. doi: 10.1111/dom.15257.
PubMed Abstract available

NAKAJIMA H, Okada H, Yoshimura Y, Tanaka T, et al
Younger patients and low c-peptide immunoreactivity index but not nutritional states affect fasting blood ketone levels in Japanese with type 1 diabetes after sodium-glucose cotransporter 2 inhibitor administration.
Diabetes Obes Metab. 2023 Sep 5. doi: 10.1111/dom.15262.
PubMed Abstract available

JI L, Lu J, Gao L, Ying C, et al
Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.
Diabetes Obes Metab. 2023 Sep 3. doi: 10.1111/dom.15261.
PubMed Abstract available

FINEMAN MS, Bryant CLN, Colbert K, Jozefiak TH, et al
First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations.
Diabetes Obes Metab. 2023;25:2447-2456.
PubMed Abstract available

PRATT E, Ma X, Liu R, Robins D, et al
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Diabetes Obes Metab. 2023;25:2634-2641.
PubMed Abstract available

LE ROUX CW, Hankosky ER, Wang D, Malik R, et al
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.
Diabetes Obes Metab. 2023;25:2626-2633.
PubMed Abstract available

BANERJEE M, Pal R, Maisnam I, Chowdhury S, et al
Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.
Diabetes Obes Metab. 2023;25:2697-2703.
PubMed Abstract available

SHIN W, Hompesch M, Byeon J, Kang S, et al
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.
Diabetes Obes Metab. 2023;25:2723-2733.
PubMed Abstract available

URVA S, O'Farrell L, Du Y, Loh MT, et al
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
Diabetes Obes Metab. 2023;25:2784-2788.
PubMed

KUNZLER J, Zuger T, Stettler C, Laimer MW, et al
Comparing the technical reliability and insulin dosing of a "do-it-yourself artificial pancreas" with a commercial hybrid closed-loop system in a "shadow-mode" scenario: An exploratory study.
Diabetes Obes Metab. 2023;25:2780-2783.
PubMed

GRADINARIU V, Ard J, van Dam RM
Effects of dietary quality, physical activity and weight loss on glucose homeostasis in persons with and without prediabetes in the PREMIER trial.
Diabetes Obes Metab. 2023;25:2714-2722.
PubMed Abstract available

MEDSCI KKF, Schnecke V, Haase CL, Harder-Lauridsen NM, et al
Weight change and risk of obesity-related complications: A retrospective population-based cohort study of a UK primary care database.
Diabetes Obes Metab. 2023;25:2669-2679.
PubMed Abstract available

TAYLOR SI, Montasser ME, Yuen AH, Fan H, et al
Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
Diabetes Obes Metab. 2023;25:2586-2594.
PubMed Abstract available

CASTANEDA J, Arrieta A, van den Heuvel T, Cohen O, et al
The significance of coefficient of variation as a measure of hypoglycaemia risk and glycaemic control in real world users of the automated insulin delivery MiniMed 780G system.
Diabetes Obes Metab. 2023;25:2545-2552.
PubMed Abstract available

KEIDAI Y, Yoshiji S, Hasebe M, Minamino H, et al
Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: A meta-analysis and meta-regression analysis.
Diabetes Obes Metab. 2023;25:2505-2513.
PubMed Abstract available

WU H, Liu X, Jiang W, Hu C, et al
The rest-activity rhythm, genetic susceptibility and risk of type 2 diabetes: A prospective study in UK Biobank.
Diabetes Obes Metab. 2023 Sep 1. doi: 10.1111/dom.15236.
PubMed Abstract available

August 2023

KIMURA T, Katakura Y, Shimoda M, Kawasaki F, et al
Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Diabetes Obes Metab. 2023 Aug 30. doi: 10.1111/dom.15258.
PubMed Abstract available

CAMPBELL MD, Alobaid AM, Hopkins M, Dempsey PC, et al
Interrupting prolonged sitting with frequent short bouts of light-intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT-LESS randomised controlled trial.
Diabetes Obes Metab. 2023 Aug 25. doi: 10.1111/dom.15254.
PubMed Abstract available

YABE D, Shiki K, Homma G, Meinicke T, et al
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (>/=65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
Diabetes Obes Metab. 2023 Aug 25. doi: 10.1111/dom.15249.
PubMed Abstract available

GUO L, Li L, Yu Q, Wang N, et al
Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.
Diabetes Obes Metab. 2023 Aug 23. doi: 10.1111/dom.15252.
PubMed Abstract available

MOLLO A, Vlacho B, Gratacos M, Mata-Cases M, et al
A multicomponent health care intervention is associated with improved glycaemic control in subjects with poorly controlled type 2 diabetes compared with routine care: The INTEGRA study.
Diabetes Obes Metab. 2023 Aug 22. doi: 10.1111/dom.15250.
PubMed Abstract available

CHE M, Xia Z, Jiang D, Wang Y, et al
Impact of sarcosine on diabetic retinopathy: Findings based on weighted gene co-expression network analysis and machine learning techniques.
Diabetes Obes Metab. 2023 Aug 22. doi: 10.1111/dom.15243.
PubMed Abstract available

LIU Y, Wang J, Xu F, Zhang S, et al
A J-shaped relationship between ketones and the risk of diabetic kidney disease in patients with type 2 diabetes: New insights from a cross-sectional study.
Diabetes Obes Metab. 2023 Aug 22. doi: 10.1111/dom.15231.
PubMed Abstract available

Correction to "Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey".
Diabetes Obes Metab. 2023 Aug 17. doi: 10.1111/dom.15253.
PubMed

MULLER A, Moser O, Sternad C, Aziz F, et al
Effects of 8 weeks of aerobic endurance training on functional capacity and metabolic variables in people with type 1 diabetes: A secondary outcome analysis of the ULTRAFLEXI-1 study.
Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15245.
PubMed

MCINNES N, Hall S, Lochnan HA, Harris SB, et al
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15234.
PubMed Abstract available

ASHRAF MT, Ahmed Rizvi SH, Kashif MAB, Shakeel Khan MK, et al
Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15237.
PubMed Abstract available

HALS IK, Balasuriya C, Casas R, Ludvigsson J, et al
A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15239.
PubMed Abstract available

HEERSPINK HJL, Vart P, Jongs N, Neuen BL, et al
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15232.
PubMed Abstract available

EDD SN, Castaneda J, Choudhary P, Kolassa R, et al
Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
Diabetes Obes Metab. 2023 Aug 8. doi: 10.1111/dom.15217.
PubMed Abstract available

ISAKSEN AA, Sandbaek A, Skriver MV, Bjerg L, et al
Glucose-lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types.
Diabetes Obes Metab. 2023 Aug 7. doi: 10.1111/dom.15230.
PubMed Abstract available

BELL DSH, Jerkins T
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome.
Diabetes Obes Metab. 2023 Aug 3. doi: 10.1111/dom.15222.
PubMed Abstract available

NIEUWLAND AJ, Waibel FWA, Flury A, Lisy M, et al
Initial antibiotic therapy for postoperative moderate or severe diabetic foot infections: Broad versus narrow spectrum, empirical versus targeted.
Diabetes Obes Metab. 2023 Aug 2. doi: 10.1111/dom.15228.
PubMed Abstract available

KAN M, Fu H, Xu Y, Yue Z, et al
Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
Diabetes Obes Metab. 2023 Aug 2. doi: 10.1111/dom.15219.
PubMed Abstract available

MANNUCCI E, Silverii GA
Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.
Diabetes Obes Metab. 2023 Aug 2. doi: 10.1111/dom.15226.
PubMed Abstract available

HOOGENDOORN M, Galekop M, van Baal P
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?
Diabetes Obes Metab. 2023;25:2351-2361.
PubMed Abstract available

SILVER HJ, Olson D, Mayfield D, Wright P, et al
Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Diabetes Obes Metab. 2023;25:2340-2350.
PubMed Abstract available

SRIDHAR VS, Neuen BL, Fletcher RA, Slee A, et al
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Diabetes Obes Metab. 2023;25:2331-2339.
PubMed Abstract available

SEN T, Curovic VR, Jongs N, Laverman GD, et al
Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.
Diabetes Obes Metab. 2023;25:2413-2418.
PubMed

SMEIJER JD, Kohan DE, de Zeeuw D, Heerspink HJL, et al
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
Diabetes Obes Metab. 2023;25:2419-2422.
PubMed

BLUHER M, Aras M, Aronne LJ, Batterham RL, et al
New insights into the treatment of obesity.
Diabetes Obes Metab. 2023;25:2058-2072.
PubMed Abstract available

GOH SY, Kosiborod MN, Lam CSP, Cavender MA, et al
Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study.
Diabetes Obes Metab. 2023;25:2402-2409.
PubMed

BJORNER JB, Larsen S, Lubker C, Holst-Hansen T, et al
The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.
Diabetes Obes Metab. 2023;25:2142-2150.
PubMed Abstract available

CUMMINGS C, Jiang A, Sheehan A, Ferraz-Bannitz R, et al
Continuous glucose monitoring in patients with post-bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability.
Diabetes Obes Metab. 2023;25:2191-2202.
PubMed Abstract available

July 2023

ROMADLON DS, Tu YK, Chen YC, Hasan F, et al
Comparative efficacy of digitally assisted interventions for glycated haemoglobin levels among patients with type 2 diabetes: A systematic review and component network Meta-Analysis.
Diabetes Obes Metab. 2023 Jul 31. doi: 10.1111/dom.15227.
PubMed Abstract available

PARK S, Jeong HE, Bea S, Yu OHY, et al
Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Jul 28. doi: 10.1111/dom.15221.
PubMed Abstract available

VAN HULTEN V, Driessen JHM, Starup-Linde JK, Al-Mashhadi ZK, et al
The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
Diabetes Obes Metab. 2023 Jul 28. doi: 10.1111/dom.15220.
PubMed Abstract available

LI R, Chen JX, Lu Q, Geng TT, et al
Associations of lipoprotein subclasses with risk of all-cause and cardiovascular disease mortality in individuals with type 2 diabetes: A prospective cohort study.
Diabetes Obes Metab. 2023 Jul 26. doi: 10.1111/dom.15224.
PubMed Abstract available

BARRON E, Khunti K, Wright AK, Ashcroft DM, et al
Impact of the COVID-19 pandemic on new diagnoses of type 2 diabetes in England.
Diabetes Obes Metab. 2023 Jul 25. doi: 10.1111/dom.15223.
PubMed

UNSWORTH R, Avari P, Lett AM, Oliver N, et al
Adaptive bolus calculators for people with type 1 diabetes: A systematic review.
Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15204.
PubMed Abstract available

VERHULST CEM, van Heck JIP, Fabricius TW, Stienstra R, et al
Hypoglycaemia induces a sustained pro-inflammatory response in people with type 1 diabetes and healthy controls.
Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15205.
PubMed Abstract available

ISMAIL HM, Barua S, Wang J, Sabharwal A, et al
Baseline leptin predicts response to metformin in adolescents with type 1 diabetes and increased body mass index.
Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15218.
PubMed

AL MALKI F, El Damanhoury B, Othman A, Alghamdi Z, et al
Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15178.
PubMed Abstract available

HUANG F, Ji X, Wang Z, Yin Y, et al
Fat-to-muscle ratio is associated with insulin resistance and cardiometabolic disorders in adults with type 1 diabetes mellitus.
Diabetes Obes Metab. 2023 Jul 17. doi: 10.1111/dom.15212.
PubMed Abstract available

LIAO WL, Huang YN, Chang YW, Liu TY, et al
Combining polygenic risk scores and human leukocyte antigen variants for personalized risk assessment of type 1 diabetes in the Taiwanese population.
Diabetes Obes Metab. 2023 Jul 17. doi: 10.1111/dom.15187.
PubMed Abstract available

RON I, Mdah R, Zemet R, Ulman RY, et al
Adipose tissue-derived FABP4 mediates glucagon-stimulated hepatic glucose production in gestational diabetes.
Diabetes Obes Metab. 2023 Jul 14. doi: 10.1111/dom.15214.
PubMed Abstract available

ZHOU C, Dong C, Wang Q, Fu C, et al
Healthy lifestyle and all-cause and cause-specific dementia in individuals with type 2 diabetes and the roles of diabetes duration and insulin use in UK Biobank cohort.
Diabetes Obes Metab. 2023 Jul 12. doi: 10.1111/dom.15215.
PubMed Abstract available

BASSAND JP, Virdone S, Camm AJ, Fox KAA, et al
Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry.
Diabetes Obes Metab. 2023 Jul 12. doi: 10.1111/dom.15202.
PubMed Abstract available

KARAKUS KE, Shah VN, Klonoff D, Akturk HK, et al
Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes.
Diabetes Obes Metab. 2023 Jul 10. doi: 10.1111/dom.15208.
PubMed Abstract available

CHERNEY DZI, Bhatt DL, Szarek M, Sun F, et al
Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab. 2023 Jul 10. doi: 10.1111/dom.15203.
PubMed

WU Y, Cheng S, Gu H, Yang K, et al
Variants within the LPL gene confer susceptility to diabetic kidney disease and rapid decline in kidney function in Chinese patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Jul 10. doi: 10.1111/dom.15199.
PubMed Abstract available

FUJIHARA K, Khin L, Murai K, Yamazaki Y, et al
Relationship between the magnitude of body mass index reductions and remission in patients with type 2 diabetes in real world settings: Analysis of nationwide patient registry in Japan (JDDM74).
Diabetes Obes Metab. 2023 Jul 7. doi: 10.1111/dom.15206.
PubMed Abstract available

ROTBAIN CUROVIC V, Houlind MB, Kroonen MYAM, Jongs N, et al
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
Diabetes Obes Metab. 2023 Jul 7. doi: 10.1111/dom.15209.
PubMed Abstract available

HALVORSEN YD, Conery AL, Lock JP, Zhou W, et al
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15192.
PubMed Abstract available

NGUYEN BN, Mital S, Bugden S, Nguyen HV, et al
Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes.
Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15201.
PubMed Abstract available

RATZKI-LEEWING AA, Black JE, Ryan BL, Zou G, et al
Development and validation of a real-world model to predict 1-year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States).
Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15186.
PubMed Abstract available

BELL DSH, McGill JB, Jerkins T
Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes.
Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15181.
PubMed Abstract available

RIGATO M, Fadini GP, Avogaro A
Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023 Jul 4. doi: 10.1111/dom.15193.
PubMed Abstract available

ROSSING P, Anker SD, Filippatos G, Pitt B, et al
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
Diabetes Obes Metab. 2023 Jul 4. doi: 10.1111/dom.15197.
PubMed Abstract available

JURGENS M, Schou M, Hasbak P, Kjaer A, et al
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15183.
PubMed Abstract available

ABRAHAMI D, D'Andrea E, Yin H, Kim SC, et al
Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.
Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15196.
PubMed Abstract available

GIORDA CB, Gnavi R, Tartaglino B, Favella L, et al
An update on the incidence of type 1 diabetes during the COVID-19 pandemic years.
Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15182.
PubMed

NICHOLAS SB, Daratha KB, Alicic RZ, Jones CR, et al
Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.
Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15194.
PubMed Abstract available

CIARALDI TP, Boeder SC, Mudaliar SR, Giovannetti ER, et al
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia.
Diabetes Obes Metab. 2023;25:1985-1994.
PubMed Abstract available

YI TW, Wong MMY, Neuen BL, Arnott C, et al
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab. 2023;25:2043-2047.
PubMed

YAZAWA R, Ishida M, Balavarca Y, Hennige AM, et al
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
Diabetes Obes Metab. 2023;25:1973-1984.
PubMed Abstract available

YILDIRIM SIMSIR I, Tuysuz B, Ozbek MN, Tanrikulu S, et al
Clinical features of generalized lipodystrophy in Turkey: A cohort analysis.
Diabetes Obes Metab. 2023;25:1950-1963.
PubMed Abstract available

MCEWAN P, Foos V, Martin B, Chen J, et al
Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence.
Diabetes Obes Metab. 2023;25:1830-1838.
PubMed Abstract available

JHUND PS
Improving heart failure outcomes with sodium-glucose cotransporter 2 inhibitors in different patient groups.
Diabetes Obes Metab. 2023;25 Suppl 3:26-32.
PubMed Abstract available

June 2023

LAURSEN JC, Rotbain Curovic V, Kroonen MYAM, Jongs N, et al
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15180.
PubMed

ZENG J, Gan S, Mi N, Liu Y, et al
Diabetes remission in drug-naive patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study.
Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15179.
PubMed Abstract available

ZHAO L, Bidargaddi N, Vakulin A, Li W, et al
A micro-randomized pilot study to examine the impact of just-in-time nudging on after-dinner snacking in adults with type 2 diabetes: A study protocol.
Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15159.
PubMed Abstract available

KOSHIZAKA M, Ishibashi R, Ishikawa K, Shoji M, et al
Urinary alpha1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15188.
PubMed

RILEY DR, Essa H, Austin P, Preston F, et al
All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15185.
PubMed Abstract available

SCHECHTER M, Melzer Cohen C, Zelter T, Yanuv I, et al
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.
Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15172.
PubMed

RETNAKARAN R, Pu J, Emery A, Kramer CK, et al
Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function.
Diabetes Obes Metab. 2023 Jun 28. doi: 10.1111/dom.15073.
PubMed Abstract available

WANG Y, Lu J, Ni J, Wang M, et al
Association between glycaemia risk index (GRI) and diabetic retinopathy in type 2 diabetes: A cohort study.
Diabetes Obes Metab. 2023 Jun 23. doi: 10.1111/dom.15068.
PubMed Abstract available

XUE P, Tan X, Benedict C
Association of socioeconomic deprivation with sleep health in patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Jun 21. doi: 10.1111/dom.15190.
PubMed Abstract available

SHAO Y, Shi L, Nauman E, Price-Haywood E, et al
Trends and disparities in telehealth use among Louisiana Medicaid beneficiaries with type 2 diabetes.
Diabetes Obes Metab. 2023 Jun 20. doi: 10.1111/dom.15155.
PubMed Abstract available

PARK HK, Kim KA, Min KW, Sohn TS, et al
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study.
Diabetes Obes Metab. 2023 Jun 20. doi: 10.1111/dom.15164.
PubMed Abstract available

ASANO M, Sekikawa A, Sugeno M, Matsuoka O, et al
Safety/tolerability, efficacy and pharmacokinetics of 600-mug cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m(2) or higher: A phase I, randomized, double-blind, placebo-controlled study.
Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15107.
PubMed Abstract available

YU HJ, Ho M, Chau PH, Fong DYT, et al
Trajectories of fasting glucose and glycated haemoglobin in obese and non-obese incident diabetes: Results from two large cohort studies.
Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15173.
PubMed Abstract available

DAVIES MJ, Alibegovic AC, Jensen AB, Munikrishnappa R, et al
Real-world study of ethnic differences in glycaemic control and clinical characteristics among insulin-naive people with type 2 diabetes initiating biphasic insulin aspart 30/70: A retrospective, observational cohort study in England.
Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15165.
PubMed Abstract available

LIN Y, Shao H, Fonseca V, Anderson AH, et al
A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States.
Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15177.
PubMed Abstract available

ALSHANNAQ H, Cogswell G, Pollock RF, Ahmed W, et al
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark.
Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15158.
PubMed Abstract available

ZUSI C, Csermely A, Rinaldi E, Bertoldo K, et al
Crosstalk between genetic variability of adiponectin and leptin, glucose-insulin system and subclinical atherosclerosis in patients with newly diagnosed type 2 diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study 14.
Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15152.
PubMed Abstract available

MARTINOT JB, Le-Dong NN, Borel AL, Tamisier R, et al
Respiratory effort during sleep and the rate of prevalent type 2 diabetes in obstructive sleep apnoea.
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15169.
PubMed Abstract available

RITZEL R, Ghosh S, Emral R, Malek R, et al
Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naive people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15121.
PubMed Abstract available

BEA S, Choi A, Kim JH, Cho YM, et al
Risk of breakthrough SARS-CoV-2 infection and clinical outcomes among vaccinated patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15163.
PubMed Abstract available

DEO SV, Al-Kindi S, Motairek I, Elgudin YE, et al
Neighbourhood-level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes.
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15174.
PubMed Abstract available

COLLIER A, Curran C, Cameron L, Wild SH, et al
Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study).
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15153.
PubMed Abstract available

SAXENA AR, Frias JP, Gorman DN, Lopez RN, et al
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15168.
PubMed Abstract available

ZHANG YN, Dai YJ, Cui Y, Wu Q, et al
Diabetes, fasting blood glucose and the efficacy of remote ischaemic conditioning: A secondary analysis of the RICAMIS trial.
Diabetes Obes Metab. 2023 Jun 8. doi: 10.1111/dom.15156.
PubMed Abstract available

HEINRICH NS, Pedersen RP, Vestergaard MB, Lindberg U, et al
Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab. 2023 Jun 6. doi: 10.1111/dom.15146.
PubMed Abstract available

DE LUCA M, Zese M, Bandini G, Chiappetta S, et al
Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta-analysis and network meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023 Jun 5. doi: 10.1111/dom.15117.
PubMed Abstract available

GRASSI B, Gomez AM, Calliari LE, Franco D, et al
Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
Diabetes Obes Metab. 2023;25:1688-1697.
PubMed Abstract available

NERILD HH, Bronden A, Gether IM, Hellmann PH, et al
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.
Diabetes Obes Metab. 2023;25:1632-1637.
PubMed Abstract available

ROSENSTOCK J, Kolkailah AA, McGuire DK, Espeland MA, et al
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
Diabetes Obes Metab. 2023;25:1453-1463.
PubMed Abstract available

PRATT E, Ma X, Liu R, Robins D, et al
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab. 2023 Jun 1. doi: 10.1111/dom.15150.
PubMed Abstract available

May 2023

VAN WEENEN E, Banholzer N, Foll S, Zueger T, et al
Glycaemic patterns of male professional athletes with type 1 diabetes during exercise, recovery and sleep: Retrospective, observational study over an entire competitive season.
Diabetes Obes Metab. 2023 May 31. doi: 10.1111/dom.15147.
PubMed Abstract available

HARTMANN B, Tittel SR, Gillesen A, Klarl B, et al
Surfing the waves of the COVID-19 pandemic with diabetes mellitus: Analysis of changes in the diabetes therapy, metabolism and physical activity of 92 992 people living with type 1 or type 2 diabetes from the German DPV registry.
Diabetes Obes Metab. 2023 May 31. doi: 10.1111/dom.15149.
PubMed

DELL'AQUILA K, Lee J, Wang SH, Alamuri TT, et al
Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID-19 patients: Comparison with influenza and pre-pandemic data.
Diabetes Obes Metab. 2023 May 30. doi: 10.1111/dom.15120.
PubMed Abstract available

FRECHTEL G, Sauque-Reyna L, Choza-Romero R, Anguiano L, et al
Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
Diabetes Obes Metab. 2023 May 30. doi: 10.1111/dom.15125.
PubMed Abstract available

SU J, Li M, Wan X, Yu H, et al
Associations of diabetes, prediabetes and diabetes duration with the risk of chronic obstructive pulmonary disease: A prospective UK Biobank study.
Diabetes Obes Metab. 2023 May 29. doi: 10.1111/dom.15142.
PubMed Abstract available

PUAR P, Ahmed S, Hibino M, Pasricha A, et al
The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease.
Diabetes Obes Metab. 2023 May 29. doi: 10.1111/dom.15119.
PubMed

PEDERSEN SD, Giorgino F, Umpierrez G, Thieu VT, et al
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
Diabetes Obes Metab. 2023 May 29. doi: 10.1111/dom.15140.
PubMed Abstract available

CHERNEY DZI, de Zeeuw D, Heerspink HJL, Cardona J, et al
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Diabetes Obes Metab. 2023 May 25. doi: 10.1111/dom.15099.
PubMed Abstract available

HAGELQVIST PG, Andersen A, Maytham K, Andreasen CR, et al
Glycaemia and cardiac arrhythmias in people with type 1 diabetes: A prospective observational study.
Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15108.
PubMed Abstract available

YUAN L, Li-Gao R, Verhoeven A, van Eyk HJ, et al
Altered high-density lipoprotein composition is associated with risk for complications in type 2 diabetes mellitus in South Asian descendants: A cross-sectional, case-control study on lipoprotein subclass profiling.
Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15118.
PubMed Abstract available

FORBES AK, Suckling RJ, Hinton W, Feher MD, et al
Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15111.
PubMed Abstract available

STAMATI A, Sotiriou G, Karagiannis T, Christoforidis A, et al
Efficacy and safety of carbohydrate restriction in patients with type 1 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15124.
PubMed

LAROSE S, Filliter C, Platt RW, Yu OHY, et al
Long-acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population-based cohort study.
Diabetes Obes Metab. 2023 May 11. doi: 10.1111/dom.15106.
PubMed Abstract available

WU Y, Wang Z, Zhao Z, Song X, et al
Bile acid metabolites in early pregnancy and risk of gestational diabetes mellitus: Results from a prospective cohort study.
Diabetes Obes Metab. 2023 May 10. doi: 10.1111/dom.15104.
PubMed Abstract available

KANG A, Smyth B, Neuen BL, Heerspink HJL, et al
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double
Diabetes Obes Metab. 2023 May 10. doi: 10.1111/dom.15091.
PubMed Abstract available

DE VRIES SAG, Bak JCG, Stangenberger VA, Wouters MWJM, et al
Use of hospital care among Dutch diabetes patients.
Diabetes Obes Metab. 2023 May 8. doi: 10.1111/dom.15105.
PubMed Abstract available

FUJIHARA K, Khin L, Murai K, Yamazaki Y, et al
Incidence and predictors of remission and relapse of type 2 diabetes mellitus in Japan: Analysis of a nationwide patient registry (JDDM73).
Diabetes Obes Metab. 2023 May 8. doi: 10.1111/dom.15100.
PubMed Abstract available

KOHAN DE, Liew A, Tang SCW, Barratt J, et al
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab. 2023 May 4. doi: 10.1111/dom.15103.
PubMed

MOSER O, Rafferty J, Eckstein ML, Aziz F, et al
Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study.
Diabetes Obes Metab. 2023 May 4. doi: 10.1111/dom.15102.
PubMed Abstract available

MADDALONI E, Cavallari I, La Porta Y, Appetecchia A, et al
Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2023;25:1341-1350.
PubMed Abstract available

ARODA VR, Erhan U, Jelnes P, Meier JJ, et al
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
Diabetes Obes Metab. 2023;25:1385-1397.
PubMed Abstract available

NAUCK MA, Mirna AEA, Quast DR
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic po
Diabetes Obes Metab. 2023;25:1361-1371.
PubMed Abstract available

STARK R, Feehan J, Mousa A, Andrews ZB, et al
Liver-expressed antimicrobial peptide 2 is associated with improved pancreatic insulin secretion in adults with overweight and obesity.
Diabetes Obes Metab. 2023;25:1213-1220.
PubMed Abstract available

April 2023

VERMA S, Husain M, Madsen CM, Leiter LA, et al
Neutrophil-lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials.
Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15088.
PubMed

CHUNG SM, Moon JS, Hong JH, Hwang IC, et al
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: the Gemi-Heart study.
Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15095.
PubMed Abstract available

JENDLE J, Reznik Y
Insulin Pump and Closed Loop Systems' Use in People Living with Diabetes: A Narrative Review of Clinical and Cost-Effectiveness to Enable Access to Technology and Meet the Need of Payers.
Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15087.
PubMed Abstract available

SHAN J, Xu Z
Effect of multifactorial intensive treatment in patients with diabetic kidney disease: a meta-analysis with trial sequential analysis.
Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15093.
PubMed Abstract available

TAKUMA K, Fuchigami A, Shigiyama F, Kumashiro N, et al
Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study.
Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15089.
PubMed Abstract available

LEE MMY, Sattar N
A review of current key guidelines for managing high risk patients with diabetes and heart failure and future prospects.
Diabetes Obes Metab. 2023 Apr 11. doi: 10.1111/dom.15085.
PubMed Abstract available

JUNG Y, Ahn E, Park T, Hwang GS, et al
Longitudinal study investigating serum metabolites and their association with type 2 diabetes risk in a Korean population.
Diabetes Obes Metab. 2023 Apr 11. doi: 10.1111/dom.15084.
PubMed Abstract available

VERMA S, David JP, Leiter LA, Michelsen MM, et al
Semaglutide reduces risk of MACE consistently across baseline triglyceride levels in patients with type 2 diabetes: Post Hoc Analyses of SUSTAIN 6 and PIONEER 6 trials.
Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15081.
PubMed

FIELD BCT, Ruan Y, Varnai KA, Davies J, et al
A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID-19.
Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15076.
PubMed Abstract available

YANG YS, Min KW, Park SO, Kim KS, et al
Efficacy and Safety of Monotherapy with Enavogliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results of a 12-week, multi-center, randomized, double-blind, placebo-controlled, phase 2 trial.
Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15080.
PubMed Abstract available

ARODA VR, Frias JP, Ji L, Niemoeller E, et al
Efficacy and Safety of Once-Weekly Efpeglenatide in People with Suboptimally Controlled Type 2 Diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S Randomised Controlled Trials.
Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15079.
PubMed Abstract available

PEMBERTON JS, Wilmot EG, Barnard-Kelly K, Leelarathna L, et al
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review.
Diabetes Obes Metab. 2023;25:916-939.
PubMed Abstract available

YU JH, Kim REY, Park SY, Lee DY, et al
Association of long-term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study.
Diabetes Obes Metab. 2023;25:1091-1100.
PubMed Abstract available

JUNGNIK A, Arrubla Martinez J, Plum-Morschel L, Kapitza C, et al
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Diabetes Obes Metab. 2023;25:1011-1023.
PubMed Abstract available

POTTEGARD A, Andersen JH, Sondergaard J, Thomsen RW, et al
Changes in the use of glucose-lowering drugs: A Danish nationwide study.
Diabetes Obes Metab. 2023;25:1002-1010.
PubMed Abstract available

SBRACCIA P, Aberle J, Olsen AH, Rathor N, et al
Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.
Diabetes Obes Metab. 2023;25:985-991.
PubMed Abstract available

KASTNER JR, Poettler T, Kopanz J, Hochfellner DA, et al
Current insulin infusion set failure criteria may be too stringent for real-life settings and may skew infusion set failure outcomes in extended-wear infusion set studies.
Diabetes Obes Metab. 2023;25:1106-1111.
PubMed

ALCORN C, Subarajan P, Kesari A, Lockhart M, et al
Sodium-glucose cotransporter-2 inhibitor prescribing practices.
Diabetes Obes Metab. 2023;25:1136-1139.
PubMed

March 2023

QUINN LM, Swaby R, Tatovic D, Narendan P, et al
What does the licensing of teplizumab mean for diabetes care?
Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15071.
PubMed

NGUYEN C, Crowe CL, Kuti E, Narsipur N, et al
Impact of pre-existing type 2 diabetes with and without cardiovascular disease on patients with COVID-19.
Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15069.
PubMed Abstract available

GUO X, Yang W, Zhang J, Dong X, et al
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15074.
PubMed Abstract available

SEEGMILLER JC, Schmit DJ, Arends VL, Steffes MW, et al
Assessment of Circulating Insulin Using Mass Spectrometry During Insulin Glargine Treatment in Type 2 Diabetes: Implications for Estimating Insulin Sensitivity and beta-cell Function.
Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15072.
PubMed Abstract available

ARONSON R, Biester T, Leohr J, Pollom R, et al
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents, and adults with type 1 diabetes mellitus.
Diabetes Obes Metab. 2023 Mar 27. doi: 10.1111/dom.15063.
PubMed Abstract available

BOONPOR J, Parra-Soto S, Gore J, Talebi A, et al
Association Between Walking Pace and Incident Type 2 Diabetes by Adiposity Levels - A Prospective Cohort Study from The UK Biobank.
Diabetes Obes Metab. 2023 Mar 23. doi: 10.1111/dom.15053.
PubMed Abstract available

JERKINS T, McGill JB, Bell DSH
Heart Failure and Diabetes: Clinical significance and epidemiology of this two-way association.
Diabetes Obes Metab. 2023 Mar 22. doi: 10.1111/dom.15062.
PubMed Abstract available

BALINTESCU A, Lind M, Andersson Franko M, Oldner A, et al
Glycemic control and sepsis risk in adults with type 1 diabetes.
Diabetes Obes Metab. 2023 Mar 22. doi: 10.1111/dom.15060.
PubMed Abstract available

EKANAYAKE P, Edelman S
Identifying Those Patients with Type 2 Diabetes Who Might Benefit from Insulin Pump Therapy: Literature Review, Clinical Opportunities, Potential Benefits & Challenges.
Diabetes Obes Metab. 2023 Mar 22. doi: 10.1111/dom.15059.
PubMed Abstract available

MCGUIRE DK, Busui RP, Deanfield J, Inzucchi SE, et al
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL, a randomized trial, design and baseline characteristics.
Diabetes Obes Metab. 2023 Mar 21. doi: 10.1111/dom.15058.
PubMed Abstract available

TSOUKAS MA, Woo V, Tobe SW, Slee A, et al
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDENCE.
Diabetes Obes Metab. 2023 Mar 21. doi: 10.1111/dom.15057.
PubMed

SIMON TG, Wexler DJ, Schneeweiss S, Patorno E, et al
Antidiabetes Medication Initiation Trends in U.S. Adults with Cirrhosis and Type 2 Diabetes: A Nationwide Study.
Diabetes Obes Metab. 2023 Mar 20. doi: 10.1111/dom.15052.
PubMed

KABTHYMER RH, Karim MN, Hodge AM, de Courten B, et al
High cereal fibre but not total fibre is associated with a lower risk of type 2 diabetes: Evidence from Melbourne Collaborative Cohort Study.
Diabetes Obes Metab. 2023 Mar 18. doi: 10.1111/dom.15054.
PubMed Abstract available

PINTAUDI B, Gironi I, Meneghini E, Conti M, et al
Advanced hybrid closed loop system use in elderly with type 1 diabetes: effectiveness and safety in a prospective, observational, one year follow-up real-world study.
Diabetes Obes Metab. 2023 Mar 18. doi: 10.1111/dom.15055.
PubMed

KANG SM, Yun HM, Sohn M, Lim S, et al
Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study.
Diabetes Obes Metab. 2023 Mar 18. doi: 10.1111/dom.15056.
PubMed Abstract available

PASQUALOTTO E, Maintinguer RDS, van de Sande-Lee S, Araujo GN, et al
EFFICACY AND SAFETY OF BEXAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Diabetes Obes Metab. 2023 Mar 16. doi: 10.1111/dom.15051.
PubMed Abstract available

BONGAERTS B, Kuss O, Bonnet F, Chen H, et al
HbA(1c) trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
Diabetes Obes Metab. 2023 Mar 12. doi: 10.1111/dom.15050.
PubMed Abstract available

MIYA A, Nakamura A, Suzuki Y, Nomoto H, et al
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion using continuous glucose monitoring: a prospective observational study.
Diabetes Obes Metab. 2023 Mar 12. doi: 10.1111/dom.15049.
PubMed Abstract available

JI L
Current challenges of diabetes and metabolic disorders in China.
Diabetes Obes Metab. 2023 Mar 7. doi: 10.1111/dom.15048.
PubMed

STOUGAARD EB, Rossing P, Vistisen D, Banks P, et al
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease as assessed by Steno T1 Risk Engine in adults with type 1 diabetes.
Diabetes Obes Metab. 2023 Mar 5. doi: 10.1111/dom.15047.
PubMed

KWAK SH, Han KA, Kim KS, Yu JM, et al
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Diabetes Obes Metab. 2023 Mar 5. doi: 10.1111/dom.15046.
PubMed Abstract available

MOHAMMEDI K, Belhatem N, Berentzen TL, Catarig AM, et al
Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study.
Diabetes Obes Metab. 2023 Mar 4. doi: 10.1111/dom.15045.
PubMed Abstract available

IBALD-MULLI A, Seufert J, Grimsmann JM, Laimer M, et al
Identification of Predictive Factors of Diabetic Ketoacidosis in Type 1 Diabetes Using a Subgroup Discovery Algorithm.
Diabetes Obes Metab. 2023 Mar 3. doi: 10.1111/dom.15039.
PubMed Abstract available

GUO X, Sang C, Tang R, Jiang C, et al
Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.
Diabetes Obes Metab. 2023 Mar 2. doi: 10.1111/dom.15043.
PubMed Abstract available

JI L, Lu Y, Li Q, Fu L, et al
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A Phase III, randomised, double-blind, placebo-controlled, parallel study.
Diabetes Obes Metab. 2023 Mar 2. doi: 10.1111/dom.15041.
PubMed Abstract available

YANG M, Chen J, Yue J, He S, et al
Liver fat is superior to visceral and pancreatic fat as a risk biomarker of impaired glucose regulation in overweight/obese subjects.
Diabetes Obes Metab. 2023;25:716-725.
PubMed Abstract available

February 2023

ALAMURI TT, Mahesh S, Dell'Aquila K, Leong TJ, et al
COVID-19 Associated Ketosis and Diabetic Ketoacidosis: A Rapid Review.
Diabetes Obes Metab. 2023 Feb 28. doi: 10.1111/dom.15036.
PubMed Abstract available

JUNG H, Tittel SR, Schloot NC, Heitmann E, et al
Clinical characteristics, treatment patterns and persistence in individuals with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry.
Diabetes Obes Metab. 2023 Feb 28. doi: 10.1111/dom.15038.
PubMed Abstract available

KJAERGAARD AD, Krakauer J, Krakauer N, Teumer A, et al
Allometric body shape indices, type 2 diabetes and kidney function: A two-sample Mendelian randomization study.
Diabetes Obes Metab. 2023 Feb 28. doi: 10.1111/dom.15037.
PubMed Abstract available

YEGGALAM A, Liebich JA, Yu K, Shrestha E, et al
Safety and efficacy of sodium glucose transport inhibitors in patients with kidney transplantation and diabetes mellitus.
Diabetes Obes Metab. 2023 Feb 27. doi: 10.1111/dom.15035.
PubMed

ARNOLD SV, de Lemos JA, Zheng L, Rosenson RS, et al
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.
Diabetes Obes Metab. 2023 Feb 27. doi: 10.1111/dom.15032.
PubMed Abstract available

VAN DER AART-VAN DER BEEK AB, Apperloo E, Jongs N, Rouw DB, et al
Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomized cross-over clinical study.
Diabetes Obes Metab. 2023 Feb 26. doi: 10.1111/dom.15033.
PubMed Abstract available

BEHARY P, Alessmii H, Miras AD, Tharakan G, et al
Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and pre-diabetes/diabetes but promotes restraint eating: A secondary analysis of a randomised single-blind placebo-controlled study.
Diabetes Obes Metab. 2023 Feb 22. doi: 10.1111/dom.15028.
PubMed Abstract available

HARRIS SB, Levrat-Guillen F
Use the FreeStyle Libre system and diabetes treatment progression in T2DM: Results from a retrospective cohort study using a Canadian private payer claims database.
Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15025.
PubMed Abstract available

LIN C, Zhu X, Jiao R, Cai X, et al
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: an analysis using national cross-sectional data.
Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15029.
PubMed Abstract available

XIA Z, You W, Li Y, Li F, et al
Association between residual islet beta-cell function and achieving the target of time in range in inpatients with T2DM undergoing anti-diabetic treatment: an observation study.
Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15026.
PubMed Abstract available

GUJA C, Kis JT, Haluzik M, Bonnemaire M, et al
iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) is effective and well-tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15027.
PubMed Abstract available

GESUITA R, Rabbone I, Marconi V, De Sanctis L, et al
Trends and Cyclic Variation in the Incidence of Childhood Type 1 Diabetes in Two Italian Regions Over 33 Years and During The Covid-19 Pandemic.
Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15024.
PubMed Abstract available

VILSBOLL T, Lindahl CO, Nielsen NF, Tikkanen CK, et al
Real-world impact of once-weekly subcutaneous semaglutide after two years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15031.
PubMed Abstract available

PALMER BF
Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes.
Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15030.
PubMed Abstract available

CHEN J, Fan L, Maughn K, Rey GG, et al
Trajectory of Glycated Hemoglobin Over Time Among Type 2 Diabetes Patients with Obesity on U-100 Basal-Bolus Insulin Regimen Using Real-World Data.
Diabetes Obes Metab. 2023 Feb 16. doi: 10.1111/dom.15022.
PubMed Abstract available

PEPIN JL, Bailly S, Texereau JB, Sonnet E, et al
Prevalence of sleep apnea in patients with type 1 diabetes and its association with comorbidities and diabetic complications: a French nationwide prospective study.
Diabetes Obes Metab. 2023 Feb 15. doi: 10.1111/dom.15015.
PubMed Abstract available

LEHMANN V, Zueger T, Maritsch M, Kraus M, et al
Machine learning for non-invasive sensing of hypoglycemia while driving in people with diabetes.
Diabetes Obes Metab. 2023 Feb 15. doi: 10.1111/dom.15021.
PubMed Abstract available

NAPOLI R, Berra C, Catarig AM, Di Loreto C, et al
Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study.
Diabetes Obes Metab. 2023 Feb 15. doi: 10.1111/dom.15020.
PubMed Abstract available

TYE SC, Oshima M, Arnott C, Neuen BL, et al
The importance of targeting multiple risk markers in patients with type 2 diabetes: a post-hoc study from the CANVAS program.
Diabetes Obes Metab. 2023 Feb 13. doi: 10.1111/dom.15018.
PubMed Abstract available

CHERNEY DZI, Ferrannini E, Umpierrez GE, Peters AL, et al
Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes and Stage 3 Chronic Kidney Disease.
Diabetes Obes Metab. 2023 Feb 13. doi: 10.1111/dom.15019.
PubMed Abstract available

VERMA S, Sabbour H, Alamuddin N, Alawadi F, et al
A cross-sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa (PACT-MEA): study design and rationale.
Diabetes Obes Metab. 2023 Feb 12. doi: 10.1111/dom.15011.
PubMed Abstract available

LI X, Hou X, Zhang H, Qian X, et al
The association between stress hyperglycemia and in-hospital cardiac events after coronary artery bypass grafting in patients without diabetes: A retrospective observational study of 5,450 patients.
Diabetes Obes Metab. 2023 Feb 12. doi: 10.1111/dom.15013.
PubMed Abstract available

ANDREASEN CR, Andersen A, Hagelqvist PG, Maytham K, et al
Sustained QTc Prolongation During Recovery from Hypoglycemia in People with Type 1 Diabetes, Independently of Recovery to Hyper- or Euglycemia.
Diabetes Obes Metab. 2023 Feb 8. doi: 10.1111/dom.15005.
PubMed Abstract available

BENHAMOU PY, Adenis A, Lebbad H, Tourki Y, et al
One year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany.
Diabetes Obes Metab. 2023 Feb 8. doi: 10.1111/dom.15008.
PubMed Abstract available

NGUYEN BN, Nguyen L, Mital S, Bugden S, et al
Comparative Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review and Network Meta-A
Diabetes Obes Metab. 2023 Feb 8. doi: 10.1111/dom.15009.
PubMed Abstract available

BROSEN JMB, Agesen RM, Kristensen PL, Alibegovic AC, et al
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
Diabetes Obes Metab. 2023 Feb 7. doi: 10.1111/dom.15003.
PubMed Abstract available

HIRUMA S, Shigiyama F, Kumashiro N
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: A prospective randomized study.
Diabetes Obes Metab. 2023 Feb 7. doi: 10.1111/dom.15006.
PubMed Abstract available

JOSHI SR, Singh G, Marwah A, Mittra S, et al
Comparative clinical efficacy and safety of insulin glargine 300 U/mL (Toujeo) versus insulin glargine 100 U/mL in Type 2 and Type 1 diabetes mellitus: A systematic literature review and meta-analysis.
Diabetes Obes Metab. 2023 Feb 6. doi: 10.1111/dom.15007.
PubMed Abstract available

BELL DSH
Detecting and treating the protean manifestations of diabetic autonomic neuropathy.
Diabetes Obes Metab. 2023 Feb 6. doi: 10.1111/dom.15004.
PubMed Abstract available

HOFFMAN EG, D'Souza NC, Aiken J, Atherley S, et al
Effects of Somatostatin Receptor Type 2 Antagonism During Insulin-Induced Hypoglycaemia in Male Rats with Pre-Diabetes.
Diabetes Obes Metab. 2023 Feb 3. doi: 10.1111/dom.15002.
PubMed Abstract available

FAWZY AM, Rivera-Caravaca JM, Fauchier L, Lip GYH, et al
Response to letter from Du et al. regarding article 'Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?'.
Diabetes Obes Metab. 2023;25:630-633.
PubMed

RODBARD D
Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy.
Diabetes Obes Metab. 2023;25:596-601.
PubMed Abstract available

EVANS M, Anupindi VR, DeKoven M, de Laguiche E, et al
Eight-year trends in obesity-related complications and health care cost progression in a US population with obesity: A retrospective cohort study.
Diabetes Obes Metab. 2023;25:536-544.
PubMed Abstract available

KOSIBOROD MN, Bhatta M, Davies M, Deanfield JE, et al
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Diabetes Obes Metab. 2023;25:468-478.
PubMed Abstract available

DU L, Qin J, Zhang Y
Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?
Diabetes Obes Metab. 2023;25:628-629.
PubMed

ZACCARDI F, Tan PS, Coupland C, Shah BR, et al
Ethnicity and risks of severe COVID-19 outcomes associated with glucose-lowering medications: A cohort study.
Diabetes Obes Metab. 2023;25:611-617.
PubMed

ISLAM N, Reynier P, Douros A, Yu OHY, et al
Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population-based cohort study.
Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.15000.
PubMed Abstract available

MCGILL JB, Agarwal R, Anker SD, Bakris GL, et al
Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.14999.
PubMed Abstract available

TAKAHASHI Y, Nomoto H, Yokoyama H, Takano Y, et al
Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (
Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.14998.
PubMed Abstract available

FERREIRA JP, Saraiva F, Sharma A, Vasques-Novoa F, et al
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials.
Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.14997.
PubMed Abstract available

January 2023

GREEN JB, Merrill P, Lokhnygina Y, Mentz RJ, et al
Sex differences in complications, care, and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Diabetes Obes Metab. 2023 Jan 26. doi: 10.1111/dom.14993.
PubMed Abstract available

QI QYD, Playfair J, Brown WA, Burton P, et al
Long-term impact of weight loss for people with overweight but not obesity, and with type 2 diabetes: ten-year outcomes of a randomised trial of gastric band surgery.
Diabetes Obes Metab. 2023 Jan 26. doi: 10.1111/dom.14992.
PubMed Abstract available

DAR MS, Wanner C, Marx N, Ofstad AP, et al
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA, and CARMELINA: assessment of a novel staging system for type 2 diabetes.
Diabetes Obes Metab. 2023 Jan 26. doi: 10.1111/dom.14989.
PubMed Abstract available

OBEROI A, Giezenaar C, Rigda RS, Horowitz M, et al
Effects of co-ingesting glucose and whey protein on blood glucose, plasma insulin and glucagon concentrations, and gastric emptying, in older men with and without type 2 diabetes.
Diabetes Obes Metab. 2023 Jan 24. doi: 10.1111/dom.14983.
PubMed Abstract available

VON ARX LB, Rachman J, Webb J, Casey C, et al
Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
Diabetes Obes Metab. 2023 Jan 24. doi: 10.1111/dom.14985.
PubMed Abstract available

HELLER S, Battelino T, Bailey TS, Pieber TR, et al
Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes.
Diabetes Obes Metab. 2023 Jan 24. doi: 10.1111/dom.14987.
PubMed Abstract available

LUND LC, Jensen PH, Pottegard A, Andersen M, et al
Identifying diabetogenic drugs using real world healthcare databases: a Danish and Australian symmetry analysis.
Diabetes Obes Metab. 2023 Jan 22. doi: 10.1111/dom.14982.
PubMed Abstract available

DI MOLFETTA S, Caruso I, Cignarelli A, Natalicchio A, et al
Professional continuous glucose monitoring in patients with diabetes mellitus: a systematic review and meta-analysis.
Diabetes Obes Metab. 2023 Jan 20. doi: 10.1111/dom.14981.
PubMed Abstract available

KOSHINO A, Oshima M, Arnott C, Fletcher RA, et al
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis of the CREDENCE trial.
Diabetes Obes Metab. 2023 Jan 19. doi: 10.1111/dom.14978.
PubMed

VALENTINE WJ, Hoog M, Mody R, Belger M, et al
Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the US.
Diabetes Obes Metab. 2023 Jan 18. doi: 10.1111/dom.14979.
PubMed Abstract available

OULHAJ A, Aziz F, Suliman A, Iqbal N, et al
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.
Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14975.
PubMed Abstract available

HARRIS SB, Mohammedi K, Bertolini M, White J, et al
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: a cross-sectional survey.
Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14973.
PubMed

MORITA R, Tsukamoto S, Obata S, Yamada T, et al
Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients.
Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14976.
PubMed Abstract available

LAJARA R, Heller C, Pantalone KM, Lew E, et al
iGlarLixi vs. premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: SoliComplex real-world study.
Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14974.
PubMed Abstract available

ANDERSEN G, Eloy R, Famulla S, Heise T, et al
A co-formulation of pramlintide and insulin A21G (ADO09) improves post-prandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14972.
PubMed Abstract available

JI L, Jiang X, Hao Q, Cheng Z, et al
Efficacy and Safety of Janagliflozin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.
Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14971.
PubMed Abstract available

BLUHER M, Malhotra A, Bader G
beta-cell function in treatment-naive patients with type 2 diabetes mellitus: Analyses of baseline data from 15 clinical trials.
Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14969.
PubMed

LI Y, Yu D, Guo L, Mu Y, et al
Efficacy and Safety of Basal-First Titration Order in Individuals with Type 2 Diabetes Receiving Short-Term Intensive Insulin Therapy: An Exploratory Analysis of BEYOND V.
Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14970.
PubMed Abstract available

FRIAS JP, Lee ML, Carter MM, Ebel ER, et al
A Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial.
Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14967.
PubMed Abstract available

RETNAKARAN M, Viana LV, Kramer CK
Lifestyle Intervention for the Prevention of Type 2 Diabetes in women with Prior Gestational Diabetes: A Systematic Review and Meta-analysis.
Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14966.
PubMed Abstract available

KIM JM, Bhatt DL, Dagogo-Jack S, Cherney DZI, et al
Potential for Residual Cardiovascular Risk Reduction: Eligibility for Icosapent Ethyl in the VERTIS CV Population with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Diabetes Obes Metab. 2023 Jan 2. doi: 10.1111/dom.14965.
PubMed

HAGELQVIST PG, Andersen A, Maytham KB, Andreasen CR, et al
Exercise-Related Hypoglycemia Induces QTc-Interval Prolongation in Individuals With Type 1 Diabetes.
Diabetes Obes Metab. 2023 Jan 2. doi: 10.1111/dom.14964.
PubMed Abstract available

BERGMANN NC, Davies MJ, Lingvay I, Knop FK, et al
Semaglutide for the treatment of overweight and obesity: A review.
Diabetes Obes Metab. 2023;25:18-35.
PubMed Abstract available

NYSTROM T, Toresson Grip E, Gunnarsson J, Casajust P, et al
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
Diabetes Obes Metab. 2023;25:261-271.
PubMed Abstract available

December 2022

PACKER M
Alleviation of Functional Iron Deficiency by SGLT2 Inhibition in Patients With Type 2 Diabetes.
Diabetes Obes Metab. 2022 Dec 30. doi: 10.1111/dom.14963.
PubMed

MEIER JJ, Bardtrum L, Cheng AYY, Malling B, et al
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis.
Diabetes Obes Metab. 2022 Dec 23. doi: 10.1111/dom.14957.
PubMed

LEE YH, Kim DM, Yu JM, Choi KM, et al
Anagliptin twice-daily regimen improves glycemic variability in subjects with type 2 diabetes: Double-Blind, Randomized Controlled Trial.
Diabetes Obes Metab. 2022 Dec 23. doi: 10.1111/dom.14959.
PubMed Abstract available

ARONSON R, Brown RE, Chu L, Bajaj HS, et al
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycemic ThErapy (IMMEDIATE): A Randomized Clinical Trial.
Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14949.
PubMed Abstract available

MOLLO A, Vlacho B, Gratacos M, Mata-Cases M, et al
Impact of a Multicomponent Healthcare Intervention on Glycemic Control in Subjects with Poorly Controlled Type 2 Diabetes: The INTEGRA Study.
Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14951.
PubMed Abstract available

GERSTEIN HC, Wolsk E, Claggett B, Diaz R, et al
Effect of Lixisenatide on Natriuretic Peptides in People With Type 2 Diabetes And Recent Acute Coronary Syndrome: The ELIXA Trial.
Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14954.
PubMed

KIYOSUE A, Dunn JP, Cui X, Hickey A, et al
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS program).
Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14952.
PubMed Abstract available

RASALAM R, Abdo S, Deed G, O'Brien R, et al
Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence.
Diabetes Obes Metab. 2022 Dec 21. doi: 10.1111/dom.14953.
PubMed Abstract available

HEISE T, Chien J, Beals JM, Benson C, et al
Pharmacokinetic and pharmacodynamic properties of the novel Basal Insulin Fc (BIF, insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes mellitus.
Diabetes Obes Metab. 2022 Dec 20. doi: 10.1111/dom.14956.
PubMed Abstract available

SAXENA AR, Lyle SA, Khavandi K, Qiu R, et al
A phase 2a, randomized, double-blind, placebo-controlled, 3-arm, parallel-group study to assess the efficacy, safety, tolerability, and pharmacodynamics of PF-06835919 in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus.
Diabetes Obes Metab. 2022 Dec 14. doi: 10.1111/dom.14946.
PubMed Abstract available

THABIT H, Mubita W, Rubio J, Karuppan M, et al
Comparison of faster-acting aspart with insulin aspart under conditions mimicking under-estimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery.
Diabetes Obes Metab. 2022 Dec 13. doi: 10.1111/dom.14942.
PubMed

LINGVAY I, Cheng AY, Levine JA, Gomez-Valderas E, et al
Achievement of glycemic targets with weight loss and without hypoglycemia in type 2 diabetes with once-weekly GIP and GLP-1 receptor agonist tirzepatide: a post-hoc analysis of the SURPASS-1 to -5 studies.
Diabetes Obes Metab. 2022 Dec 13. doi: 10.1111/dom.14943.
PubMed Abstract available

KOLKAILAH AA, Lingvay I, Dobrecky-Mery I, Aharonovich A, et al
Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the SUSTAIN-6 Trial.
Diabetes Obes Metab. 2022 Dec 13. doi: 10.1111/dom.14941.
PubMed

AZURI J, Hammerman A, Aboalhasan E, Sluckis B, et al
Tirzepatide vs. Semaglutide for Weight Loss In Patients With Type 2 Diabetes Mellitus - A Value For Money Analysis.
Diabetes Obes Metab. 2022 Dec 12. doi: 10.1111/dom.14940.
PubMed Abstract available

DELVECCHIO M, Galati A, Maffeis C, Passanisi S, et al
Retrospective analysis of 24-month real-world glucose control for children and adolescents with type 1 diabetes using the MiniMed(TM) 670G insulin pump.
Diabetes Obes Metab. 2022 Dec 12. doi: 10.1111/dom.14934.
PubMed

BRANDT-JACOBSEN NH, Jurgens M, Hasbak P, Gaede P, et al
Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: a sub-study from the SIMPLE randomized clinical trial.
Diabetes Obes Metab. 2022 Dec 9. doi: 10.1111/dom.14933.
PubMed Abstract available

MCCARTHY OM, Birch Kristensen K, Christensen MB, Schmidt S, et al
Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy.
Diabetes Obes Metab. 2022 Dec 8. doi: 10.1111/dom.14938.
PubMed Abstract available

THAMMAKOSOL K, Sriphrapradang C
Effectiveness and Safety of Early Insulin Glargine Administration in Combination with Continuous Intravenous Insulin Infusion in Management of Diabetic Ketoacidosis: A Randomized Controlled Trial.
Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14929.
PubMed Abstract available

BIANZANO S, Rose S, Nordaby M, Plum-Morschel L, et al
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14932.
PubMed Abstract available

ZHAO Y, Zheng Y, Tian Y, Yu Q, et al
Objective sleep characteristics and continuous glucose monitoring profiles of type 2 diabetes patients in real-life settings.
Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14930.
PubMed Abstract available

MATSUBAYASHI Y, Yoshida A, Suganami H, Oe M, et al
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
Diabetes Obes Metab. 2022;24:2469-2473.
PubMed

KADOWAKI T, Maegawa H, Watada H, Yabe D, et al
Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan.
Diabetes Obes Metab. 2022;24:2283-2296.
PubMed Abstract available

HUANG CJ, Wang WT, Sung SH, Chen CH, et al
Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.
Diabetes Obes Metab. 2022;24:2341-2352.
PubMed Abstract available

TANDAY N, Lafferty RA, Flatt PR, Irwin N, et al
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.
Diabetes Obes Metab. 2022;24:2353-2363.
PubMed Abstract available

OTTO T, Diesing J, Borchert J, Heitmann E, et al
Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles, and use of diabetes drugs in Germany using health claims data.
Diabetes Obes Metab. 2022 Dec 1. doi: 10.1111/dom.14924.
PubMed Abstract available

November 2022

KRESS S, Bramlage P, Holl RW, Moller CD, et al
Validation of a Risk Prediction Model for Early Chronic Kidney Disease in Patients with Type 2 Diabetes: Data from the German/Austrian DPV Registry.
Diabetes Obes Metab. 2022 Nov 29. doi: 10.1111/dom.14925.
PubMed Abstract available

ONO R, Furihata K, Ichikawa Y, Nakazuru Y, et al
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
Diabetes Obes Metab. 2022 Nov 26. doi: 10.1111/dom.14928.
PubMed Abstract available

YANG R, Bai J, Fang Z, Wang Y, et al
Effects of Intensive Blood Pressure Lowering in Patients with Diabetes: A Pooled Analysis of the STEP and ACCORD-BP Randomized Trials.
Diabetes Obes Metab. 2022 Nov 26. doi: 10.1111/dom.14927.
PubMed Abstract available

GAO L, Cheng Z, Su B, Su X, et al
Efficacy and Safety of Janagliflozin as Add-on Therapy to Metformin in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.
Diabetes Obes Metab. 2022 Nov 25. doi: 10.1111/dom.14926.
PubMed Abstract available

CORBIN KD, Dagogo-Jack S, Cannon CP, Cherney DZI, et al
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease - analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin.
Diabetes Obes Metab. 2022 Nov 17. doi: 10.1111/dom.14923.
PubMed Abstract available

NEW RRC, Sukumar R, Chaudhari V, Bogus M, et al
Safety and Efficacy of an Oral Insulin (Capsulin) in Patients with Early-Stage Type 2 Diabetes: A Dose-Ranging Phase IIb Study.
Diabetes Obes Metab. 2022 Nov 15. doi: 10.1111/dom.14922.
PubMed Abstract available

NILSSON K, Andersson E, Persson S, Karlsdotter K, et al
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.
Diabetes Obes Metab. 2022 Nov 12. doi: 10.1111/dom.14921.
PubMed Abstract available

PERSSON S, Nilsson K, Karlsdotter K, Skogsberg J, et al
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital-based care, days absent from work, costs, and mortality.
Diabetes Obes Metab. 2022 Nov 12. doi: 10.1111/dom.14919.
PubMed Abstract available

WU MZ, Teng TK, Tay WT, Ren QW, et al
Chronic kidney disease begets heart failure and vice versa; temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes.
Diabetes Obes Metab. 2022 Nov 8. doi: 10.1111/dom.14916.
PubMed Abstract available

EVANS M, Berry S, Nazeri A, Malkin SJ, et al
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modeling of type 2 diabetes.
Diabetes Obes Metab. 2022 Nov 7. doi: 10.1111/dom.14917.
PubMed Abstract available

THABIT H, Boughton C, Mubita W, Rubio J, et al
Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes.
Diabetes Obes Metab. 2022 Nov 6. doi: 10.1111/dom.14914.
PubMed

ROSSING P, Garweg JG, Anker SD, Osonoi T, et al
Effect of finerenone on occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFin
Diabetes Obes Metab. 2022 Nov 4. doi: 10.1111/dom.14915.
PubMed

HAN Y, Hu H, Liu Y, Wang Z, et al
Nomogram model and risk score to predict 5-year risk of progression from pre-diabetes to diabetes in Chinese adults: development and validation of a novel model.
Diabetes Obes Metab. 2022 Nov 2. doi: 10.1111/dom.14910.
PubMed Abstract available

LIU SC, Chuang SM, Wang CH, Chien MN, et al
Comparison of two titration programs for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus.
Diabetes Obes Metab. 2022 Nov 2. doi: 10.1111/dom.14912.
PubMed Abstract available

KHUNTI K, Aroda VR, Bhatt DL, Bozkurt B, et al
Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Diabetes Obes Metab. 2022;24:2071-2080.
PubMed Abstract available

SNITKER S, Egebjerg C, Frederiksen M, Sparre T, et al
Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
Diabetes Obes Metab. 2022;24:2273-2276.
PubMed

CASTANEDA J, Mathieu C, Aanstoot HJ, Arrieta A, et al
Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
Diabetes Obes Metab. 2022;24:2212-2221.
PubMed Abstract available

CHOI IY, Chang Y, Cho Y, Kang J, et al
Prediabetes diagnosis is associated with the progression of coronary artery calcification: The Kangbuk Samsung Health Study.
Diabetes Obes Metab. 2022;24:2118-2126.
PubMed Abstract available

RIVELINE JP, Wojtusciszyn A, Guerci B, Alves C, et al
Real world hypoglycaemia related to glucose variability and Flash glucose scan frequency assessed from global FreeStyle Libre data.
Diabetes Obes Metab. 2022;24:2102-2107.
PubMed Abstract available

JONES B, Burade V, Akalestou E, Manchanda Y, et al
In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist.
Diabetes Obes Metab. 2022;24:2090-2101.
PubMed Abstract available

October 2022

IGUDESMAN D, Crandell J, Corbin KD, Zaharieva DP, et al
Weight Management in Young Adults with Type 1 Diabetes: The Advancing Care for Type 1 Diabetes and Obesity Network Sequential Multiple Assignment Randomized Trial Pilot Results.
Diabetes Obes Metab. 2022 Oct 31. doi: 10.1111/dom.14911.
PubMed Abstract available

HE F, Chen W, Xu W, Liu D, et al
Safety and Efficacy of Liraglutide on Reducing Visceral and Ectopic Fat in Adults with or without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Diabetes Obes Metab. 2022 Oct 31. doi: 10.1111/dom.14908.
PubMed Abstract available

DU Y, Gao L, Xiao X, Hou X, et al
A Multi-center, Randomized, Double-Blinded, Parallel, Active and Placebo-Controlled Phase 3 Clinical Study of the glucokinase activator PB-201 in Treatment-naive Patients with Type 2 Diabetes Mellitus: A Study Protocol.
Diabetes Obes Metab. 2022 Oct 30. doi: 10.1111/dom.14909.
PubMed Abstract available

HARPER R, Bashan E, Williams KJ, Sritharan S, et al
Challenging the 50-50 rule for the basal-bolus insulin ratio in patients with type 2 diabetes who maintain stable glycemic control.
Diabetes Obes Metab. 2022 Oct 30. doi: 10.1111/dom.14904.
PubMed

HOME PD, McCrimmon RJ, Rosenstock J, Bluher M, et al
Findings for iGlarLixi vs BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
Diabetes Obes Metab. 2022 Oct 30. doi: 10.1111/dom.14907.
PubMed Abstract available

MASHAYEKHI M, Beckman JA, Nian H, Garner EM, et al
Comparative Effects of Weight Loss and Incretin-Based Therapies on Vascular Endothelial Function, Fibrinolysis, and Inflammation in Individuals with Obesity and Pre-Diabetes: A Randomized, Controlled Trial.
Diabetes Obes Metab. 2022 Oct 28. doi: 10.1111/dom.14903.
PubMed Abstract available

ELDOR R, Francis BH, Fleming A, Neutel J, et al
Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study.
Diabetes Obes Metab. 2022 Oct 24. doi: 10.1111/dom.14901.
PubMed Abstract available

BATTELINO T, Danne T, Edelman SV, Choudhary P, et al
CGM-based Time-in-Range Using Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled InRange Trial.
Diabetes Obes Metab. 2022 Oct 20. doi: 10.1111/dom.14898.
PubMed Abstract available

AVGERINOS I, Karagiannis T, Liakos A, Tsapas A, et al
Racial, ethnic and sex disparities among participants in cardiovascular outcomes trials in type 2 diabetes: A systematic review and descriptive analysis.
Diabetes Obes Metab. 2022 Oct 19. doi: 10.1111/dom.14900.
PubMed Abstract available

EVANS M, Chubb B, Malkin SJ, Berry S, et al
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Diabetes Obes Metab. 2022 Oct 17. doi: 10.1111/dom.14892.
PubMed Abstract available

LI P, Zhang P, Guan D, Guo J, et al
Changes in racial and ethnic disparities in glucose-lowering drug utilization and HbA1c in US adults with diabetes: 2005-2018.
Diabetes Obes Metab. 2022 Oct 17. doi: 10.1111/dom.14894.
PubMed Abstract available

HINTON W, Ansari AS, Whyte MB, McGovern AP, et al
Sodium-glucose co-transporter-2 (SGLT2) inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
Diabetes Obes Metab. 2022 Oct 14. doi: 10.1111/dom.14893.
PubMed Abstract available

HONG SN, Mak IL, Chin WY, Yu EYT, et al
Age-specific associations between the number of comorbidities and all-cause mortality and public direct medical costs in patients with type 2 diabetes: a retrospective cohort study.
Diabetes Obes Metab. 2022 Oct 7. doi: 10.1111/dom.14889.
PubMed Abstract available

MANNUCCI E, Gallo M, Giaccari A, Candido R, et al
Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events.
Diabetes Obes Metab. 2022 Oct 7. doi: 10.1111/dom.14888.
PubMed Abstract available

MOODY AJ, Molina-Wilkins M, Clarke GD, Merovci A, et al
Pioglitazone Reduces Epicardial Fat and Improves Diastolic Function in Patients with Type 2 Diabetes.
Diabetes Obes Metab. 2022 Oct 7. doi: 10.1111/dom.14885.
PubMed Abstract available

LIU L, Yan F, Yan H, Wang Z, et al
Impact of iron supplementation on gestational diabetes mellitus: a literature review.
Diabetes Obes Metab. 2022 Oct 6. doi: 10.1111/dom.14886.
PubMed Abstract available

CHEN Y, Wang Q, Xie Z, Huang G, et al
The impact of family history of type 2 diabetes on the clinical heterogeneity in idiopathic type 1 diabetes.
Diabetes Obes Metab. 2022 Oct 6. doi: 10.1111/dom.14884.
PubMed Abstract available

BLEKEN OSTERGAARD H, Humphreys V, Hengeveld EM, Honore JB, et al
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: a post hoc analysis of the CAPTURE study.
Diabetes Obes Metab. 2022 Oct 5. doi: 10.1111/dom.14887.
PubMed Abstract available

HU S, Gu S, Qi C, Wang S, et al
Cost-Utility Analysis of Semaglutide for type 2 diabetes after its Addition to the National Medical Insurance System in China.
Diabetes Obes Metab. 2022 Oct 4. doi: 10.1111/dom.14881.
PubMed Abstract available

ROSSING P, Agarwal R, Anker SD, Filippatos G, et al
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by GLP-1RA use.
Diabetes Obes Metab. 2022 Oct 4. doi: 10.1111/dom.14883.
PubMed Abstract available

YAMAGUCHI S, Shimabukuro M, Tanaka A, Imai T, et al
Canagliflozin reduces proteinuria by targeting hyperinsulinemia in diabetic patients with heart failure: a post-hoc analysis of the CANDLE trial.
Diabetes Obes Metab. 2022 Oct 4. doi: 10.1111/dom.14876.
PubMed Abstract available

YABE D, Kawamori D, Seino Y, Oura T, et al
Change of pharmacodynamics parameters following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono sub-study).
Diabetes Obes Metab. 2022 Oct 2. doi: 10.1111/dom.14882.
PubMed Abstract available

PROIETTI R, Lip GYH
Sodium-glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?
Diabetes Obes Metab. 2022;24:1897-1900.
PubMed

CHO SJ, Oh IS, Jeong HE, Cho YM, et al
Long-term clinical outcomes of oral antidiabetic drugs as fixed-dose combinations: A nationwide retrospective cohort study.
Diabetes Obes Metab. 2022;24:2051-2060.
PubMed Abstract available

CHOUDHARY P, Kao K, Dunn TC, Brandner L, et al
Glycaemic measures for 8914 adult FreeStyle Libre users during routine care, segmented by age group and observed changes during the COVID-19 pandemic.
Diabetes Obes Metab. 2022;24:1976-1982.
PubMed Abstract available

SEN T, Koshino A, Neal B, Bijlsma MJ, et al
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
Diabetes Obes Metab. 2022;24:1950-1956.
PubMed Abstract available

LIU N, Wang G, Liu C, Liu J, et al
Non-alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study.
Diabetes Obes Metab. 2022 Oct 1. doi: 10.1111/dom.14877.
PubMed Abstract available

September 2022

HALVORSEN YD, Lock JP, Frias JP, Tinahones FJ, et al
A 96-Week, Double-Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults.
Diabetes Obes Metab. 2022 Sep 30. doi: 10.1111/dom.14875.
PubMed Abstract available

BIDULKA P, Mathur R, Lugo-Palacios DG, O'Neill S, et al
Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study.
Diabetes Obes Metab. 2022 Sep 22. doi: 10.1111/dom.14874.
PubMed Abstract available

PHILIS-TSIMIKAS A, Bajaj HS, Begtrup K, Cailleteau R, et al
Rationale and design of the phase 3 development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
Diabetes Obes Metab. 2022 Sep 15. doi: 10.1111/dom.14871.
PubMed Abstract available

LU L, Wan B, Sun M
Mendelian Randomization Identifies Age at Menarche as an Independent Causal Effect Factor for Gestational Diabetes Mellitus.
Diabetes Obes Metab. 2022 Sep 14. doi: 10.1111/dom.14869.
PubMed Abstract available

VARGAS-URICOECHEA H, Burga Nunez JL, Rosas Guzman J, Silva Gomez L, et al
Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive People with Type 2 Diabetes in the Latin America Region: A Subgroup Analysis of the ATOS Study.
Diabetes Obes Metab. 2022 Sep 14. doi: 10.1111/dom.14868.
PubMed Abstract available

CHEN X, Jiang H, Li H, Kuang H, et al
Saxagliptin combined with additional oral antihyperglycemic agents in drug-naive diabetic patients with high glycosylated hemoglobin: a 24-week, multicenter, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS).
Diabetes Obes Metab. 2022 Sep 13. doi: 10.1111/dom.14873.
PubMed Abstract available

SCHOLTES RA, Mosterd CM, Hesp AC, Smits MM, et al
Mechanisms underlying the blood pressure lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: a secondary analysis of a randomized cross-over trial.
Diabetes Obes Metab. 2022 Sep 11. doi: 10.1111/dom.14864.
PubMed Abstract available

RAZAGHIZAD A, Sharma A, Ni J, Ferreira JP, et al
External Validation and Extension of the TIMI Risk Score for Heart Failure in Diabetes for Patients with Recent Acute Coronary Syndrome: An Analysis of the EXAMINE Trial.
Diabetes Obes Metab. 2022 Sep 9. doi: 10.1111/dom.14867.
PubMed Abstract available

SUGIMOTO T, Tokuda H, Miura H, Kawashima S, et al
Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes mellitus.
Diabetes Obes Metab. 2022 Sep 9. doi: 10.1111/dom.14866.
PubMed Abstract available

LIM LL, Lau ESH, Cheung JTK, Chan SP, et al
Real world usage of sulphonylurea in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) Register.
Diabetes Obes Metab. 2022 Sep 9. doi: 10.1111/dom.14865.
PubMed Abstract available

HIROTA Y, Xu Y, Yamamoto A, Matsuoka A, et al
Type 1 diabetes iron-deficiency anemia case report and the clinical relevance of RBC lifespan adjusted A1C.
Diabetes Obes Metab. 2022 Sep 7. doi: 10.1111/dom.14860.
PubMed

NESTI L, Pugliese NR, Chiriaco M, Trico D, et al
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function.
Diabetes Obes Metab. 2022 Sep 6. doi: 10.1111/dom.14861.
PubMed Abstract available

SOURIJ C, Aziz F, Kojzar H, Obermayer AM, et al
SARS-CoV-2S antibody level decline is more pronounced after second vaccination but response to the third COVID-19 vaccination is similar in people with type 1 and type 2 diabetes compared to healthy controls - the prospective COVAC-DM cohort study.
Diabetes Obes Metab. 2022 Sep 4. doi: 10.1111/dom.14855.
PubMed

DIALLO A, Carlos-Bolumbu M, Renard E, Galtier F, et al
Large Effect Size in Composite Kidney Outcomes than in Majors Cardiovascular Events of SGLT2 inhibitors compared with GLP-1 RAs: A Pooled Analysis of Type 2 Diabetes Trials.
Diabetes Obes Metab. 2022 Sep 3. doi: 10.1111/dom.14859.
PubMed Abstract available

LING S, Zaccardi F, Vlacho B, Li P, et al
All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: a comparative, trend analysis in Canada, Spain, and the UK.
Diabetes Obes Metab. 2022 Sep 3. doi: 10.1111/dom.14856.
PubMed Abstract available

FUKUSHIMA T, Chubachi S, Namkoong H, Asakura T, et al
Clinical significance of pre-diabetes, undiagnosed diabetes, and diagnosed diabetes on clinical outcomes in COVID-19: Integrative analysis from the Japan COVID-19 Task Force.
Diabetes Obes Metab. 2022 Sep 3. doi: 10.1111/dom.14857.
PubMed Abstract available

SUBRAMANIAN A, Gokhale K, Sainsbury C, Nirantharakumar K, et al
Sodium/glucose co-transporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus a propensity score matched, new user design study with an active comparator in IQVIA Medical Research Data - UK.
Diabetes Obes Metab. 2022 Sep 2. doi: 10.1111/dom.14858.
PubMed Abstract available

HEISE T, Piras de Oliveira C, Juneja R, Ribeiro A, et al
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
Diabetes Obes Metab. 2022;24:1689-1701.
PubMed Abstract available

ABDUL-GHANI T, Puckett C, Migahid O, Abdelgani S, et al
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.
Diabetes Obes Metab. 2022;24:1810-1818.
PubMed Abstract available

FRANEK E, Gerstein HC, Riddle MC, Nicolay C, et al
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
Diabetes Obes Metab. 2022;24:1753-1761.
PubMed Abstract available

August 2022

FAWZY AM, Rivera-Caravaca JM, Underhill P, Fauchier L, et al
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium glucose co-transporter 2 (SGLT2) inhibitor use in diabetic patients: Insights from a global federated electronic medical record database.
Diabetes Obes Metab. 2022 Aug 31. doi: 10.1111/dom.14854.
PubMed Abstract available

MOON SJ, Kim KS, Lee WJ, Lee MY, et al
Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: a randomized controlled trial.
Diabetes Obes Metab. 2022 Aug 28. doi: 10.1111/dom.14852.
PubMed Abstract available

WADWA RP, Laffel LM, Franco DR, Dellva MA, et al
Efficacy and safety of ultra rapid lispro (URLi) versus Lispro in children and adolescents with type 1 diabetes: PRONTO-Peds.
Diabetes Obes Metab. 2022 Aug 24. doi: 10.1111/dom.14849.
PubMed Abstract available

WU Z, Lebbar M, Taleb N, Legault L, et al
Comparing dual-hormone and single-hormone automated insulin delivery systems on nocturnal glucose management among children and adolescents with type 1 diabetes: a pooled analysis.
Diabetes Obes Metab. 2022 Aug 23. doi: 10.1111/dom.14850.
PubMed

MCCRIMMON RJ, Home P, Cheng A, Giorgino F, et al
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
Diabetes Obes Metab. 2022 Aug 23. doi: 10.1111/dom.14825.
PubMed Abstract available

POLONSKY WH, Giorgino F, Rosenstock J, Whitmire K, et al
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
Diabetes Obes Metab. 2022 Aug 23. doi: 10.1111/dom.14822.
PubMed Abstract available

CHEN L, Sun S, Gao Y, Ran X, et al
Global mortality of diabetic foot ulcer: a systematic review and meta-analysis of observational studies.
Diabetes Obes Metab. 2022 Aug 20. doi: 10.1111/dom.14840.
PubMed Abstract available

HADJADJ S, Saulnier PJ, Ruan Y, Zhu X, et al
Associations of microvascular complications with all-cause death in patients with diabetes and COVID-19: the CORONADO, ABCD Covid-19 audit and AMERICADO study groups.
Diabetes Obes Metab. 2022 Aug 20. doi: 10.1111/dom.14845.
PubMed Abstract available

MCCRIMMON RJ, Cheng AYY, Galstyan G, Djaballah K, et al
iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.
Diabetes Obes Metab. 2022 Aug 19. doi: 10.1111/dom.14844.
PubMed Abstract available

CHARBONNEL BH, Chen H, Cid-Ruzafa J, Cooper A, et al
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Diabetes Obes Metab. 2022 Aug 19. doi: 10.1111/dom.14842.
PubMed Abstract available

PIERI B, Deshmukh H, Wilmot EG, Choudhary P, et al
Impaired awareness of hypoglycaemia; prevalence and associated factors before and after FreeStyle Libre use in the Association of British Clinical Diabetologists (ABCD) audit.
Diabetes Obes Metab. 2022 Aug 18. doi: 10.1111/dom.14841.
PubMed

VAZEOU A, Tittel SR, Kordonouri O, Birkebaek NH, et al
Increased prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes and hypertension: The SWEET international database.
Diabetes Obes Metab. 2022 Aug 18. doi: 10.1111/dom.14834.
PubMed Abstract available

WHARTON W, Anderson A, Hayden KM, Carmichael OT, et al
Effect of renin-angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look AHEAD) trial.
Diabetes Obes Metab. 2022 Aug 16. doi: 10.1111/dom.14838.
PubMed Abstract available

RABBONE I, Pozzi E, Savastio S, Luca G, et al
A comparison of the effectiveness and safety of insulin glargine 300 U/ml vs. 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: a retrospective, observational , short-term study.
Diabetes Obes Metab. 2022 Aug 15. doi: 10.1111/dom.14839.
PubMed

PARRY-STRONG A, Wright-McNaughton M, Weatherall M, Hall RM, et al
Very low carbohydrate (ketogenic) diets in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2022 Aug 15. doi: 10.1111/dom.14837.
PubMed Abstract available

NUNES JC, Yu J, Arnott C, Jardine MJ, et al
CANAGLIFLOZIN, MENTAL HEALTH ADVERSE EVENTS, AND DIABETES: EXPLORATORY ANALYSIS OF THE CREDENCE TRIAL AND CANVAS PROGRAM.
Diabetes Obes Metab. 2022 Aug 8. doi: 10.1111/dom.14832.
PubMed Abstract available

DE BLOCK C, Bailey C, Wysham C, Hemmingway A, et al
Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective.
Diabetes Obes Metab. 2022 Aug 5. doi: 10.1111/dom.14831.
PubMed Abstract available

ARODA VR, Eckel RH
Reconsidering the role of glycemic control on cardiovascular disease risk in type 2 diabetes: A 21(st) century assessment.
Diabetes Obes Metab. 2022 Aug 5. doi: 10.1111/dom.14830.
PubMed Abstract available

SANG M, Xie C, Qiu S, Wang X, et al
Cholecystectomy is associated with dysglycaemia: Cross-sectional and prospective analyses.
Diabetes Obes Metab. 2022;24:1656-1660.
PubMed Abstract available

CORBETT JP, Hsu L, Brown SA, Kollar L, et al
Smartwatch gesture-based meal reminders improve glycaemic control.
Diabetes Obes Metab. 2022;24:1667-1670.
PubMed

HUMMEL J, Machann J, Dannecker C, Kullmann S, et al
Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes.
Diabetes Obes Metab. 2022;24:1661-1666.
PubMed

WILDING JPH, Batterham RL, Davies M, Van Gaal LF, et al
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Diabetes Obes Metab. 2022;24:1553-1564.
PubMed Abstract available

NANDAKUMAR M, Moin ASM, Ramanjaneya M, Qaissi AA, et al
Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response.
Diabetes Obes Metab. 2022;24:1483-1497.
PubMed Abstract available

July 2022

GUERCI B, Giorgino F, Sapin H, Boye K, et al
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Disposition, Clinical Characteristics, and Treatment Persistence at 12 Months.
Diabetes Obes Metab. 2022 Jul 25. doi: 10.1111/dom.14823.
PubMed Abstract available

YAHANG L, Xu H, Li J, Yang Y, et al
Separate and joint effect of visit-to-visit glycemic variability and mean glucose level on all-cause mortality in patients with type 2 diabetes: a population-based cohort study.
Diabetes Obes Metab. 2022 Jul 25. doi: 10.1111/dom.14826.
PubMed Abstract available

XU Y, Oriot P, Dunn TC, Hermans MP, et al
Evaluation of continuous glucose monitoring-derived person-specific HbA1c in the presence and absence of complications in type 1 diabetes.
Diabetes Obes Metab. 2022 Jul 25. doi: 10.1111/dom.14824.
PubMed Abstract available

SUCCURRO E, Vizza P, Papa A, Miceli S, et al
Effects of 26-week treatment with empagliflozin versus glimepiride on myocardial glucose metabolic rate in patients with type 2 diabetes: the randomized, open-label, active-controlled crossover FIORE trial.
Diabetes Obes Metab. 2022 Jul 15. doi: 10.1111/dom.14816.
PubMed Abstract available

HOOD KK, Garcia-Willingham N, Hanes S, Tanenbaum ML, et al
Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents.
Diabetes Obes Metab. 2022 Jul 15. doi: 10.1111/dom.14815.
PubMed Abstract available

SIRVENT P, Chavanelle V, Otero YF, Bargetto M, et al
TOTUM-63, a plant-based polyphenol-rich extract, improves glycemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2022 Jul 15. doi: 10.1111/dom.14817.
PubMed Abstract available

MACDONALD CJ, Frenoy P, Boutron-Ruault MC
Response to Boonpor et al: Types of diet, obesity, and incident type 2 diabetes: Findings from the UK Biobank prospective cohort study.
Diabetes Obes Metab. 2022 Jul 11. doi: 10.1111/dom.14813.
PubMed

LIN Y, Shao H, Shi L, Anderson AH, et al
Predicting incident heart failure among patients with type 2 diabetes mellitus: the DM-CURE risk score.
Diabetes Obes Metab. 2022 Jul 8. doi: 10.1111/dom.14806.
PubMed Abstract available

XU J, Ling H, Geng J, Huang Y, et al
Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.
Diabetes Obes Metab. 2022 Jul 6. doi: 10.1111/dom.14810.
PubMed Abstract available

GRIMSMANN JM, Tittel SR, Bramlage P, Mayer B, et al
Disease heterogeneity of adult diabetes based on routine clinical parameters at diagnosis: Results from the German/Austrian DPV registry.
Diabetes Obes Metab. 2022 Jul 6. doi: 10.1111/dom.14812.
PubMed Abstract available

AMBERY P, Eryd SA, Jenkins-Jones S, Heywood B, et al
The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups.
Diabetes Obes Metab. 2022 Jul 6. doi: 10.1111/dom.14808.
PubMed Abstract available

ARRIETA A, Battelino T, Scaramuzza AE, Da Silva J, et al
Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
Diabetes Obes Metab. 2022;24:1370-1379.
PubMed Abstract available

VON DEM BERGE T, Remus K, Biester S, Reschke F, et al
In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial.
Diabetes Obes Metab. 2022;24:1319-1327.
PubMed Abstract available

ARODA VR, Bauer R, Christiansen E, Haluzik M, et al
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Diabetes Obes Metab. 2022;24:1338-1350.
PubMed Abstract available

CRABTREE TSJ, Adamson K, Reid H, Barnes D, et al
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
Diabetes Obes Metab. 2022;24:1398-1401.
PubMed Abstract available

AGARWAL R, Hauske SJ, Wheeler DC, Doi K, et al
Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals.
Diabetes Obes Metab. 2022;24:1390-1393.
PubMed

MENG Q, Chepurny OG, Leech CA, Pruekprasert N, et al
The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
Diabetes Obes Metab. 2022;24:1255-1266.
PubMed Abstract available

DAGOGO-JACK S, Cannon CP, Cherney DZI, Cosentino F, et al
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Diabetes Obes Metab. 2022;24:1245-1254.
PubMed Abstract available

June 2022

YUAN X, Guo X, Zhang J, Dong X, et al
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan-L-CN randomize
Diabetes Obes Metab. 2022 Jun 28. doi: 10.1111/dom.14803.
PubMed Abstract available

BRUNETTI VC, Yu OHY, Platt RW, Filion KB, et al
The Association of Long-Acting Insulin Analogue Use Versus Neutral Protamine Hagedorn Insulin Use With Major Adverse Cardiovascular Events Among Individuals With Type 2 Diabetes: A Population-Based Cohort Study.
Diabetes Obes Metab. 2022 Jun 21. doi: 10.1111/dom.14802.
PubMed Abstract available

YANG S, Zhao L, Mi Y, He W, et al
Effects of sodium-glucose cotransporter 2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and
Diabetes Obes Metab. 2022 Jun 16. doi: 10.1111/dom.14801.
PubMed Abstract available

TELL SS, Schafer M, Vigers T, Baumgartner AD, et al
Bromocriptine Quick-Release as Adjunct Therapy in Youth and Adults with Type 1 Diabetes: A Randomized, Placebo-Controlled Crossover Study.
Diabetes Obes Metab. 2022 Jun 16. doi: 10.1111/dom.14800.
PubMed Abstract available

TOP WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, et al
Effect of metformin on arginine and dimethylarginines in patients with advanced type 2 diabetes: A post hoc analysis of a randomized trial.
Diabetes Obes Metab. 2022 Jun 15. doi: 10.1111/dom.14784.
PubMed Abstract available

ALI MK, Kadir MM, Gujral UP, Fatima S, et al
Obesity associated metabolites in relation to type 2 diabetes risk: a Prospective Nested Case-Control Study of the CARRS Cohort.
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14788.
PubMed Abstract available

WEWER ALBRECHTSEN NJ, Moller A, Martinussen C, Gluud LL, et al
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14789.
PubMed Abstract available

SHAH A, Prasad M, Mark V, Holst JJ, et al
GLP-1 effect on ss-cell function varies according to diabetes remission status after RYGB.
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14793.
PubMed Abstract available

IDRIS I, Zhang R, Mamza JB, Ford M, et al
Significant reduction in chronic kidney disease progression with sodium glucose co-transporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in UK clinical setting: An observational outcomes study based on i
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14799.
PubMed Abstract available

CHIRIACO M, Sacchetta L, Forotti G, Leonetti S, et al
Prognostic value of 24-hour ambulatory blood pressure patterns in diabetes: a 21-year longitudinal study.
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14798.
PubMed Abstract available

MADDALONI E, Bolli GB, Frier BM, Little RR, et al
C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective.
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14785.
PubMed Abstract available

KENG MJ, Leal J, Bowman L, Armitage J, et al
Hospital costs associated with adverse events in people with diabetes in the UK.
Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14796.
PubMed Abstract available

HRAMIAK I, Gerstein HC, Leiter LA, Yale JF, et al
Comparing a Daily vs. Weekly Titration Algorithm in People with Type 2 Diabetes Switching from Basal Insulin to iGlarLixi in the LixiLan ONE CAN Randomized Trial.
Diabetes Obes Metab. 2022 Jun 7. doi: 10.1111/dom.14787.
PubMed Abstract available

ANDREASEN CR, Andersen A, Hagelqvist PG, Lauritsen JV, et al
Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes.
Diabetes Obes Metab. 2022 Jun 7. doi: 10.1111/dom.14790.
PubMed Abstract available

PHAM TT, Chen X, Barron J, Hart R, et al
Effectiveness, safety, and treatment adherence of biosimilar follow-on insulin in diabetes management.
Diabetes Obes Metab. 2022 Jun 7. doi: 10.1111/dom.14786.
PubMed Abstract available

CAO H, Liu T, Wang L, Ji Q, et al
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
Diabetes Obes Metab. 2022 Jun 6. doi: 10.1111/dom.14702.
PubMed Abstract available

KLEIN KR, Boeder SC, Freeman JLR, Dunn I, et al
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.
Diabetes Obes Metab. 2022 Jun 4. doi: 10.1111/dom.14697.
PubMed Abstract available

SPENCE JD, Viscoli C, Kernan WN, Young LH, et al
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
Diabetes Obes Metab. 2022;24:1150-1158.
PubMed Abstract available

CHERNEY DZI, Cosentino F, Pratley RE, Dagogo-Jack S, et al
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
Diabetes Obes Metab. 2022;24:1114-1122.
PubMed Abstract available

BARRACLOUGH JY, Yu J, Figtree GA, Perkovic V, et al
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab. 2022;24:1072-1083.
PubMed Abstract available

KAHL S, Ofstad AP, Zinman B, Wanner C, et al
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
Diabetes Obes Metab. 2022;24:1061-1071.
PubMed Abstract available

SHEEHAN A, Goldfine A, Bajwa M, Wolfs D, et al
Pramlintide for post-bariatric hypoglycaemia.
Diabetes Obes Metab. 2022;24:1021-1028.
PubMed Abstract available

YOSHIJI S, Minamino H, Tanaka D, Yamane S, et al
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis.
Diabetes Obes Metab. 2022;24:1029-1037.
PubMed Abstract available

PRATLEY RE, Gorst-Rasmussen A
Indirect treatment comparisons: Choosing the right tool for the job.
Diabetes Obes Metab. 2022;24:1180-1181.
PubMed

WAIJER SW, Provenzano M, Mulder S, Rossing P, et al
Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology.
Diabetes Obes Metab. 2022;24:983-990.
PubMed Abstract available

PAN Q, Li Y, Wan H, Wang J, et al
Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: the multicentre, open-label, r
Diabetes Obes Metab. 2022 Jun 1. doi: 10.1111/dom.14780.
PubMed Abstract available

May 2022

ZENG B, Jia H, Gao L, Yang Q, et al
Dual-hormone artificial pancreas for glucose control in type 1 diabetes: a meta-analysis.
Diabetes Obes Metab. 2022 May 31. doi: 10.1111/dom.14781.
PubMed Abstract available

O'MAHONEY LL, Highton PJ, Kudlek L, Morgan J, et al
The impact of the Covid-19 pandemic on glycaemic control in people with diabetes: a systematic review and meta-analysis.
Diabetes Obes Metab. 2022 May 23. doi: 10.1111/dom.14771.
PubMed Abstract available

SEGAR MW, Kolkailah AA, Frederich R, Pong A, et al
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes.
Diabetes Obes Metab. 2022 May 23. doi: 10.1111/dom.14769.
PubMed Abstract available

PANG H, Lin J, Luo S, Huang G, et al
The missing heritability in type 1 diabetes mellitus.
Diabetes Obes Metab. 2022 May 23. doi: 10.1111/dom.14777.
PubMed Abstract available

VADHER K, Patel H, Mody R, Levine JA, et al
Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison.
Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14775.
PubMed Abstract available

YUAN D, Sharma H, Krishnan A, Vangaveti VN, et al
Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A Systematic Review and Meta-Analysis.
Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14776.
PubMed Abstract available

LI C, Yu J, Hockham C, Perkovic V, et al
Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta-analysis.
Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14772.
PubMed Abstract available

PIEMONTI L, Keymeulen B, Gillard P, Linn T, et al
Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14770.
PubMed Abstract available

RYANG S, Kim SS, Bae JC, Han JM, et al
A Double-blind, Randomized Controlled Trial on Glucose-lowering Effects and Safety of Adding 0.25 or 0.5 mg Lobeglitazone in Type 2 Diabetes Patients with Inadequate Control on Metformin and DPP-4 Inhibitor Therapy: REFIND Study.
Diabetes Obes Metab. 2022 May 17. doi: 10.1111/dom.14766.
PubMed Abstract available

COX DA, Wang H, Nicolay C, Bethel MA, et al
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14762.
PubMed Abstract available

KELLERER M, Kaltoft MS, Lawson J, Nielsen LL, et al
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial.
Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14765.
PubMed Abstract available

WEINSTOCK RS, Bode BW, Garg SK, Klonoff DC, et al
Reduced Hypoglycemia Using Liver Targeted Insulin in Persons with Type 1 Diabetes.
Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14761.
PubMed Abstract available

HEJJAJI V, Gorgojo-Martinez JJ, Tang F, Garnelo JB, et al
Factors Associated with Weight Loss in People with Overweight or Obesity Living with Type 2 Diabetes Mellitus: Insights from the Global DISCOVER Study.
Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14745.
PubMed Abstract available

XU Y, Bergenstal RM, Dunn TC, Ram Y, et al
Inter-individual Variability in Average Glucose-HbA1c Relationship in type 1 diabetes and Implications for Clinical Practice.
Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14763.
PubMed Abstract available

AL-SALAMEH A, Wiernsperger N, Cariou B, Lalau JD, et al
A comment on metformin and COVID-19 with regard to "Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy".
Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14746.
PubMed

GARVEY WT, Umpierrez GE, Dunn JP, Kwan AYM, et al
Weighing the evidence for weight management in individuals with type 2 diabetes.
Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14764.
PubMed Abstract available

BELL DSH
Metformin induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes.
Diabetes Obes Metab. 2022 May 2. doi: 10.1111/dom.14734.
PubMed Abstract available

YADAV Y, Dunagan K, Khot R, Venkatesh SK, et al
Inhibition of 11beta-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.
Diabetes Obes Metab. 2022;24:881-890.
PubMed Abstract available

NUYUJUKIAN DS, Newell MS, Zhou JJ, Koska J, et al
Baseline blood pressure modifies the role of blood pressure variability in mortality: Results from the ACCORD trial.
Diabetes Obes Metab. 2022;24:951-955.
PubMed

CHERTOW GM, Vart P, Jongs N, Langkilde AM, et al
Quetelet (body mass) index and effects of dapagliflozin in chronic kidney disease.
Diabetes Obes Metab. 2022;24:827-837.
PubMed Abstract available

BENSIGNOR MO, Wolf JM, Rudser KD, Kelly AS, et al
Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14681.
PubMed

DONG YH, Chang CH, Lin JW, Yang WS, et al
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a population-based cohort study.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14741.
PubMed Abstract available

MIYAMOTO S, Heerspink HJL, de Zeeuw D, Toyoda M, et al
Rationale, Design and Baseline Characteristics of the Effect of Canagliflozin in Type 2 Diabetic Patients with Microalbuminuria in Japanese Population (CANPIONE) study.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14731.
PubMed Abstract available

VAN RUITEN CC, Veltman DJ, Wijdeveld M, Ten Kulve JS, et al
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: a randomized controlled trial.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14732.
PubMed Abstract available

ZACCARDI F, Kloecker DE, Khunti K, Davies MJ, et al
Noninferiority and clinical superiority of GLP-1 receptor agonists and SGLT2 inhibitors: systematic analysis of cardiorenal outcome trials in type 2 diabetes.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14735.
PubMed Abstract available

BAILEY TS, Gill J, Jones M, Shenoy L, et al
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14739.
PubMed Abstract available

SPILIOTIS II, Chalk R, Gough S, Rorsman P, et al
Reducing hyperglucagonemia in type 2 diabetes using low dose Glibenclamide: Results of the LEGEND-A pilot study.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14740.
PubMed Abstract available

STENSEN S, Krogh LL, Sparre-Ulrich AH, Dela F, et al
Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14736.
PubMed Abstract available

DEO SV, Marsia S, McAllister DA, Elgudin Y, et al
The Time-varying Cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials.
Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14738.
PubMed Abstract available

April 2022

SEN T, Scholtes R, Greasley PJ, Cherney D, et al
Effects of dapagliflozin on volume status and systemic hemodynamics in patients with CKD without diabetes: Results from DAPASALT and DIAMOND.
Diabetes Obes Metab. 2022 Apr 28. doi: 10.1111/dom.14729.
PubMed Abstract available

VENCIO S, Caiado-Vencio R, Caixeta LF, Masierek M, et al
A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication.
Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14724.
PubMed Abstract available

ZIELINSKI M, Zalinska M, Iwaszkiewicz-Grzes D, Gliwinski M, et al
Combined therapy with CD4 + CD25highCD127- T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy - randomized phase I/II trial.
Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14723.
PubMed Abstract available

SARGEANT JA, King JA, Yates T, Redman EL, et al
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: the SEESAW randomised, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14721.
PubMed Abstract available

YANG W, Dong X, Li Q, Cheng Z, et al
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14722.
PubMed Abstract available

NOWAK C, Hannelius U, Ludvigsson J
Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of GAD-alum immunotherapy in recent-onset Type 1 diabetes.
Diabetes Obes Metab. 2022 Apr 17. doi: 10.1111/dom.14720.
PubMed

SEIDU S, Almaqhawi A, Abdool M, Kunutsor SK, et al
Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus stepwise approach in newly diagnosed or treatment naive type 2 diabetes: a systematic review and meta-analysis.
Diabetes Obes Metab. 2022 Apr 17. doi: 10.1111/dom.14715.
PubMed Abstract available

SIVALINGAM S, Zobel EH, Hansen CS, Ripa RS, et al
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
Diabetes Obes Metab. 2022 Apr 12. doi: 10.1111/dom.14717.
PubMed

PARKER VER, Hoang T, Schlichthaar H, Gibb FW, et al
Efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab. 2022 Apr 11. doi: 10.1111/dom.14712.
PubMed Abstract available

DE BLOCK CEM, Van Cauwenberghe J, Bochanen N, Dirinck E, et al
Rapid-Acting Insulin Analogues: Theory and Best Clinical Practice in Type 1 and Type 2 Diabetes.
Diabetes Obes Metab. 2022 Apr 11. doi: 10.1111/dom.14713.
PubMed Abstract available

EVANS M, Chandramouli AS, Faurby M, Matthiessen KS, et al
Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET).
Diabetes Obes Metab. 2022 Apr 5. doi: 10.1111/dom.14703.
PubMed Abstract available

PENG ZY, Yang CT, Ou HT, Kuo S, et al
Cost-effectiveness of SGLT2is versus DPP4is among type 2 diabetes patients with and without established cardiovascular disease: A model-based simulation analysis using 10-year real-world data and targeted literature review.
Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14708.
PubMed Abstract available

BOONPOR J, Petermann-Rocha F, Parra-Soto S, Pell JP, et al
Types of Diet, Obesity, and Incident Type 2 Diabetes: Findings from The UK Biobank Prospective Cohort Study.
Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14711.
PubMed Abstract available

WHYTE MB, Joy M, Hinton W, McGovern A, et al
Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events (MACE) in people with type 2 diabetes: primary care cohort study.
Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14705.
PubMed Abstract available

LEITE AR, Angelico-Goncalves A, Vasques-Novoa F, Borges-Canha M, et al
Effect of GLP-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: a meta-analysis of placebo-controlled randomized trials.
Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14707.
PubMed Abstract available

GOMEZ-PERALTA F, Choudhary P, Cosson E, Irace C, et al
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin.
Diabetes Obes Metab. 2022;24:599-608.
PubMed Abstract available

HALL RM, Dyhrberg S, McTavish A, McTavish L, et al
Where can you wear your Libre? Using the FreeStyle Libre continuous glucose monitor on alternative sites.
Diabetes Obes Metab. 2022;24:675-683.
PubMed Abstract available

CLEMENS KK, Ouedraogo AM, Lam M, Muanda FT, et al
Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population-based analysis from 2010 to 2020.
Diabetes Obes Metab. 2022;24:641-651.
PubMed Abstract available

HE K, Guo Q, Zhang H, Xi W, et al
Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis.
Diabetes Obes Metab. 2022;24:722-726.
PubMed

March 2022

VERMA S, Al-Omran M, Leiter LA, Mazer CD, et al
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Diabetes Obes Metab. 2022 Mar 24. doi: 10.1111/dom.14700.
PubMed Abstract available

NORHAMMAR A, Bodegard J, Eriksson JW, Hermann H, et al
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries.
Diabetes Obes Metab. 2022 Mar 23. doi: 10.1111/dom.14698.
PubMed Abstract available

PIEBER TR, Aronson R, Christiansen MP, Bode B, et al
Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus as a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe
Diabetes Obes Metab. 2022 Mar 23. doi: 10.1111/dom.14699.
PubMed

DEFRONZO RA, Bakris GL
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
Diabetes Obes Metab. 2022 Mar 18. doi: 10.1111/dom.14696.
PubMed Abstract available

ENG PC, Distaso W, Durreshahwar H, Shaikhali Y, et al
The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.
Diabetes Obes Metab. 2022 Mar 15. doi: 10.1111/dom.14692.
PubMed

SETTLES J, Kan H, Child CJ, Gorritz M, et al
Previously unrecognised risk factors for severe hypoglycaemia requiring emergency medical care in insulin-treated type 2 diabetes: results from a real-world nested case-control study.
Diabetes Obes Metab. 2022 Mar 9. doi: 10.1111/dom.14690.
PubMed Abstract available

KASTNER JR, Venkatesh N, Brown K, Muchmore DB, et al
Feasibility Study of a Prototype Extended-Wear Insulin Infusion Set in Adults with Type 1 Diabetes.
Diabetes Obes Metab. 2022 Mar 8. doi: 10.1111/dom.14685.
PubMed Abstract available

FERRANNINI E, Niemoeller E, Dex T, Servera S, et al
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ss-cell function in people with type 2 diabetes.
Diabetes Obes Metab. 2022 Mar 7. doi: 10.1111/dom.14688.
PubMed Abstract available

WILLIAMS BA, Brady JP, Voyce S, Kumar N, et al
Changes Over Time in the Cardiovascular Risk Profile of Type 2 Diabetes from 2007-2020: A Community-Based Study.
Diabetes Obes Metab. 2022 Mar 7. doi: 10.1111/dom.14686.
PubMed Abstract available

BAE J, Liu D, Chinthammit C, Kadziola Z, et al
Type 2 Diabetes Pharmacotherapy Trends in High-Risk Subgroups.
Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14678.
PubMed Abstract available

ANDERSEN A, Jorgensen PG, Bagger JI, Baldassarre MPA, et al
Acute changes in plasma glucose increases left ventricular systolic function in insulin-treated patients with type 2 diabetes and controls.
Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14682.
PubMed Abstract available

WANG X, Chen C, Xie C, Huang W, et al
Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2h plasma glucose in individuals without diabetes.
Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14683.
PubMed Abstract available

KHUNTIV K, Jabbour S, Cos X, Mudaliar S, et al
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice.
Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14684.
PubMed Abstract available

SIMONSON DC, Hu B, Arterburn DE, Schauer PR, et al
Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D): Study Rationale, Design, and Methods.
Diabetes Obes Metab. 2022 Mar 1. doi: 10.1111/dom.14680.
PubMed

LEE M, Lee WJ, Kim JH, Lee BW, et al
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study.
Diabetes Obes Metab. 2022 Mar 1. doi: 10.1111/dom.14679.
PubMed Abstract available

ABDELHALEEM IA, Abd-Elhamied MA, Morsi AE, Kenawy S, et al
Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2022;24:555-560.
PubMed

REGITTNIG W, Tschaikner M, Tuca AC, Simic A, et al
Insulin induces a progressive increase in the resistance of subcutaneous tissue to fluid flow: Implications for insulin pump therapy.
Diabetes Obes Metab. 2022;24:455-464.
PubMed Abstract available

UEDA P, Wintzell V, Dahlqwist E, Eliasson B, et al
The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Diabetes Obes Metab. 2022;24:473-485.
PubMed Abstract available

PATORNO E, Pawar A, Wexler DJ, Glynn RJ, et al
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Diabetes Obes Metab. 2022;24:442-454.
PubMed Abstract available

LIN C, Cai X, Ji L
Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta-analyses.
Diabetes Obes Metab. 2022;24:550-554.
PubMed

February 2022

SCHECHTER M, Fischer M, Mosenzon O
Preventing all-cause hospitalizations in type-2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists - narrative review and clinical approach.
Diabetes Obes Metab. 2022 Feb 25. doi: 10.1111/dom.14675.
PubMed Abstract available

HETHERINGTON-RAUTH M, Magalhaes JP, Rosa GB, Correia IR, et al
Morning vs. Afternoon Physical Activity and Health-Related Outcomes in Individuals with Type 2 Diabetes.
Diabetes Obes Metab. 2022 Feb 24. doi: 10.1111/dom.14676.
PubMed

WANG W, Song X, Lou Y, Du L, et al
Immunogenicity of LY2963016 insulin glargine and Lantus(R) insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
Diabetes Obes Metab. 2022 Feb 20. doi: 10.1111/dom.14674.
PubMed Abstract available

KOTSOPOULOS N, Connolly MP, Willis M, Nilsson A, et al
The public economic burden of sub-optimal type-2 diabetes control on tax payors in Sweden: Looking beyond health costs.
Diabetes Obes Metab. 2022 Feb 8. doi: 10.1111/dom.14667.
PubMed Abstract available

RHEE JJ, Han J, Montez-Rath ME, Kim SH, et al
Cardiovascular outcomes associated with prescription of SGLT-2 inhibitors versus DPP-4 inhibitors in patients with diabetes mellitus and chronic kidney disease.
Diabetes Obes Metab. 2022 Feb 3. doi: 10.1111/dom.14657.
PubMed Abstract available

BIRABAHARAN M, Kaelber DC, Pettus JH, Smith DM, et al
Risk of New-Onset Type 2 Diabetes Mellitus in 600,055 Persons after COVID-19: a cohort study.
Diabetes Obes Metab. 2022 Feb 3. doi: 10.1111/dom.14659.
PubMed

GAO B, Gao W, Wan H, Xu F, et al
Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin, and inadequately controlled with metformin monotherapy or drug naive: a multicenter, ra
Diabetes Obes Metab. 2022 Feb 3. doi: 10.1111/dom.14661.
PubMed Abstract available

NEWBY D, Garfield V
Understanding the interrelationships of type-2 diabetes and hypertension with brain and cognitive health: a UK Biobank study.
Diabetes Obes Metab. 2022 Feb 2. doi: 10.1111/dom.14658.
PubMed Abstract available

FADINI GP, Del Prato S, Avogaro A, Solini A, et al
Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors.
Diabetes Obes Metab. 2022;24:177-186.
PubMed Abstract available

CAI M, Shao X, Xing F, Zhang Y, et al
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
Diabetes Obes Metab. 2022;24:312-320.
PubMed Abstract available

THAM LS, Pantalone KM, Dungan K, Munir K, et al
A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
Diabetes Obes Metab. 2022;24:302-311.
PubMed Abstract available

COWART K, Gonzalez R, Carris NW
Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.
Diabetes Obes Metab. 2022;24:348-353.
PubMed

FINER N
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes.
Diabetes Obes Metab. 2022;24 Suppl 2:44-54.
PubMed Abstract available

HU X, Yang Y, Hu X, Jia X, et al
Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
Diabetes Obes Metab. 2022;24:228-238.
PubMed Abstract available

BORODAVKIN P, Sheridan W, Coelho C, Ostarijas E, et al
Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Diabetes Obes Metab. 2022;24:337-342.
PubMed

BUZZETTI R, Bonadonna RC, Giaccari A, Perseghin G, et al
Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis.
Diabetes Obes Metab. 2022;24:327-331.
PubMed

January 2022

BENHAMOU PY, Lablanche S, Vambergue A, Pou S, et al
Beneficial effects of closed-loop insulin delivery in highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months. An extension study of DBLHU-WP10 trial.
Diabetes Obes Metab. 2022 Jan 31. doi: 10.1111/dom.14654.
PubMed

GOEDECKE JH, Nguyen K, Kufe C, Masemola M, et al
Waist circumference thresholds predicting incident dysglycaemia and type 2 diabetes in Black African men and women.
Diabetes Obes Metab. 2022 Jan 27. doi: 10.1111/dom.14655.
PubMed Abstract available

FARHAT R, Aiken J, D'Souza NC, Appadurai D, et al
ZT-01 - A Novel Somatostatin Receptor Antagonist for Restoring the Glucagon Response to Hypoglycemia in Type 1 Diabetes.
Diabetes Obes Metab. 2022 Jan 21. doi: 10.1111/dom.14652.
PubMed Abstract available

CARIOU B
The metabolic triad of NAFLD, visceral adiposity and type 2 diabetes: implications for treatment.
Diabetes Obes Metab. 2022 Jan 11. doi: 10.1111/dom.14651.
PubMed Abstract available

OJEDA-FERNANDEZ L, Foresta A, Macaluso G, Colacioppo P, et al
Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy.
Diabetes Obes Metab. 2022 Jan 10. doi: 10.1111/dom.14648.
PubMed Abstract available

VAN DEN BOOM L, Kostev K
Persistence of the insulin pump therapy in children and young adults with Type 1 diabetes (T1D) in Germany: an update.
Diabetes Obes Metab. 2022 Jan 10. doi: 10.1111/dom.14647.
PubMed

LAVYNENKO O, Abdul-Ghani M, Alatrach M, Puckett C, et al
Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial.
Diabetes Obes Metab. 2022 Jan 10. doi: 10.1111/dom.14650.
PubMed Abstract available

KOBAYATI A, Haidar A, Tsoukas MA
GLP-1 Receptor Agonists as Adjunctive Treatment for Type 1 Diabetes: Renewed Opportunities through Tailored Approaches?
Diabetes Obes Metab. 2022 Jan 6. doi: 10.1111/dom.14637.
PubMed Abstract available

ANTLANGER M, Domenig O, Kaltenecker CC, Kovarik JJ, et al
Combined SGLT-2 and ACE inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14639.
PubMed Abstract available

REILHAC C, Dubourg J, Thang C, Grouin JM, et al
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14642.
PubMed Abstract available

RAUBENHEIMER PJ, Cushman WC, Avezum A, Basile J, et al
Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14634.
PubMed Abstract available

GRAM-KAMPMANN EM, Hansen CD, Hugger MB, Jensen JM, et al
Effects of a six-month low-carbohydrate diet on glycemic control, body composition and cardiovascular risk factors in patients with type 2 diabetes: an open-label RCT.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14633.
PubMed Abstract available

SOURIJ C, Tripolt NJ, Aziz F, Aberer F, et al
Humoral immune response to Covid-19 vaccination in diabetes: age-dependent but independent of type of diabetes and glycaemic control - the prospective COVAC-DM cohort study.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14643.
PubMed Abstract available

MEIER JJ, Quast DR, Nauck MA, Schenker N, et al
Acute effects of linagliptin on intact and total GLP-1 and GIP levels in insulin-dependent type 2 diabetic patients with and without moderate renal impairment.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14636.
PubMed Abstract available

DE BLOCK CEM, Dirinck E, Verhaegen A, Van Gaal LF, et al
Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14640.
PubMed Abstract available

RENARD E, Riveline JP, Hanaire H, Guerci B, et al
Reduction of clinically important low glucose excursions with a long-term implantable continuous glucose monitoring (CGM) system in adults with type 1 diabetes prone to hypoglycemia. France Adoption randomized clinical trial.
Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14644.
PubMed Abstract available

LEITER LA, Banach M, Catapano AL, Duell PB, et al
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.
Diabetes Obes Metab. 2022 Jan 3. doi: 10.1111/dom.14645.
PubMed Abstract available

TURNER LV, Riddell MC
Pushing the limits of insulin delivery 100 years later: A case study of a race across Canada.
Diabetes Obes Metab. 2022;24 Suppl 1:58-62.
PubMed

OWENS DR, Monnier L, Ceriello A, Bolli GB, et al
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922.
Diabetes Obes Metab. 2022;24 Suppl 1:27-42.
PubMed Abstract available

BIESTER T, Tauschmann M, Chobot A, Kordonouri O, et al
The automated pancreas: A review of technologies and clinical practice.
Diabetes Obes Metab. 2022;24 Suppl 1:43-57.
PubMed Abstract available

EKANAYAKE P, Mudaliar S
A novel hypothesis linking low-grade ketonaemia to cardio-renal benefits with sodium-glucose cotransporter-2 inhibitors.
Diabetes Obes Metab. 2022;24:3-11.
PubMed Abstract available

RETNAKARAN R, Zinman B
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future.
Diabetes Obes Metab. 2022;24 Suppl 1:17-26.
PubMed Abstract available

WHARTON S, Calanna S, Davies M, Dicker D, et al
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Diabetes Obes Metab. 2022;24:94-105.
PubMed Abstract available

TOKUTSU A, Okada Y, Mita T, Torimoto K, et al
Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study.
Diabetes Obes Metab. 2022;24:82-93.
PubMed Abstract available

TANG H, Kimmel SE, Hernandez I, Brooks MM, et al
Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
Diabetes Obes Metab. 2022;24:154-159.
PubMed

WEIR MR, Gogate J, Damaraju CV, Correa-Rotter R, et al
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab. 2022;24:12-20.
PubMed Abstract available

PAGET MB, Murray HE, Bailey CJ, Downing R, et al
From insulin injections to islet transplantation: An overview of the journey.
Diabetes Obes Metab. 2022;24 Suppl 1:5-16.
PubMed Abstract available

December 2021

MEIER JJ, Granhall C, Hoevelmann U, Navarria A, et al
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
Diabetes Obes Metab. 2021 Dec 26. doi: 10.1111/dom.14632.
PubMed Abstract available

CZUPRYNIAK L, Danne T, Szymanska-Garbacz E, Zozulinska-Ziolkiewicz D, et al
SGLT-2 inhibitor for type 1 diabetes - not any more?
Diabetes Obes Metab. 2021 Dec 21. doi: 10.1111/dom.14631.
PubMed

HAN E, Huh JH, Lee EY, Bae JC, et al
Efficacy and Safety of Evogliptin in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Multicenter, Double-blind, Randomized, Comparative trial.
Diabetes Obes Metab. 2021 Dec 17. doi: 10.1111/dom.14623.
PubMed

REIFSNIDER OS, Pimple P, Brand S, Bergrath Washington E, et al
Cost-Effectiveness of Second-Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States.
Diabetes Obes Metab. 2021 Dec 14. doi: 10.1111/dom.14625.
PubMed Abstract available

KAKU K, Wanner C, Anker SD, Pocock S, et al
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Diabetes Obes Metab. 2021 Dec 14. doi: 10.1111/dom.14626.
PubMed Abstract available

LIM S, Sohn M, Shin Y, Ferrannini E, et al
Initial combination of metformin, sitagliptin, and empagliflozin in drug-naive patients with type 2 diabetes: Safety and metabolic effects.
Diabetes Obes Metab. 2021 Dec 14. doi: 10.1111/dom.14627.
PubMed

SEUFERT J, Lanzinger S, Danne T, Bramlage P, et al
Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis.
Diabetes Obes Metab. 2021 Dec 12. doi: 10.1111/dom.14620.
PubMed

MEYHOFER S, Eckert AJ, Hummel M, Laimer M, et al
Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database.
Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14616.
PubMed

PERLMAN JE, Gooley TA, Meyers J, Hirsch IB, et al
The relationship between hypoglycaemia and glucose variability in type 1 diabetes.
Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14617.
PubMed

MIDDLETON TL, Constantino MI, McGill M, D'Souza M, et al
Improving beta-cell secretory function and glycemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, CGM-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14621.
PubMed

XUE P, Tang X, Tan X, Benedict C, et al
Self-reported regular daytime napping is associated with indicators of poor type 2 diabetes control: a cohort study.
Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14619.
PubMed

KENG MJ, Leal J, Bowman L, Armitage J, et al
Decrements in health-related quality of life associated with adverse events in people with diabetes.
Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14610.
PubMed Abstract available

DUBOURG J, Fouqueray P, Quinslot D, Grouin JM, et al
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week open-label, multicenter phase 3 trial.
Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14613.
PubMed Abstract available

ALAM NN, Wright AK, Rutter MK, Buchan I, et al
Body mass index and cancer mortality in patients with incident type 2 diabetes: a population-based study of adults in England.
Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14614.
PubMed Abstract available

MOSER O, Sternad C, Eckstein ML, Szadkowska A, et al
Performance of intermittently scanned continuous glucose monitoring (isCGM) systems in people with type 1 diabetes: a pooled analysis.
Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14609.
PubMed Abstract available

JODAR E, Romera I, Wang Q, Roche SL, et al
Glycemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized, clinical trials.
Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14615.
PubMed Abstract available

IIZUKA K, Baxter M, Watanabe D, Yabe D, et al
Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
Diabetes Obes Metab. 2021;23:2795-2803.
PubMed Abstract available

MARIAM A, Miller-Atkins G, Pantalone KM, Iyer N, et al
Associations of weight loss with obesity-related comorbidities in a large integrated health system.
Diabetes Obes Metab. 2021;23:2804-2813.
PubMed Abstract available

FRIAS JP, Bonora E, Cox DA, Bethel MA, et al
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.
Diabetes Obes Metab. 2021;23:2819-2824.
PubMed Abstract available

HOME PD, Mehta R, Hafidh KAS, Gurova OY, et al
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.
Diabetes Obes Metab. 2021;23:2660-2669.
PubMed Abstract available

KALANTAR-ZADEH K, Beddhu S, Kovesdy CP, Kramer HJ, et al
Biologically plausible trends suggesting that a low-protein diet may enhance the effect of flozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria.
Diabetes Obes Metab. 2021;23:2825-2826.
PubMed

SUISSA K, Schneeweiss S, Lin KJ, Brill G, et al
Validation of obesity-related diagnosis codes in claims data.
Diabetes Obes Metab. 2021;23:2623-2631.
PubMed Abstract available

November 2021

DOVC K, Van Name M, Jenko Bizjan B, Rusak E, et al
Continuous Glucose Monitoring Use and Glucose Variability in Very Young Children with Type 1 Diabetes (VibRate): A Multinational Prospective Observational Real-World Cohort Study.
Diabetes Obes Metab. 2021 Nov 24. doi: 10.1111/dom.14607.
PubMed Abstract available

RENARD E, Tubiana-Rufi N, Bonnemaison E, Coutant R, et al
Outcomes of Hybrid Closed-Loop Insulin Delivery Activated 24/7 versus Evening and Night in Free-living Pre-pubertal Children with Type 1 Diabetes. A Multicenter Randomized Clinical Trial.
Diabetes Obes Metab. 2021 Nov 23. doi: 10.1111/dom.14605.
PubMed Abstract available

WEEDA ER, Burnette B, Rowe S, Haas S, et al
Disparity of rural-urban distribution of clinical trial sites used in studies cited by diabetes treatment guidelines.
Diabetes Obes Metab. 2021 Nov 23. doi: 10.1111/dom.14606.
PubMed

EVANS M, Engberg S, Faurby M, Fernandes JDDR, et al
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.
Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14603.
PubMed Abstract available

HIROSE N, Tsujimoto N, Katayose T, Chin R, et al
Utilization of glucagon-like peptide-1 receptor agonists and changes in clinical characteristics in type 2 diabetes mellitus patients by chronic kidney disease stage in Japan: A descriptive observational study using nationwide electronic medical recor
Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14600.
PubMed Abstract available

CHAUDHURI A, Ghanim H, Arora P
Improving Residual Risk of Renal and Cardiovascular Outcomes in Diabetic Kidney Disease: Review of Pathophysiology, Mechanisms and Evidence from Recent Trials.
Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14601.
PubMed Abstract available

ALHAKAK A, Butt JH, Gerds TA Dr.rer.nat, Fosbol EL, et al
Glycated haemoglobin (HbA1c) levels among 3,295 hospitalised COVID-19 patients with and without diabetes and risk of severe infection, admission to an intensive care unit, and all-cause mortality.
Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14604.
PubMed Abstract available

MISTRY N, Shehata N, Carmona P, Bolliger D, et al
Restrictive versus Liberal Transfusion in Patients with Diabetes Undergoing Cardiac Surgery: An Open-Label Randomized, Blinded Outcome Evaluation Trial.
Diabetes Obes Metab. 2021 Nov 7. doi: 10.1111/dom.14591.
PubMed Abstract available

PAAVILAINEN E, Tertti K, Nikkinen H, Veijola R, et al
Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years-A follow-up study of two open-label, randomised, controlled trials.
Diabetes Obes Metab. 2021 Nov 5. doi: 10.1111/dom.14589.
PubMed Abstract available

QIU M, Zhou X, Zhang M
Cardiorenal benefits of SGLT2i versus DPP4i in type 2 diabetes without cardiovascular and renal diseases.
Diabetes Obes Metab. 2021 Nov 2. doi: 10.1111/dom.14588.
PubMed

MCDIARMID S, Harvie M, Johnson R, Vyas A, et al
Manchester Intermittent versus Daily Diet App Study (MIDDAS): A pilot randomized controlled trial in patients with type 2 diabetes.
Diabetes Obes Metab. 2021 Nov 2. doi: 10.1111/dom.14592.
PubMed Abstract available

KLONOFF DC, Bassock S, Engels E, Frederiksen M, et al
Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.
Diabetes Obes Metab. 2021;23:2590-2594.
PubMed Abstract available

PRATLEY RE, Catarig AM, Lingvay I, Viljoen A, et al
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
Diabetes Obes Metab. 2021;23:2513-2520.
PubMed Abstract available

SUISSA K, Schneeweiss S, Douros A, Filion KB, et al
The modifying effects of adiposity on the cardiovascular safety of sulphonylureas.
Diabetes Obes Metab. 2021;23:2502-2512.
PubMed Abstract available

MAI L, Wen W, Qiu M, Liu X, et al
Association between prediabetes and adverse outcomes in heart failure.
Diabetes Obes Metab. 2021;23:2476-2483.
PubMed Abstract available

October 2021

ROBERTSON CA, Earnest A, Chee M, Craig ME, et al
Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network (ADDN).
Diabetes Obes Metab. 2021 Oct 29. doi: 10.1111/dom.14584.
PubMed

ARSENYADIS F, Redman E, Coull N, Henson J, et al
Energy intake and weight during the COVID-19 lockdown is not altered in a sample of older adults with Type 2 Diabetes in England.
Diabetes Obes Metab. 2021 Oct 27. doi: 10.1111/dom.14585.
PubMed

ZOBEL EH, von Scholten BJ, Hansen TW, Persson F, et al
The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER and SUSTAIN 6 trials.
Diabetes Obes Metab. 2021 Oct 21. doi: 10.1111/dom.14578.
PubMed Abstract available

VAN DEN BOOM L, Kostev K
Patterns of insulin therapy and insulin daily doses in children and adolescents with type 1 diabetes in Germany.
Diabetes Obes Metab. 2021 Oct 21. doi: 10.1111/dom.14581.
PubMed Abstract available

WEBB J, Mount J, von Arx LB, Rachman J, et al
Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK.
Diabetes Obes Metab. 2021 Oct 20. doi: 10.1111/dom.14580.
PubMed Abstract available

DIALLO A, Pichelin M, Wargny M, Gourdy P, et al
Influenza vaccination and prognosis of COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study.
Diabetes Obes Metab. 2021 Oct 17. doi: 10.1111/dom.14577.
PubMed

FURIHATA K, Mimura H, Urva S, Oura T, et al
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
Diabetes Obes Metab. 2021 Oct 13. doi: 10.1111/dom.14572.
PubMed Abstract available

PEDERSEN-BJERGAARD U, Agesen RM, Brosen JMB, Alibegovic AC, et al
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomised, controlled, open-label, cross-over trial.
Diabetes Obes Metab. 2021 Oct 12. doi: 10.1111/dom.14574.
PubMed Abstract available

UNGER J, Allison DC, Kaltoft M, Lakkole K, et al
Maintenance of Glycemic Control with Liraglutide versus Oral Antidiabetic Drugs as Add-on Therapies in Patients with Type 2 Diabetes Uncontrolled with Metformin Alone: A Randomized Clinical Trial in Primary Care (LIRA-PRIME).
Diabetes Obes Metab. 2021 Oct 7. doi: 10.1111/dom.14566.
PubMed Abstract available

YAMADA Y, Yabe D, Hertz CL, Horio H, et al
Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.
Diabetes Obes Metab. 2021 Oct 7. doi: 10.1111/dom.14571.
PubMed Abstract available

DAVIES MJ, Rosenstock J, Ali A, Russell-Jones D, et al
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin >/=8%, >/=64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Diabetes Obes Metab. 2021 Oct 6. doi: 10.1111/dom.14543.
PubMed Abstract available

JOHANSEN NJ, Dejgaard TF, Lund A, Schluntz C, et al
Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
Diabetes Obes Metab. 2021 Oct 6. doi: 10.1111/dom.14568.
PubMed Abstract available

LEOHR J, Kazda C, Liu R, Reddy S, et al
Ultra Rapid Lispro Shows Faster Pharmacokinetics and Reduces Postprandial Glucose Excursions vs. Humalog(R) in Patients with Type 2 Diabetes Mellitus in a Randomized, Controlled Cross-over Meal Test Early Phase Study.
Diabetes Obes Metab. 2021 Oct 4. doi: 10.1111/dom.14561.
PubMed Abstract available

PIEBER TR, Bajaj HS, Heller SR, Jia T, et al
Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.
Diabetes Obes Metab. 2021 Oct 4. doi: 10.1111/dom.14564.
PubMed

SAFFO S, Kaplan DE, Mahmud N, Serper M, et al
Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.
Diabetes Obes Metab. 2021;23:2402-2408.
PubMed Abstract available

BAILEY TS, Willard J, Klaff LJ, Yager Stone J, et al
Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
Diabetes Obes Metab. 2021;23:2329-2335.
PubMed Abstract available

FRIAS JP, Bonora E, Nevarez Ruiz L, Hsia SH, et al
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
Diabetes Obes Metab. 2021;23:2279-2288.
PubMed Abstract available

BLONDE L, Fainberg U, Kaltoft MS, Mosenzon O, et al
Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
Diabetes Obes Metab. 2021;23:2234-2241.
PubMed Abstract available

TAN X, Yang L, Khunti K, Zhang R, et al
Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States.
Diabetes Obes Metab. 2021;23:2251-2260.
PubMed Abstract available

September 2021

SCHMIDT S, Frandsen CS, Dejgaard TF, Vistisen D, et al
Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
Diabetes Obes Metab. 2021 Sep 30. doi: 10.1111/dom.14567.
PubMed Abstract available

KAZDA C, Leohr J, Liu R, Reddy S, et al
Ultra Rapid Lispro (URLi) Shows Accelerated Pharmacokinetics and Greater Reduction in Postprandial Glucose versus Humalog(R) in Patients with Type 1 Diabetes Mellitus in a Randomized, Double-blind Meal Test Early Phase Study.
Diabetes Obes Metab. 2021 Sep 30. doi: 10.1111/dom.14563.
PubMed Abstract available

ROSSING P, Agarwal R, Anker SD, Filippatos G, et al
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
Diabetes Obes Metab. 2021 Sep 28. doi: 10.1111/dom.14558.
PubMed Abstract available

MUSKIET MHA, Tonneijck L, Smits MM, Kramer MHH, et al
Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial.
Diabetes Obes Metab. 2021 Sep 28. doi: 10.1111/dom.14557.
PubMed Abstract available

HUGHES MS, Bailey R, Calhoun P, Shah VN, et al
Off-label use of sodium glucose co-transporter inhibitors among adults in type 1 diabetes exchange registry.
Diabetes Obes Metab. 2021 Sep 21. doi: 10.1111/dom.14556.
PubMed

BAIN EK, Bain SC
Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class.
Diabetes Obes Metab. 2021;23 Suppl 3:30-39.
PubMed

NAUCK MA, Quast DR, Wefers J, Pfeiffer AFH, et al
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Diabetes Obes Metab. 2021;23 Suppl 3:5-29.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.